Publications

MYC in cancer: from undruggable target to clinical trials. Whitfield JR, Soucek L. Nat Rev Drug Discov. 2025 Jun;24(6):445-457. IF: 101.8.

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. André T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, Garcia-Carbonero R, Tougeron D, Mendez GA, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Manzano Mozo JL, Dahan L, Tortora G, Chalabi M, Goekkurt E, Braghiroli MI, Joshi R, Cil T, Aubin F, Cela E, Chen T, Lei M, Jin L, Blum SI, Lonardi S. Lancet. 2025 Feb 1;405(10476):383-395. IF: 88.5.

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N. Lancet. 2025 Aug 2;406(10502):461-474 IF: 88.5.

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K. Lancet. 2025 Aug 2;406(10502):447-460. IF: 88.5.

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Barlesi F, Yao W, Duruisseaux M, Doucet L, Martínez AA, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, Michenzie MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. Lancet. 2025 Aug 9;406(10503):615-626. IF: 88.5.

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Lancet. 2025 Jun 21;405(10496):2205-2216. IF: 88.5.

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A; STELLAR-303 study investigators. Lancet. 2025 Nov 15;406(10517):2360-2370. IF: 88.5.

Nonoperative Management of dMMR Tumors - A Patient-Centered Approach. Elez E. N Engl J Med. 2025 Jun 19;392(23):2380-2382. IF: 78.5.

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. N Engl J Med. 2025 Feb 6;392(6):566-576. IF: 78.5.

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, Chernock R, Tahara M, Harrington KJ, Klochikhin AL, Braña I, Vasconcelos Alves G, Hughes BGM, Oliva M, Pinto Figueiredo Lima I, Ueda T, Rutkowski T, Schroeder U, Mauz PS, Fuereder T, Laban S, Oridate N, Popovtzer A, Mach N, Korobko Y, Costa DA, Hooda-Nehra A, Rodriguez CP, Bell RB, Manschot C, Benjamin K, Gumuscu B, Adkins D; KEYNOTE-689 Investigators. N Engl J Med. 2025 Jul 3;393(1):37-50. IF: 78.5.

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, Loi S, Thanopoulou E, Shankar N, Jin Y, Stout TJ, Clark TD, Song C, Juric D, Turner NC. N Engl J Med. 2025 Jul 10;393(2):151-161. IF: 78.5.

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators. N Engl J Med. 2025 Jun 26;392(24):2425-2437. IF: 78.5.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M; CLL17 Trial Investigators. N Engl J Med. 2025 Dec 6. doi: 10.1056/NEJMoa2515458. IF: 78.5.

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gümüş M, Lugini A, Zhu B, Yu Y, Korantzis I, Han JY, Ciuleanu TE, Ahn MJ, Rocha P, Mazières J, Lau SCM, Schuler M, Blackhall F, Yoshida T, Owonikoko TK, Paz-Ares L, Jiang T, Hamidi A, Gauto D, Recondo G, Rudin CM; DeLLphi-304 Investigators. N Engl J Med. 2025 Jul 24;393(4):349-361. IF: 78.5.

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. N Engl J Med. 2025 Aug 7;393(6):569-580. IF: 78.5.

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N; CheckMate 816 Investigators. N Engl J Med. 2025 Aug 21;393(8):741-752. IF: 78.5.

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. Yang JC, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Passaro A, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Kim SW, Gadgeel SM, Owen S, Xie J, Sun T, Mehta J, Venkatasubramanian R, Ennis M, Fennema E, Daksh M, Roshak A, Man J, Knoblauch RE, Bauml JM, Baig M, Shah S, Sethi S, Cho BC; MARIPOSA Investigators. N Engl J Med. 2025 Oct 30;393(17):1681-1693. IF: 78.5.

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators. N Engl J Med. 2025 Jul 24;393(4):336-348. IF: 78.5.

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. N Engl J Med. 2025 Jul 17;393(3):217-230. IF: 78.5.

Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. N Engl J Med. 2025 Jun 19;392(23):2321-2333. IF: 78.5.

Belzutifan for Advanced Pheochromocytoma or Paraganglioma. Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, Garcia-Carbonero R, Fassnacht M, Capdevila J, Del Rivero J, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A; LITESPARK-015 Investigators. N Engl J Med. 2025 Nov 20;393(20):2012-2022. IF: 78.5.

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Şendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. N Engl J Med. 2025 Oct 29. doi: 10.1056/NEJMoa2508668. IF: 78.5.

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Jänne PA, Goto K, Rüttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS; SOHO-01 Investigators. N Engl J Med. 2025 Nov 6;393(18):1819-1832. IF: 78.5.

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. Cortés J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. N Engl J Med. 2025 Nov 13;393(19):1912-1925. IF: 78.5.

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Ürün Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE; IMvigor011 Investigators. N Engl J Med. 2025 Dec 18;393(24):2395-2408. IF: 78.5.

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zuo Y, Fogelman D, Adelberg D, Diaz LA. Ann Oncol. 2025 Mar;36(3):277-284. IF: 65.4.

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial. Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, Shah R, de Marinis F, Cove Smith L, Bernabé R, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Nadal E, Vila Martinez L, Talbot T, Roschitzki-Voser H, Dimopoulou G, Schär S, Ruepp B, Savic S, Peters S, Stahel R; ETOP 13-18 BEAT-meso Collaborators. Ann Oncol. 2025 May;36(5):548-560. IF: 65.4.

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, Duran I, Morales-Barrera R, Guo J, Sternberg CN, Bellmunt J, Goebell PJ, Kovalenko M, Boateng F, Sierecki M, Wang L, Sima CS, Waldes J, Loriot Y, Grivas P. Ann Oncol. 2025 May;36(5):561-571. IF: 65.4.

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Westphalen CB, Boscolo Bielo L, Aftimos P, Beltran H, Benary M, Chakravarty D, Collienne M, Dienstmann R, El Helali A, Gainor J, Horak P, Le Tourneau C, Marchiò C, Massard C, Meric-Bernstam F, Pauli C, Pruneri G, Roitberg F, Russnes HEG, Solit DB, Starling N, Subbiah V, Tamborero D, Tarazona N, Turnbull C, van de Haar J, André F, Mateo J, Curigliano G. Ann Oncol. 2025 Jun;36(6):614-625. IF: 65.4.

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Felip E, Rojas CI, Schenker M, Kowalski DM, Casarini IA, Csöszi T, Şendur MAN, Martins J, Calles Blanco A, Wang CC, Wang M, Ramirez Fallas RAL, Yoshioka H, Nair S, Song X, Deng X, Lala M, Eiras R, Takahashi T. Ann Oncol. 2025 Jul;36(7):775-785. IF: 65.4.

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suarez C, Maroto P, Grünwald V, Oosting SF, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Haanen JB; Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN). Ann Oncol. 2025 Jul;36(7):796-806. IF: 65.4.

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study. Toss A, Blondeaux E, Tenedini E, Bonamici L, Graffeo R, Livraghi L, Villarreal-Garza C, Bernstein Molho R, Kwong A, Balmana J, Wildiers H, Agostinetto E, Phillips KA, Pogoda K, Renaud T, Rousset-Jablonski C, Ferrari A, Moore HCF, Peccatori FA, Paluch-Shimon S, Fruscio R, Micheri C, Wong SM, Cui W, Vernieri C, Lee MK, De Marchis L, Couch FJ, Del Mastro L, Puglisi F, Meireles PA, Kemp Z, Matikas A, Plichta J, Del Pilar Estevez-Diz M, Di Meglio A, Cichowska-Cwalinska N, Gianni C, Yerushalmi R, Sanchez-Bayona R, Mrinakova B, Matos L, Bianchini G, Caleffi M, Krivokuca A, Abdou Y, Mariño-Mariño M, Parokonnaya A, Okano M, Antone N, Saavedra C, Sonnenblick A, Duchnowska R, Pais HL, Harbeck N, Cortesi L, Delucchi V, De Angelis C, Lambertini M. Ann Oncol. 2025 Nov 17. doi: 10.1016/j.annonc.2025.11.004. IF: 65.4.

ESMO basic requirements for AI-based biomarkers in oncology (EBAI). Aldea M, Salto-Tellez M, Marra A, Umeton R, Stenzinger A, Koopman M, Prelaj A, Kehl KL, Gilbert S, Leßmann ME, Lipkova J, Provenzano L, Meric-Bernstam F, Halabi S, Wu J, Pellat A, Suijkerbuijk KPM, Besse B, Ryll B, Marchió C, Crispin-Ortuzar M, Fehrmann R, Vibert J, Ferber D, Pauli C, Valachis A, Corso F, Brinker TJ, Mateo J, Harbeck N, Winkler EC, Lopez-Rios F, Perez-Lopez R, Pentheroudakis G, Delaloge S, Benedikt Westphalen C, Kather JN. Ann Oncol. 2025 Nov 18. doi: 10.1016/j.annonc.2025.11.009. IF: 65.4.

Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. Saura C, Cortés J, Modi S, Kim SB, Hamilton E, Hurvitz SA, Krop IE, Curigliano G, Iwata H, Im SA, Herbolsheimer P, Karnoub M, Boran A, Kuwahara Y, Egorov A, André F. Ann Oncol. 2025 Nov 18. doi: 10.1016/j.annonc.2025.11.007. IF: 65.4.

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02. Hurvitz SA, Loi S, O'Shaughnessy J, Okines AFC, Tolaney SM, Sohn J, Saura C, Zhu X, Cameron D, Bachelot T, Hamilton E, Curigliano G, Wolff AC, Harbeck N, Masuda N, Vahdat L, Zaman K, Valdes-Albini F, Block M, Pluard T, Tan TJ, Gawryletz C, Chan A, Bedard PL, Yerushalmi R, Xu B, Schmitt M, Xie D, Borges VF; HER2CLIMB-02 study investigators. Ann Oncol. 2025 Nov 17. doi:10.1016/j.annonc.2025.11.005. IF: 65.4.

Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G. Ann Oncol. 2025 Jul;36(7):726-736. IF: 65.4.

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Martín-Lluesma S, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, Villacampa G, Galvao V, Lostes J, Muñoz-Couselo E, Rotxés M, Villalobos X, Muñoz S, Haanen JBAG, Svane IM, Piulats JM, Martin-Liberal J, Gros A, Coukos G, Garralda E. Ann Oncol. 2025 Aug;36(8):909-919. IF: 65.4.

Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations. Turnbull C, Achatz MI, Balmaña J, Castro E, Curigliano G, Cybulski C, Domchek SM, Evans DG, Hanson H, Hoogerbrugge N, James PA, Krause A, Nathanson KL, Ngeow Yuen Yie J, Robson M, Tischkowitz M, Westphalen B, Foulkes WD. Ann Oncol. 2025 Aug;36(8):853-865. IF: 65.4.

Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors. Castet F, Tian TV, Macarulla T. Ann Oncol. 2025 Nov;36(11):1422-1424. IF: 65.4.

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma. Rini BI, Albiges L, Tang X, Koeppen H, Bex A, Suárez C, Uzzo R, Hamidi H, Assaf ZJ, Dubey S, Goluboff ET, Carter C, Pal SK, Banchereau RF, Xu W, Huseni MA. Ann Oncol. 2025 Dec;36(12):1525-1534. IF: 65.4.

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, Shah AY, Porta C, Suárez C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, Scheffold C, Askelson M, Panzica J, Zhang J, van Kooten Losio M, Choueiri TK. Ann Oncol. 2025 Sep 23. doi: 10.1016/j.annonc.2025.09.006. IF: 65.4.

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13). Mayer EL, Hlauschek D, Gnant M, O'Brien PJ, Bellet-Ezquerra M, Goetz MP, Ruiz-Borrego M, Chan A, Clifton K, Egle D, Lake D, Cabrera P, Mamounas T, Pristauz-Telsnigg G, Dayao Z, Gil Gil M, Cameron D, Traina T, Morris PG, Sabanathan D, Rinnerthaler G, Meisel J, Prat A, Wolff AC, Tseng LM, Isaacs C, Singer CF, Rubovszky G, Foukakis T, Jassem J, Winer EP, Vetter M, Federmann J, Metzger O, Schurmans C, Gauthier E, Lu DR, Fesl C, Dueck A, DeMichele A. Ann Oncol. 2025 Oct 17. doi: 10.1016/j.annonc.2025.10.003. IF: 65.4.

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study. Kristeleit RS, Ghamande S, Lisyanskaya A, Oaknin A, Prendergast E, Kim YB, Fuentes Pradera J, Littell RD, Gao B, Valabrega G, O'Malley DM, Dean A, Pisano C, Buscema J, Provencher D, Zagouri F, Martin LP, Chou HH, Demirkiran F, Ueland F, Chudecka-Głaz A, Yeku O, Beiner M, Anderson C, Drochytek V, Eskander RN, Agarwal R, Maloney L, Despain D, Connor C, Craib M, Shih D, Fujiwara K, Monk BJ. Ann Oncol. Oct 18. doi: 10.1016/j.annonc.2025.10.007. IF: 65.4.

Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. Suarez C, Rojas C, Shin SJ, Yanez Weber P, Albiges L, Motzer R, Hammers H, Peer A, Lee JL, Miller WH, Waddell T, Neiman V, Keizman D, Zwenger Kloster A, Weickhardt A, Dziadziuszko R, Suttner L, Sharma M, Burgents JE, Powles T. Ann Oncol. 2025 Oct 18. doi: 10.1016/j.annonc.2025.10.010. IF: 65.4.

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF; DESTINY-Breast11 Trial Investigators. Ann Oncol. 2025 Oct 21. doi: 10.1016/j.annonc.2025.10.019. IF: 65.4.

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial. Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Watanabe J, Lim E, Huang J, Qingyuan Z, Llombart-Cussac A, Huang C, Desai B, Limay Y, Wang XA, Cao S, Bidard FC. Ann Oncol. 2025 Dec 12. doi: 10.1016/j.annonc.2025.11.018. IF: 65.4.

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors. Llorente S, Lamarca A, Tian TV. Signal Transduct Target Ther. 2025 Jun 27;10(1):194. IF: 52.7.

NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts. Amengual J, Gonzalez-Sanchez E, Yáñez-Bartolome M, Sererols-Viñas L, Ravichandra A, Guiton C, Fuste NP, Alay A, Hijazo-Pechero S, Martín-Mur B, Gut M, Esteve-Codina A, Cantos-Cortes A, Espinosa-Sotelo R, Ramos E, Serrano T, Calvo M, Laquente B, Ferrer J, Pons G, Mendez-Lucas A, Dooley S, Ilyas SI, Vallette M, Aoudjehane L, Lequoy M, Fouassier L, Coulouarn C, Affò S, Scheiter A, Calvisi DF, Tian TV, Fabregat I, Vaquero J. Signal Transduct Target Ther. 2025 Aug 18;10(1):257. IF: 52.7.

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher GA, Schmidt M, Schuler M, Sullivan RJ, Burris HA, Galvao V, Henick BS, Dirix L, Jaeger D, Ott PA, Wong KM, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner RS, Rittmeyer A, Laurie SA, Gort E, Aljumaily R, Melero I, Sabado RL, Rhee I, Mancuso MR, Muller L, Fine GD, Yadav M, Kim L, Leveque VJP, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao GK, Low DW, Petry C, Lo AA, Schartner JM, Delamarre L, Mellman I, Löwer M, Müller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, Lörks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kröner C, Tadmor AD, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn AN, Sahin U, Türeci Ö, Camidge DR. Nat Med. 2025 Jan;31(1):152-164. IF: 50.0

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Loi S, Salgado R, Curigliano G, Romero Díaz RI, Delaloge S, Rojas García CI, Kok M, Saura C, Harbeck N, Mittendorf EA, Yardley DA, Suárez Zaizar A, Caminos FR, Ungureanu A, Reinoso-Toledo JG, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu JQ, Pusztai L, McArthur H. Nat Med. 2025 Feb;31(2):433-441. IF: 50.0.

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Beyzarov E, Zhang X, Ferrier G, Zhang X, Tabernero J. Nat Med. 2025 Mar;31(3):901-908. IF: 50.0.

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. Preusser M, Garde-Noguera J, García-Mosquera JJ, Gion M, Greil R, Arumi M, Ruiz-Borrego M, Llombart-Cussac A, Valero M, Cortés J, Campolier M, Guerrero JA, González-Alonso P, Jiménez-Cortegana C, Rodríguez-Morató J, Vaz-Batista M, Oberndorfer F, Marhold M, Berghoff AS, Furtner J, Fuereder T, Bartsch R. Nat Med. 2025 Aug;31(8):2797-2805. IF: 50.0.

Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Kopetz S, Boni V, Kato K, Raghav KPS, Vieito M, Pallis A, Habermehl C, Siddiqui A, Courlet P, Sloot W, Raab-Westphal S, Hart F, Rodriguez-Rivera I. Nat Med. 2025 Oct;31(10):3504-3513. IF: 50.0.

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, Staedler N, Amaria RN, Ascierto PA, Tarhini AA, Robert C, Hamid O, Gaudy-Marqueste C, Lebbe C, Munoz-Couselo E, Menzies AM, Pages C, Curigliano G, Mandala M, Jessop N, Bader U, Perdicchio M, Teichgräber V, Muecke M, Markert C, Blank C. Nat Med. 2025 Nov;31(11):3700-3712. IF: 50.0.

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Muñoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Nat Med. 2025 Dec;31(12):4301-4309. IF: 50.0.

Many paths, one destination: Bridging the gap in cancer care. Sahai E, Wang H, Kok M, Wu CJ, Shen L, Carpten J, Serrano C, Venkataramani V. Cancer Cell. 2025 Apr 14;43(4):577-580. IF: 44.5.

Stromal barriers to the abscopal effect. Tian TV, Affò S. Cancer Cell. 2025 May 12;43(5):810-812. IF: 44.5.

Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials. Gallois C, Sroussi M, André T, Mouillet-Richard S, Agueeff N, Mulot C, Vernerey D, Louvet C, Bachet JB, Dourthe LM, Mazard T, Jary M, Coutzac C, Lecaille C, Tabernero J, Van Laethem JL, Lepage C, Emile JF, de Reyniès A, Taieb J, Laurent-Puig P. J Clin Oncol. 2025 May 20;43(15):1765-1776. IF: 43.4.

Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. Lambertini M, Blondeaux E, Tomasello LM, Agostinetto E, Hamy AS, Kim HJ, Franzoi MA, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg KA, Duhoux FP, Livraghi L, Bruzzone M, Boni L, Balmaña J. J Clin Oncol. 2025 May 10;43(14):1706-1719. IF: 43.4.

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Pérol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. J Clin Oncol. 2025 Apr;43(10):1254-1265. IF: 43.4.

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. Liu J, Farrow M, Seymour L, Desai J, Loong HH, Ivy P, Koyoma T, Cook N, Blagden S, Garralda E, Massard C, Tolcher AW, Adashek JJ, Zhang L, Zhao S, Shen L, Kurzrock R, El-Deiry WS, Subbiah V, Joshua AM. J Clin Oncol. 2025 Feb 20;43(6):735-747. IF: 43.4.

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. Liu JF, Colombo N, Oza AM, Frenel JS, Corr BR, Rubinstein MM, Nevadunsky NS, Lheureux S, Gaba L, González Cortijo L, Salutari V, You B, Chiang S, O'Connor MJ, Oplustil O'Connor L, Meulendijks D, Khatun M, Ghiorghiu D, Oaknin A. J Clin Oncol. 2025 Sep 10;43(26):2897-2907. IF: 43.4.

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts. Pal SK, Loriot Y, Necchi A, Singh P, Castellano D, Pagliaro L, Suarez C, McGregor BA, Vaishampayan UN, Hauke RJ, Powles T, Van Herpen CML, Courtney KD, Dreicer R, Sudhagoni R, Schwickart M, Andrianova S, Agarwal N. J Clin Oncol. 2025 May 10;43(14):1650-1662. IF: 43.4.

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study Investigators. J Clin Oncol. 2025 Jul 20;43(21):2343-2349.I F: 43.4.

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database. Bachet JB, de Gramont A, Raeisi M, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JR, Mayer RJ, Lichtman SM, Benson AB, Sobrero AF, Tabernero J, Adams R, Zalcberg JR, Grothey A, Yoshino T, André T, Shi Q, Chibaudel B. J Clin Oncol. 2025 Jun 20;43(18):2094-2106. IF: 43.4.

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. Bhatia S, Topalian SL, Sharfman W, Meyer T, Steven N, Lao CD, Fariñas-Madrid L, Devriese LA, Moore K, Ferris RL, Honma Y, Elias I, Srirangam A, Garnett-Benson C, Lee M, Nghiem P. J Clin Oncol. 2025 Mar 20;43(9):1137-1147. IF: 43.4.

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer. Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N, Provencio Pulla M. J Clin Oncol. 2025 Apr 20;43(12):1453-1462. IF: 43.4.

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. Zampini M, Riva E, Lanino L, Sauta E, Antunes Dos Reis R, Ejarque RMA, Maggioni G, Termanini A, Merlotti A, Campagna A, Dall'Olio L, Kulasekararaj A, Calvi M, Di Vito C, Bonometti A, Rahal D, Croci G, Boveri E, Gianelli U, Ponzoni M, Caselli R, Albertazzi S, Todisco G, Ubezio M, Crisafulli L, Frigo A, Lugli E, Mosca E, Acha P, Ghisletti S, Nicassio F, Santoro A, Diez-Campelo M, Solé F, Ades L, Platzbecker U, Santini V, Fenaux P, Haferlach T, Sallman D, Garcia-Manero G, Mavilio D, Remondini D, Castellani G, D'Amico S, Zeidan AM, Komrokji R, Kordasti S, Ficara F, Della Porta MG; CALR Consortium. J Clin Oncol. 2025 Jun 20;43(18):2069-2083. IF: 43.4.

Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial. Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Satersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. J Clin Oncol. 2025 Aug 20;43(24):2712-2719. IF: 43.4.

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. Steuer CE, Hayashi H, Su WC, Nishio M, Johnson ML, Kim DW, Massarelli E, Felip E, Gold KA, Murakami H, Baik CS, Kim SW, Smit EF, Fujimura M, Fan PD, Truchon K, Su X, Sternberg DW, Jänne PA. J Clin Oncol. 2025 Sep;43(25):2816-2826. IF: 43.4.

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. Tomasini P, Wang Y, Li Y, Felip E, Wu L, Cui J, Besse B, Spira AI, Neal JW, Goto K, Baik CS, Marmarelis ME, Ichihara E, Zhang Y, Lee JS, Lee SH, Yang JC, Michels S, Anastasiou Z, Curtin JC, Lyu X, Mahoney J, Demirdjian L, Meyer CS, Zhang Y, Leconte I, Lorenzini P, Knoblauch RE, Trani L, Baig M, Bauml JM, Cho BC; CHRYSALIS-2 Cohort C. J Clin Oncol. 2025 Dec 1. doi: 10.1200/JCO-24-02835. IF: 43.4.

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. J Clin Oncol. 2025 Sep;43(25):2782-2792. IF: 43.4.

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. J Clin Oncol. 2025 Aug;43(22):2538-2549. IF: 43.4.

Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. Palmerini E, Meazza C, Tamburini A, Márquez-Vega C, Bisogno G, Fagioli F, Ferraresi V, Milano GM, Coccoli L, Rubio-San-Simón A, Gallego O, Llinares Riestra ME, Manzitti C, Mora J, Vaz-Salgado MÁ, Luksch R, Mata C, Pierini M, Carretta E, Cesari M, Paioli A, Marrari A, Scotlandi K, Serra M, Asaftei SD, Gambarotti M, Picci P, Ferrari S, Valverde C, Ibrahim T, Broto JM. J Clin Oncol. 2025 Oct;43(28):3113-3122. IF: 43.4.

Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. Pérol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. J Clin Oncol. 2025 Jun;43(16):1920-1929. IF: 43.4.

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed MF, Alese OB, Sayehli CM, Arriola E, Wolf J, Villaruz LC, Bertulis J, Studeny M, Bouzaggou M, Fang X, Morgensztern D. J Clin Oncol. 2025 Sep 20;43(27):3021-3031. IF: 43.4.

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. Baldini C, Verlingue L, Goldschmidt V, Doger de Spéville B, Lostes J, Italiano A, Cousin S, Falchook GS, Necchi A, Reig Torras O, Fontana E, Carter L, Rodon Ahnert J, Brown JR, DeMars LR, Josephs K, Dickson A, Xu C, Bader J, Campbell C, Sharma R, McKean M. J Clin Oncol. 2025 Dec 10;43(35):3728-3738. IF: 43.4.

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. Babiker HM, Picozzi V, Chandana SR, Melichar B, Kasi A, Gang J, Gallego J, Bullock A, Chunyi H, Wyrwicz L, Hitre E, Osipov A, de la Fouchardiere C, Ales I, Dragovich T, Lee W, Feeney K, Philip P, Ueno M, Van Cutsem E, Seufferlein T, Macarulla T; PANOVA-3 Study Investigators. J Clin Oncol. 2025 Jul 20;43(21):2350-2360. IF: 43.4.

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. Shitara K, Lorenzen S, Li J, Bai Y, Fernández MG, Aguilar M, Shoji H, Reyes-Cosmelli F, Peña YR, Corrales L, Wyrwicz L, Eyzaguirre DA, Pan Y, Ryu MH, Cohen DJ, Wainberg ZA, Ku G, Tabernero J, Van Cutsem E, Qin SK, Oh DY, Xu J, Liang LW, Bordia S, Bhagia P, Rha SY; LEAP-015 Investigators. J Clin Oncol. 2025 Aug;43(22):2502-2514. IF: 43.4.

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, Huang D, Greillier L, Planchard D, Hong Q, Mazieres J, Felip E, Li X, Hu Y, Fang J, Bazhenova L, Ghiringhelli F, Cobo Dols MA, Rodriguez LP, Bearz A, Pellini B, Kim YJ, Bosch-Barrera J, Shim BY, Luo YH, Tiseo M, Yang TY, Carcereny E, Memmott RM, Zalcman G, de Castro Carpeno J, Di Noia V, Parra HS, Streich G, Lee DH, Shum E, Han JY, Jaime JC, Brungs D, John T, D'Arcangelo M, Joaquin AB, Liu G, Antonuzzo L, Hinojal GF, Le X, Zheng L, Jänne PA; WU-KONG1B. J Clin Oncol. 2025 Oct 10;43(29):3198-3208. IF: 43.4.

TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. Hammel P, Metges JP, Macarulla Mercade T, Garcia-Carbonero R, Bouché O, Portales F, Pazo Cid RA, Mineur L, Cubillo Gracian A, Trouilloud I, Guimbaud R, Tougeron D, Reina JJ, Feliu J, Sauri T, Fountzilas C, Lecomte T, Molin Y, Ponz-Sarvise M, Forget F, Berardi R, Van Cutsem E, Gelsomino F, Tournigand C, Bockorny B, Bachet JB, Marin Vera M, Cuyle PJ, Wasan H, Noel M, Van Laethem JL, Kay R, Youssoufian H, El-Hariry I, Hidalgo M. J Clin Oncol. 2025 Dec 10;43(35):3714-3727. IF: 43.4.

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE; NeoADAURA Investigators. J Clin Oncol. 2025 Sep 10;43(26):2875-2887. IF: 43.4.

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR. J Clin Oncol. 2025 Dec 10;43(35):3698-3705. IF: 43.4.

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ, Dominguez AR, Pinto A, Skarbnik A, Cordoba R, Jørgensen JM, Zinzani PL, Leung W, Bottos A, Li D, Relf J, Tandon M, Sellam G, Gritti G. J Clin Oncol. 2025 Dec 20;43(36):3788-3798. IF: 43.4.

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. Harter P, Marmé F, Redondo A, Reuss A, Lindemann K, Kurzeder C, Van Nieuwenhuysen E, Marth C, Pietzner K, Ray-Coquard I, Garcia-Duran C, Jonuskiene G, Heitz F, Béllier C, Pérez-Fidalgo JA, El-Balat A, Selle F, Romero I, Wimberger P, Follana P, Pardo B, de Gregorio N, Joly F, Gaba L, Burges A, Fabbro M, Hasenburg A, Fehm T, Schmalfeldt B, Pautier P. J Clin Oncol. 2025 Dec 3. doi: 10.1200/JCO-25-01210. IF: 43.4.

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai KK, Lebbé C, Gaudy-Marqueste C, Middleton MR, Skolariki A, Samson A, Chesney JA, VanderWalde AM, Zakharia Y, Harrington KJ, Appleton E, Bommareddy PK, Zhu J, Viana M, Hou JW, Coffin RS, Robert C. J Clin Oncol. 2025 Nov 20;43(33):3589-3599. IF: 43.4.

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. Wang ES, Montesinos P, Foran J, Erba H, Rodríguez-Arbolí E, Fedorov K, Heiblig M, Heidel FH, Altman JK, Baer MR, Ades L, Pettit K, Peterlin P, Papayannidis C, Berthon C, Walter RB, Shah MV, Balasubramanian S, Khawandanah M, Salamero Garcia O, Bergeron J, Madanat YF, Roboz GJ, Ulrickson M, Redner RL, McCloskey J, Pigneux A, de la Fuente Burguera A, Mitra A, Soifer HS, Tabachri M, Zhang Z, Riches M, Corum D, Leoni M, Issa GC, Fathi AT; KOMET-001. J Clin Oncol. 2025 Nov;43(31):3381-3390. IF: 43.4.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study. Montesinos P, Rodríguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodríguez-Arbolí E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, López-López JA, Vives S, López-Lorenzo JL, Colorado M, Vidriales MB, García Boyero R, Olave MT, Herrera Puente P, Arce O, Barrios M, Jose Sayas M, Polo M, Gómez-Roncero MI, Barragán E, Ayala R, Chillón C, Calasanz MJ, Paiva B, Boluda B, Casas-Avilés I, Lloret-Madrid P, Sánchez MJ, Rodríguez-Medina C, Cuevas L, Raposo-Puglia JÁ, Mateos MC, Olivares M, Martínez-Chamorro C, Alonso N, Suárez S, Sánchez-Vadillo I, Solé Rodríguez M, González BJ, Martínez-Francés A, Cuello R, Fernández A, Martínez-Cuadrón D, Labrador J; PETHEMA group; PETHEMA Group. J Clin Oncol. 2025 Oct 13. doi: 10.1200/JCO-25-01841. IF: 43.4.

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. J Clin Oncol. 2025 Dec 10;43(35):3706-3713. IF: 43.4.

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N, Rocha P, Hayashi H, Sakai T, Kim YJ, Hu H, Qian M, Singh J, Godard J, Tang M, Ahn MJ. J Clin Oncol. 2025 Oct 14. doi: 10.1200/JCO-25-02142. IF: 43.4.

FDA fast-track approval of belzutifan is a milestone in rare cancer therapy. Arenillas C, Toledo RA. Nat Rev Endocrinol. 2025 Dec;21(12):739-740. IF: 42.3.

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study. Roncaglia E, Gaffo E, Calabretto G, Fürstenau M, Rogers KA, Baliakas P, Cui C, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen-Khac F, Rigolin GM, Athanasiadou A, Baran-Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, Scarfò L, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Ruocco V, Orsi S, Salek K, Merlo R, Caregari A, Glogovitis I, Cellini A, Angotzi F, Serafin A, Yi S, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Visentin A, Bortoluzzi S. J Hematol Oncol. 2025 Jul 22;18(1):74. IF: 40.4.

ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, Ledermann J, Mirza MR, Vergote I, Abu-Rustum NR, Bosse T, Chargari C, Espenel S, Fagotti A, Fotopoulou C, Gatius S, González-Martin A, Lax S, Levy B, Lorusso D, Macchia G, Marth C, Morice P, Oaknin A, Raspollini MR, Schwameis R, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Planchamp F, Nout RA. Lancet Oncol. 2025 Aug;26(8):e423-e435. IF: 35.9.

Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial. Oza AM, Lisyanskaya A, Fedenko A, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Kristeleit R. Lancet Oncol. 2025 Feb;26(2):249-264. IF: 35.9.

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Graham CE, Velasco R, Alarcon Tomas A, Stewart OP, Dachy G, Del Bufalo F, Doglio M, Henter JI, Ortí G, Peric Z, Roddie C, van de Donk NWCJ, Frigault MJ, Ruggeri A, Onida F, Sánchez-Ortega I, Yakoub-Agha I, Penack O. Lancet Oncol. 2025 Apr;26(4):e203-e213. IF: 35.9.

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K. Lancet Oncol. 2025 Apr;26(4):470-480. IF: 35.9.

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Chang J, Healy CG, Niyazov A, Agarwal N. Lancet Oncol. 2025 Apr;26(4):481-490. IF: 35.9.

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B. Lancet Oncol. 2025 Apr;26(4):491-502. IF: 35.9.

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. Escrivá-de-Romani S, Cejalvo JM, Alba E, Friedmann J, Rodríguez-Lescure Á, Savard MF, Pezo RC, Gion M, Ruiz-Borrego M, Hamilton E, Pluard T, Webster M, Beeram M, Linden H, Saura C, Shpektor D, Salim B, Harvey P, Hurvitz SA. Lancet Oncol. 2025 Jun;26(6):745-758. IF: 35.9.

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA Jr, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M. Lancet Oncol. 2025 Jun;26(6):759-770. IF: 35.9.

Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Agarwal N, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK. Lancet Oncol. 2025 Jul;26(7):860-876. IF: 35.9.

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis. Villacampa G, Pascual T, Tarantino P, Cortés J, Perez-García J, Llombart-Cussac A, Conte P, Mancino M, Guarneri V, Dieci MV, Waks AG, Schettini F, Brasó-Maristany F, Griguolo G, de Castro BA, Reboredo C, Antolín S, Bueno-Muiño C, Echavarría I, López-Tarruella S, Massarrah T, Del Monte-Millán M, Martín M, Buckingham W, Parker JS, Vivancos A, Polyak K, Filho OM, Wolff AC, DeMichele A, Tung NM, Perou CM, Paré L, Villagrasa P, Prat A, Tolaney SM. Lancet Oncol. 2025 Aug;26(8):1100-1112. IF: 35.9.

Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Fuereder T, Garde-Noguera J, García-Mosquera JJ, Ruiz-Borrego M, Valero M, Llombart-Cussac A, Gion M, Greil R, Arumi M, Campolier M, Guerrero JA, Raimondi G, Mancino M, Jiménez-Cortegana C, Vaz-Batista M, Oberndorfer F, Marhold M, Berghoff AS, Furtner J, Bartsch R, Preusser M. Lancet Oncol. 2025 Nov;26(11):1454-1466. IF: 35.9.

The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer. Avolio M, Leto SM, Sassi F, Lupo B, Grassi E, Catalano I, Zanella ER, Vurchio V, Cottino F, Tsantoulis PK, Lazzari L, Luraghi P, Ferri M, Galimi F, Berrino E, Bellomo SE, Viviani M, Sogari A, Mauri G, Tosi F, Cruciani F, Sartore-Bianchi A, Siena S, Borghi F, Torri V, Élez E, Tabernero J, Nieva M, Montagut C, Tarazona N, Cervantes A, Tejpar S, Bardelli A, Marchiò C, Marsoni S, Bertotti A, Trusolino L. Cancer Discov. 2025 Sep 22. doi: 10.1158/2159-8290.CD-24-0556. IF: 33.3.

Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes. Arenillas C, Celada L, Ruiz-Cantador J, Calsina B, Datta D, García-Galea E, Fasani R, Moreno-Cárdenas AB, Alba-Linares JJ, Miranda-Barrio B, Martínez-Montes ÁM, Alvarez-Escola C, Lecumberri B, González García A, K Flores S, Esquivel E, Ding Y, Peitzsch M, Robles-Guirado JÁ, Regojo Zapata RM, Pozo-Kreilinger JJ, Iglesias C, Dwight T, Muir CA, Oleaga A, Garrido-Lestache Rodríguez-Monte ME, Del Cerro MJ, Martínez-Bendayán I, Álvarez-González E, Cubiella T, Lourenço DM Jr, A Pereira MA, Burnichon N, Buffet A, Broberg C, Dickson PV, Fraga MF, Llorente Pendás JL, Rueda Soriano J, Buendía Fuentes F, Toledo SPA, Clifton-Bligh R, Dienstmann R, Villanueva J, Capdevila J, Gimenez-Roqueplo AP, Favier J, Nuciforo P, Young WF Jr, Bechmann N, Opotowsky AR, Vaidya A, Bancos I, Weghorn D, Robledo M, Casteràs A, Dos-Subirà L, Adameyko I, Chiara MD, Dahia PLM, Toledo RA. Cancer Discov. 2025 May 2;15(5):1037-1062. IF: 33.3.

Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancer. Gumpert N, Sagie S, Arnedo-Pac C, Babu T, Weller C, Gonzalez-Perez A, Wang Y, Michel Todó L, Levy R, Chen X, Greenberg P, Dayan-Rubinov M, Yakubovich E, Wasserman-Bartov T, Zerbib M, Gong J, Rebernick RJ, Oliveira Tercero A, Agundez Muriel L, Benedek G, Kedmi M, Oren R, Ben-Dor S, Levin Y, Troyanskaya OG, Munzur AD, Wyatt AW, Cieslik MP, Quigley DA, Van Allen EM, Anandasabapathy N, Mateo J, Yang X, Martínez-Jiménez F, Lopez-Bigas N, Samuels Y. Cancer Discov. 2025 Oct 8. doi: 10.1158/2159-8290.CD-24-1213. IF: 33.3.

A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer. Centonze A, Roura AJ, Novillo-Font M, Giordano C, Hernando-Momblona X, Llanses M, Prats P, Sevillano M, Cabot D, Novell M, Pabst G, Andersch F, Cañellas-Socias A, Zhang C, Giakoumakis NN, Sparks H, Dunsby C, Colombelli J, Fernández-Barral A, Sancho E, Stephan-Otto Attolini C, Muñoz A, Barbachano A, Palmer HG, Martínez-Quintanilla J, Zuber J, Blaj C, Quintana E, Cortina C, Marti-Renom MA, Batlle E. Cancer Discov. 2025 Oct 21. doi: 10.1158/2159-8290.CD-25-0679. IF: 33.3.

Detecting Cancer Early with Ultrasensitive Multimodal Liquid Biopsy. Crisafulli G, Saoudi Gonzalez N, Patelli G, Bardelli A. Cancer Discov. 2025 Sep 4;15(9):1774-1776. IF: 33.3.

A phase III randomized study of first-line NUC-1031/cisplatin vs.gemcitabine/cisplatin in advanced biliary tract cancer. Knox JJ, McNamara MG, Bazin IS, Oh DY, Zubkov O, Breder V, Bai LY, Christie A, Goyal L, Cosgrove DP, Springfeld C, Sjoquist KM, Park JO, Verdaguer H, Braconi C, Ross PJ, De Gramont A, Shroff RT, Zalcberg JR, Palmer DH, Smith JR, Oelmann E, Bruce T, Valle JW. J Hepatol. 2025 Aug;83(2):358-366. IF: 33.0.

Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer. Castet F, Fabregat-Franco C, Bridgewater J, Kim JW, Rimini M, La Casta A, Lamarca A, Kang M, Salani F, Castillo A, Lopes A, Hyung J, Rimassa L, Adeva J, López-Valbuena D, Basagaña-Farres M, Vaja S, Mak KM, Tian TV, Muñoz A; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD); Casadei-Gardini A; DURVABTC Group; Yoo C, Valle JW, Macarulla T. J Hepatol. 2025 Nov;83(5):1102-1115. IF: 33.0.

The barriers to uptake of artificial intelligence in hepatology and how to overcome them. Clusmann J, Balaguer-Montero M, Bassegoda O, Schneider CV, Seraphin T, Paintsil E, Luedde T, Lopez RP, Calderaro J, Gilbert S, Marjot T, Spann A, Shawcross DL, Lens S, Trépo E, Kather JN. J Hepatol. 2025 Dec;83(6):1410-1426. IF: 33.0.

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. in phase 2 ELM-2 trial. Nat Cancer. 2025 Mar;6(3):528-539. IF: 28.5.

SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence. Tsanov KM, Barriga FM, Ho YJ, Alonso-Curbelo D, Livshits G, Tian S, Koche RP, Baslan T, Simon J, Wuest AN, Reyes J, Park J, Luan W, Wilkinson JE, Bhanot U, Ray-Kirton J, Masilionis I, Dimitrova N, Iacobuzio-Donahue CA, Chaligné R, Pe'er D, Massagué J, Lowe SW. Nat Cancer. 2025 Nov;6(11):1839-1856. IF: 28.5.

Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls. Lobo S, Dias A, Pedro AM, Ferreira M, Pinto-Oliveira A, São José C, Herrera-Mullar J, Pinto N, Colas C, Hüneburg R, Nattermann J, Boussemart L, van Hest LP, Moreira L, Horton C, Farengo Clark D, Tinschert S, Golmard L, Spier I, López-Fernández A, Oliveira D, Svrcek M, Bourgoin P, Coulet F, Delhomelle H, Davis J, Zäncker B, Lazaro C, Guerra J, Almeida ML, Carrera S, Patiño A, Gundlach P, Laszkowska M, Strong VE, Teixeira MR, Schrader I, Steinke-Lange V, Gullo I, Sousa S, Batista M, Aretz S, Balmaña J, Aronson M, Antoniazzi AP, Palmero EI, Mansfield P, van der Kolk LE, Cats A, van Dieren JM, Castellví-Bel S, Katona B, Karam R, Pereira PS, Benusiglio PR, Oliveira C. Gut. 2025 Nov 26. doi: 10.1136/gutjnl-2024-334601. IF: 26.2.

Gene-Specific Detection Rate of Adenomas and Advanced Adenomas in Lynch Syndrome. Sánchez A, Castillo-Iturra J, Roos VH, Dueñas N, Pineda M, Moreno L, Rodríguez-Alonso L, Ramon Y Cajal T, Llort G, Piñol V, Lopez Fernandez A, Salces I, Picó MD, Rivas L, Bujanda L, Garzon M, Pizarro A, Martinez de Castro E, Lopez-Arias MJ, Poves C, Garau C, Rodriguez-Alcalde D, Herraiz M, Alvarez-Urrutia C, Dacal A, Carrillo-Palau M, Cid L, Ponce M, Barreiro-Alonso E, Saperas E, Aguirre E, Bastiaansen B, Ocaña T, Carballal S, Rivero-Sanchez L, Ortiz O, Daca-Alvarez M, Prat-Galito R, Bessa X, Cubiella J, Jover R, Rodríguez-Moranta F, Balmaña J, Brunet J, Castells A, Capellá G, Ladabaum U, Dekker E, Moreira L, Pellisé M, Balaguer F. Gastroenterology. 2025 Sep;169(4):663-675. IF: 25.9.

Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis. Naqvi SAA, Riaz IB, Bibi A, Khan MA, Imran M, Khakwani KZR, Raina A, Anjum MU, Cobran EK, Warner JL, Hussain SA, Singh P, Childs DS, Baca SC, Orme JJ, Mateo J, Agarwal N, Gillessen S, Murad MH, Sartor O, Bryce AH. Eur Urol. 2025 Jun;87(6):626-640. IF: 25.2.

First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. Voss MH, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthélémy P, Lee JL, Nalbandian T, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Cornell J, Sharma M, Burgents JE, Albiges L. Eur Urol. 2025 Dec;88(6):614-624. IF: 25.2.

Building the future management of follicular lymphoma with T-cell-redirecting strategies. Iacoboni G,Morschhauser F. Blood. 2025. 145. (2):p. 170-175. Iacoboni G, Morschhauser F. Blood. 2025 Jan 9;145(2):170-175. IF: 23.1.

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3. van Meerten T, Kersten MJ, Iacoboni G, Hess GR, Mutsaers PGNJ, Martin Garcia-Sancho AM, Goy A, Gine E, Hill BT, Weng WK, Reagan PM, Patel K, Galal A, Herbaux C, Sanderson R, Forcade E, Topp MS, Houot R, Zheng D, Zhang W, Kanska J, Shen RR, Damico Khalid R, Kloos I, Dreyling M, Wang ML. Blood. 2025 Oct 29. doi: 10.1182/blood.2025029734. IF: 23.1.

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Falchi L, Sureda A, Leppä S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton KM, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D. Blood. 2025 Nov 27;146(22):2629-2640. IF: 23.1.

New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor-Positive Breast Cancer. Pathak N, Oliveira M. Annu Rev Med. 2025 Jan;76(1):243-255. IF: 22.1.

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A. Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Bernabe Caro R, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, de Miguel MJ, Helissey C, Shu CA, Spira AI, Tomasini P, Yang JC, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. J Thorac Oncol. 2025 May;20(5):651-664. IF: 20.8.

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study.Calles A, Navarro A, Doger de Speville Uribe BG, Colomé EÁ, de Miguel M, Álvarez R, Arregui M, Moreno V, Rocha P, Calvo E, Ramon-Patino J, Corral de la Fuente E, Alcalá-López D, Boix O, Fernández-Pinto M, Rodríguez-Morató J, Palmero R, Nadal E, Jove M, Felip E. J Thorac Oncol. 2025 Jul;20(7):969-982. IF: 20.8.

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study. Krebs MG, Cho BC, Hiret S, Han JY, Lee KH, Pérez CL, De Braud F, Haura EB, Sanborn RE, Chih-Hsin Yang J, Shu CA, Goto K, Nishio M, Zhao J, Wang Z, Tomasini P, Felip E, Goldman JW, Ignatius Ou SH, Boyer M, Gao G, Qu S, Curtin JC, Lyu X, Schnepp RW, Kim P, Thayu M, Knoblauch RE, Lorenzini P, Baig M, Spira AI, Leighl NB. J Thorac Oncol. 2025 Sep;20(9):1289-1301. IF: 20.8.

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report. Riely GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, Esper R, Felip E, Gelsomino F, Goldman JW, Hussein M, Johnson M, Marrone KA, Morgensztern D, Nadal E, Negrao MV, Offin M, Provencio M, Ramalingam SS, Roof L, Sanborn RE, Smit EF, Tsao A, Usari T, Alcasid A, Wilner K, Tonkovyd S, Zhang X, Johnson BE. J Thorac Oncol. 2025 Oct;20(10):1538-1547. IF: 20.8.

First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, Felip E, Cappuzzo F, Garon EB, Neal JW, Mekan S, Safavi F, Fernando N, Zavodovskaya M, Jürgensmeier JM, Chisamore M, Cho BC. J Thorac Oncol. 2025 Oct 30. doi: 10.1016/j.jtho.2025.10.016. IF: 20.8.

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Pérol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I. J Thorac Oncol. 2025 Nov;20(11):1669-1682. IF: 20.8.

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA. Lee SH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Dias JM, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Chih-Hsin Yang J, Besse B, Thomas M, Shah S, Baig M, Curtin JC, Zhang J, Xie J, Sun T, Sethi S, Wang M, Fennema E, Daksh M, Ennis M, Bauml JM, Cho BC. J Thorac Oncol. 2025 Nov;20(11):1655-1668. IF: 20.8.

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. Cho BC, Li W, Spira AI, Sauder M, Feldman J, Bozorgmehr F, Mak M, Smith J, Voon PJ, Liu B, Tian P, Tan JL, Yang CT, Shih JY, Karadurmus N, Cundom JE, Bertollo G, Cicin I, Nieva J, Ortega-Granados AL, Tomasini P, Nguyen D, Felip E, Schuchard J, Murphy SP, Anderson BG, Romero T, Xia Y, Sheng S, Bauml JM, Mahadevia PJ, Kam J, Nematian-Samani M, Simoes J, Wildgust M, Girard N. J Thorac Oncol. 2025 Oct;20(10):1517-1530. IF: 20.8.

Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis. Moreno-Cárdenas AB, Ros J, Gil-Vila A, Datta D, Fasani R, Serna G, Jimenez J, Trallero-Araguás E, Viaplana C, Lostes J, Milisenda JC, Grau-Junyent JM, Lopez-Perez R, Pinal-Fernández I, Nuciforo P, Toledo RA, Selva-O'Callaghan A. Ann Rheum Dis. 2025 Nov 25. doi: 10.1016/j.ard.2025.10.018. IF: 20.6.

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. Audisio A, Gallio C, Velenik V, Meillat H, Ruiz-Garcia E, Riesco MC, Alecha JS, Rasschaert G, Carvalho C, Randrian V, Kirac I, Hernando J, Artaç M, O'Connor JM, Waldhorn I, Braam PM, Shamseddine A, Moretto R, De la Pinta C, De Felice F, Dulskas A, Páez López-Bravo D, Vanden Bulcke A, Bock F, Deleporte A, Van Den Eynde M, Geboes KP, Loi M, Messina M, Houlzé-Laroye C, Puccini A, Pastorino A, Papamichael D, Fiore M, Sur D, Eid M, Antoun C, Salati M, Garajovà I, Jakubauskas M, Tomášek J, Sousa Pinto CM, Schwingel J, Morano F, Adams RA, Dermine A, Chau A, Javed MA, Ghidini M, Fiorica F, Montenegro P, Petrillo A, Spolverato G, Mulet Margalef N, Diaz M, Baratelli C, Puleo F, Karampeazis A, Sert F, Gilliaux Q, De Stefano A, Liberale G, Moretti L, Martinive P, Deltuvaite Thomas V, Staggs V, Saad ED, Van Laethem JL, Sclafani F; International Real-World TNT Study Consortium. JAMA Oncol. 2025 Sep 1;11(9):1045-1054. IF: 20.1.

Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review. Serrano C, Bauer S, Blay JY, Casali PG, Cicala CM, Dei Tos AP, Digklia A, Gelderblom H, Italiano A, Jones RL, Kasper B, Kyriazoglou A, Le Loarer F, Martín-Broto J, Napolitano A, Rutkowski P, Stacchiotti S, Tap W, Thomas D, Thway K, Valverde C, van der Graaf WTA, Wardelmann E, Bovée JVMG. JAMA Oncol. 2025 Dec 1;11(12):1527-1537. IF: 20.1.

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01. Pant S, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Wasan H, Ducreux M, Bao Y, Wu X, Zhao Y, Garfin PM, Gable J, Harding JJ; HERIZON-BTC-01 Study Group. JAMA Oncol. 2025 Nov 20. doi: 10.1001/jamaoncol.2025.4736. IF: 20.1.

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies. Bröckelmann PJ, Cliff ERS, Iacoboni G, Simon F, Horowitz MM, Keating A, Mateos MV, Mohty M, Sidana S, Song Y, Wingard JR, Thanarajasingam G. Lancet Haematol. 2025 Jun;12(6):e470-e481. IF: 17.7.

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial. Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J. Lancet Haematol. 2025 Aug;12(8):e588-e598. IF: 17.7.

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Lancet Haematol. 2025 Aug;12(8):e599-e610. IF: 17.7.

Exposomal determinants of non-genetic plasticity in tumor initiation. Carra D, Maas SCE, Seoane JA, Alonso-Curbelo D. Trends Cancer. 2025 Apr;11(4):295-308. IF: 17.5.

Molecular and clinical insights into early-onset endometrial cancer. Wu Z, Hu Z, Li Q, Liu G, Oaknin A, Grau Bejar JF, Mills GB, Ma D, Sun C, Chen G. Trends Cancer. 2025 Jun;11(6):503-519. IF: 17.5.

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer. Pedretti F, Abdalfttah M, Pellegrino B, Mateo F, Martínez-Sanz P, Herencia-Ropero A, Òdena A, Clavell-Revelles P, Casali G, Domènech H, Monserrat L, Papić D, Mas Malavila A, Pascual-Reguant A, Eixarch H, Guzmán M, Rodríguez O, Grueso J, Simonetti S, Fasani R, Nuciforo P, Espejo C, Florian S, Pujana MÁ, Nonell L, Seoane J, Valge-Archer V, O'Connor MJ, Nieto JC, Heyn H, Balmaña J, Llop-Guevara A, Serra V. Cancer Res. 2025 May 15;85(10):1888-1908. IF: 16.6.

The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer. Kittane S, Ladewig E, Li T, Love JR, Blawski R, Gao Y, Arruabarrena-Aristorena A, Zhao P, Dalrymple SL, Liu H, Guo X, Sallaku M, Kelkar N, Garcia-Martinez L, Carmona Sanz J, Chen W, Stoudmann C, Baldino L, Razavi-Mohseni M, Kalemi I, Beer MA, Castel P, Brennen WN, Scaltriti M, Morey L, Cocco E, Ji H, Chan HM, Battle A, Leslie CS, Karthaus WR, Toska E. Cancer Res. 2025 Dec 11. doi: 10.1158/0008-5472.CAN-25-2053. IF: 16.6.

TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy. Eskander R, Lee JY, Mirza M, Lorusso D, Mackay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr B, Wu X, Leary A, Hu T, Dutta L, Okpara C, McKenzie J, Makker V. J Natl Compr Canc Netw. 2025 Mar 28;23(3.5):TIP25-243. IF: 16.4.

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial. Gounder M, Johnson M, Heist RS, Shapiro GI, Postel-Vinay S, Wilson FH, Garralda E, Wulf G, Almon C, Nabhan S, Aguado-Fraile E, He P, Romagnoli M, Hossain M, Narayanaswamy R, Sadou-Dubourgnoux A, Cooper M, Askoxylakis V, Burris HA, Tabernero J. Nat Commun. 2025 Jan 6;16(1):423. IF: 15.7.

Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane. Hastie KM, Salie ZL, Ke Z, Halfmann PJ, DeWald LE, McArdle S, Grinyó A, Davidson E, Schendel SL, Hariharan C, Norris MJ, Yu X, Chennareddy C, Xiong X, Heinrich M, Holbrook MR, Doranz B, Crozier I, Kawaoka Y, Branco LM, Kuhn JH, Briggs JAG, Worwa G, Davis CW, Ahmed R, Saphire EO. Nat Commun. 2025 Feb 3;16(1):1293. IF: 15.7.

Unlocking the potential of engineered immune cell therapy for solid tumors. Albarrán-Fernández V, Angelats L, Delgado J, Gros A, Urbano-Ispizua Á, Guedan S, Prat A. Nat Commun. 2025 Jan 29;16(1):1144. IF: 15.7.

The impact of a high fat diet and platelet activation on pre-metastatic niche formation. Hergueta-Redondo M, Sánchez-Redondo S, Hurtado B, Santos V, Pérez-Martínez M, Ximénez-Embún P, McDowell SAC, Mazariegos MS, Mata G, Torres-Ruiz R, Rodríguez-Perales S, Martínez L, Graña-Castro O, Megias D, Quail D, Quintela-Fandino M, Peinado H. Nat Commun. 2025 Apr 2;16(1):2897. IF: 15.7.

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Nat Commun. 2025 Aug 19;16(1):7717. IF: 15.7.

EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma. Hernández-Muñoz I, Cuervas I, Prada E, Pulecio J, Gimeno R, Andrades E, Gómez-González S, Berenguer-Molins P, Acedo-Terrades A, Perera-Bel J, Bódalo-Torruella M, Nonell L, Pérez E, Grases D, Mata C, Yélamos J, Richaud-Patin Y, Vidal E, Cuartero Y, Le Dily F, Suñol M, Manzanares A, Raya A, Mora J. Nat Commun. 2025 Oct 24;16(1):9427. IF: 15.7.

HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy. Nozawa K, Sawaki M, Uemura Y, Tsuneizumi M, Takano T, Gondo N, Hara F, Harao M, Toyama T, Taira N, Vivancos A, Perou CM, Sanfeliu E, Brasó-Maristany F, Parker JS, Buckingham W, Paré L, Villacampa G, Marín-Aguilera M, Villagrasa P, Prat A, Iwata H. Nat Commun. 2025 Nov 4;16(1):9585. IF: 15.7.

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial. Serra-Aracil X, Pericay C, Cidoncha A, Badia-Closa J, Golda T, Kreisler E, Hernández P, Targarona E, Borda-Arrizabalaga N, Reina A, Delgado S, Espín-Bassany E, Caro-Tarrago A, Gallego-Plazas J, Pascual M, Álvarez-Laso C, Guadalajara-Labajo H, Otero A, Biondo S; TAUTEM Collaborative Group. JAMA Surg. 2025 Jul 1;160(7):783-793. IF: 14.9.

Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy. de Mestier L, Halfdanarson TR, Apostolidis L, Koumarianou A, Hernando J, Riechelmann R, Bergsland EK, Cingarlini S, Shaheen S, Crona J, Kreutzfeldt S, Mosalem O, Al-Toubah T, Cros J, Strosberg JR. Endocr Pathol. 2025 Nov 3;36(1):42. IF: 14.7.

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL. Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland JB, Brieghel C, Andersen MK, Karypidou M, Biderman B, Doubek M, Lazarian G, Rapado I, Vynck M, Porret NA, Andres M, Rosenberg D, Sahar D, Martínez-Laperche C, Buño I, Hindley A, Donaldson D, Sánchez JB, García-Marco JA, Serrano-Alcalá A, Ferrer-Lores B, Fernández-Rodriguez C, Bellosillo B, Stilgenbauer S, Tausch E, Nikdin H, Quinn F, Atkinson E, van de Corput L, Yildiz C, Bilbao-Sieyro C, Florido Y, Thiede C, Schuster C, Stoj A, Czekalska S, Chatzidimitriou A, Laidou S, Bidet A, Dussiau C, Nollet F, Piras G, Monne M, Smirnova S, Nikitin E, Sloma I, Claudel A, Largeaud L, Ysebaert L, Valk PJM, Christian A, Walewska R, Oscier D, Sebastião M, da Silva MG, Galieni P, Angelini M, Rossi D, Spina V, Matos S, Martins V, Stokłosa T, Pepek M, Baliakas P, Andreu R, Luna I, Kahre T, Murumets Ü, Pikousova T, Kurucova T, Laird S, Ward D, Alcoceba M, Balanzategui A, Scarfo L, Gandini F, Zapparoli E, Blanco A, Abrisqueta P, Rodríguez-Vicente AE, Benito R, Bravetti C, Davi F, Gameiro P, Martinez-Lopez J, Tazón-Vega B, Baran-Marszak F, Davis Z, Catherwood M, Sudarikov A, Rosenquist R, Niemann CU, Stamatopoulos K, Ghia P, Pospisilova S. Hemasphere. 2025 Jan 20;9(1):e70065. IF: 14.6.

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. Bastos-Oreiro M, Iacoboni G, Garcés VN, Caballero AC, Martínez N, Delgado J, Balaguer A, Kwon M, Gonzalez de Villambrosia S, Hernani R, Jimenez-Ubieto A, Bailen R, Zaberio I, Martín García-Sancho A, Barba P. Hemasphere. 2025 Feb 4;9(2):e70077. IF: 14.6.

Caplacizumab treatment in elderly patients with iTTP: Experience from the Spanish TTP Registry. Gómez-Seguí I, Cid J, Lozano M, Mingot-Castellano ME, Pascual-Izquierdo C, Gonzalez Del Castillo LM, Vidan Estevez JM, Garcia-Candel F, Jiménez Balarezo M, Valcarcel D, Cuellar Perez-Avila C, Arraiz Ramirez M, Lakhwani S, Moreno Jimenez MG, Oliva Hernandez AY, Garcia Gala JM, Martinez Nieto J, Goterris R, Fernández Docampo M, Sopeña Pell-Ilderton C, de la Rubia J. Hemasphere. 2025 Apr 16;9(4):e70109. IF: 14.6.

High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy. Manubens A, Paiva B, Gutiérrez NC, Fernandez M, Calasanz MJ, Rosiñol L, Oriol A, Blanchard MJ, Carrillo E, Benavente C, Martínez-López J, Bargay J, Hernández MT, de la Rubia J, González Y, Paricio M, de Arriba F, Ocio EM, Teruel AI, de la Guia AL, Sirvent M, Gironella M, Sampol A, Arguiñano JM, Cabrera C, Alegre A, Granell M, Cabañas V, Núñez-Córdoba JM, Mateos MV, Lahuerta JJ, San Miguel JF, Bladé J, Rodriguez-Otero P. Hemasphere. 2025 Apr 24;9(4):e70127. IF: 14.6.

Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials. González-Gil C, Lopes T, Morgades M, Fuster-Tormo F, Montesinos P, Medina CR, Hermosín L, González-Martínez T, Queipo MP, González-Campos J, Martínez-Sánchez P, Díaz-Beya M, Coll R, Maluquer C, Zamora L, Artola T, Vall-Llovera F, Tormo M, Torrent A, Martínez-Laperche C, Gil-Cortés C, Barba P, Cervera M, Ribera J, Fernández-Delgado M, Ayala R, Cladera A, Mateos MC, Vidal MJ, Feliu J, Torres A, Azaceta G, Calasanz MJ, Bigas A, Esteller M, Orfao A, Ribera JM, Genescà E. Hemasphere. 2025 May 26;9(5):e70148. IF: 14.6.

Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies. Vaghi C, Tosi F, Mauri G, Bonazzina E, Amatu A, Bencardino K, Piscazzi D, Roazzi L, Villa F, Maggi M, Monti L, Bombelli A, Marrapese G, Ghezzi S, Patelli G, Ros J, Elez E, Sartore-Bianchi A, Siena S. Drugs. 2025 Nov 17. doi: 10.1007/s40265-025-02253-2. IF: 14.4.

USP10/GSK3ß-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer. Kumari N, Wright SC, Witham CM, Monserrat L, Palafox M, Richard JL, Costa C, Elkabets M, Agostino M, Klemm T, Eccles M, Garnham A, Wu T, Nilsson JA, Walz N, Venugopal V, Cerra A, Vasilevski N, Bridgeman S, Bassi S, Saei A, Helal M, Neundorf P, Riedel A, Rosenfeldt M, Gill J, Pahor N, Hartmann O, Chung J, Sidhu SS, Moderau N, Jha S, Rodon J, Diefenbacher ME, Komander D, Serra V, Eichhorn PJA. J Clin Invest. 2025 Sep 23;135(22):e180927. IF: 13.6.

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer. Schab A, Compadre A, Drexler R, Loeb M, Rodriguez K, Brill J, Harrington S, Sandoval C, Sanders B, Kuroki L, McCourt C, Hagemann AR, Thaker P, Mutch D, Powell M, Serra V, Hagemann IS, Walts AE, Karlan BY, Orsulic S, Fuh KC, Sun L, Verma P, Lomonosova E, Zhao P, Khabele D, Mullen MM. J Clin Invest. 2025 May 20;135(13):e189511. IF: 13.6.

Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer. Palomeque JÁ, Serra-Mir G, Blasco-Benito S, Brunel H, Torren-Duran P, Pérez-Núñez I, Cannatá C, Comerma L, Menendez S, Servitja S, Martos T, Castro M, Borges RL, López-Velazco JI, Manzano S, Duro-Sánchez S, Arribas J, Caffarel MM, Urruticoechea A, Seoane JA, Morey L, Albanell J, Celià-Terrassa T. J Clin Invest. 2025 Nov 25;136(2):e193153. IF: 13.6.

Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults. Galán-Gómez V, González-Martínez B, Alonso-Saladrigues A, Rives S, Herrero B, Kwon M, Sánchez-Pina J, Minguillón J, Martínez-Romera I, Mirones Aguilar I, Mestre-Durán C, Casado G, Sánchez-Martín M, Echecopar C, González-Pérez C, León-Triana O, Aguirre-Portolés C, Molinos-Quintana Á, Barba P, Balsalobre P, Pérez-Martínez A. Exp Hematol Oncol. 2025 Apr 2;14(1):49. IF: 13.5.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study. Zugasti I, Lopez-Guerra M, Castaño-Díez S, Esteban D, Avendaño A, Pomares H, Perez A, García-Ávila S, Conejo IP, de la Fuente Montes C, Martínez-Roca A, Merchán B, Jiménez-Vicente C, Guijarro F, Álamo JR, Cortes-Bullich A, Torrecillas V, Mont L, Carcelero E, Riu G, Zamora L, Bargay J, Triguero A, Suarez-Lledó M, Salas MQ, López-Cadenas F, Ramos F, Xicoy B, Valcárcel D, Arnan M, Martínez C, Rovira M, Fernández-Avilés F, Díez-Campelo M, Esteve J, Díaz-Beyá M. Exp Hematol Oncol. 2025 Apr 26;14(1):61. IF: 13.5.

Multiple phenotypes and epigenetic profiles in a three-generation family history with GATA2 deficiency. Romero-Moya D, Pera J, Marin-Bejar O, Torralba-Sales E, Murillo-Sanjuán L, Diaz-de-Heredia C, Montoro J, Rodríguez-Ubreva J, Liquori A, Cervera J, Wlodarski MW, Català A, Giorgetti A. Leukemia. 2025 Apr;39(4):962-966. IF: 13.4.

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy. Iacoboni G, Rejeski K, Navarro V, van Meerten T, Rampotas A, Martín-López AÁ, Bastos M, Benzaquén A, Reguera-Ortega JL, Carpio C, Roddie C, López-Corral L, Delgado-Serrano J, Landwehr M, Stock S, Silva de Tena P, Abrisqueta P, de Boer J, Martin Garcia-Sancho A, Hernani R, Kwon M, Subklewe M, O'Reilly M, Barba P. Leukemia. 2025 May;39(5):1196-1205. IF: 13.4.

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker. Thorvaldsdottir B, Mansouri L, Sutton LA, Nadeu F, Meggendorfer M, Parker H, Brieghel C, Laidou S, Moia R, Rossi D, Kotaskova J, Delgado J, Rodríguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfò L, Mattsson M, Davis Z, Baliakas P, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Hernández Rivas JM, Larráyoz MJ, Calasanz MJ, Smedby KE, Espinet B, Puiggros A, Bullinger L, Bosch F, Tazón-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hernández-Sánchez M, Pospisilova S, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R. Leukemia. 2025 Jul;39(7):1650-1660. IF: 13.4.

Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes. Novoa-Jáuregui S, Huber S, Gabarrós-Subirà M, Chen-Liang TH, Torres-Esquius S, Carrillo-Tornel S, Santiago M, Bernal Del Castillo T, Martín-Castillo I, Hernandez FM, Del Rey M, Liquori A, Tormo M, Cervera J, Bosch F, Valcárcel D, Haferlach C, Díez-Campelo M, Montoro MJ, Haferlach T, Jerez A. Leukemia. 2025 Jul;39(7):1791-1794. IF: 13.4.

Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study. Visentin A, Gaffo E, Fürstenau M, Rogers KA, Panagiotis B, Cui C, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen-Khac F, Roncaglia E, Rigolin GM, Athanasiadou A, Baran-Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, Scarfò L, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Calabretto G, Ruocco V, Orsi S, Cellini A, Angotzi F, Serafin A, Yi S, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Bortoluzzi S. Leukemia. 2025 Dec;39(12):2957-2967. IF: 13.4.

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study. Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, López-Esteban M, Martínez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S. Leukemia. 2025 Dec 3. doi: 10.1038/s41375-025-02814-0. IF: 13.4.

Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium. Bettegowda C, Noushmehr H, Affinito A, Ahluwalia MS, Ansorge O, Ayasoufi K, Bagley S, Barnholtz-Sloan J, Best M, Brandsma D, Brodie C, Brüning-Richardson A, Castro AV, Chang SM, Condorelli G, Daher A, Datta V, de Groot J, French P, Galanis E, Golebiewska A, Hamerlik P, Hanemann CO, Holdhoff M, Huse J, Khasraw M, LeBlang S, Melin B, Mouliere F, O'Leary C, Rak J, Ray A, Robinson S, Rominiyi O, Roncaroli F, Rudà R, Seoane J, Sol N, van den Bent MJ, Vogelbaum MA, Walbert T, Watts C, Weiss T, Weller M, Wen PY, Wykes V, Yip S, Short SC, Soffietti R. Neuro Oncol. 2025 Oct 1;27(10):2496-2513. IF: 13.4.

New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe. Rimassa L, Lamarca A, O'Kane GM, Edeline J, McNamara MG, Vogel A, Fassan M, Forner A, Kendall T, Adeva J, Casadei-Gardini A, Fornaro L, Hollebecque A, Lowery MA, Macarulla T, Malka D, Mariamidze E, Niger M, Ustav A, Bridgewater J, Macias RIR, Braconi C. Lancet Reg Health Eur. 2025 Feb 19;50:101170. IF: 13.0.

Biliary tract cancers: addressing healthcare disparities and improving access to innovative treatments in Europe. Turpin A, Tian TV, Boilève A, Neuzillet C. Lancet Reg Health Eur. 2025 Feb 19;50:101215. IF: 13.0.

Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. Uyar GC, Mirallas O, Başkurt K, Martin-Cullell B, Yeşilbaş E, Recuero-Borau J, Kaya S, Garcés VN, Yücel SE, Vega Cano KS, Gómez-Puerto D, Gómez AP, Salva de Torres C, Çakmak Öksüzoğlu ÖB, Serradell S, Dienstmann R, Sütcüoğlu O. Lancet Reg Health Eur. 2025 May 8;54:101317. IF: 13.0.

Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. Oyon D, Lopez-Pascual A, Castello-Uribe B, Uriarte I, Orsi G, Llorente S, Elurbide J, Adan-Villaescusa E, Valbuena-Goiricelaya E, Irigaray-Miramon A, Latasa MU, Martinez-Perez LA, Bonetti LR, Prosper F, Ponz-Sarvise M, Vicent S, Pineda-Lucena A, Ruiz-Clavijo D, Sangro B, Larracoechea UA, Tian TV, Casadei-Gardini A, Amat I, Arechederra M, Berasain C, Urman JM, Avila MA, Fernandez-Barrena MG. J Exp Clin Cancer Res. 2025 Jan 15;44(1):13. IF: 12.8.

Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS). Pantel K, Alix-Panabières C, Hofman P, Stoecklein NH, Lu YJ, Lianidou E, Giacomini P, Koch C, de Jager V, Deans ZC, Fairley J, Patton SJ, Toledo RA, Schuuring E, Heitzer E, Hendrix A, Ricklefs FL, Thakur BK, von Bubnoff N, Pierga JY, Gebhardt C, Andersen CL, Fijneman R, Malats N, Hallermayr A, Chelala C, Joosse SA, Ciliberto G. J Exp Clin Cancer Res. 2025 May 23;44(1):156. IF: 12.8.

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma. Tix T, Alhomoud M, Shouval R, Iacoboni G, Cliff ERS, Hansen DK, Usmani SZ, Salles G, Perales MA, Cordas Dos Santos DM, Rejeski K. Mol Ther. 2025 Jul 2;33(7):3163-3176. IF: 12.0.

Metabolic dysfunction-associated steatohepatitis reduces hepatic H(2)S-producing enzymes altering persulfidome composition. Shen TK, Vignane T, Gilglioni EH, Traini L, Kalaitsidou E, Conan P, Li A, St-Pierre-Wijckmans W, Herranz JM, Elvira B, Otero Sanchez L, Trépo E, Deelman L, Wu W, Filipovic MR, Messens J, Ezeriņa D, Gurzov EN. Redox Biol. 2025 Oct;86:103809. IF: 11.9.

Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of =2 years. Ruiz ES, Muñoz-Couselo E, Montaudié H, Berciano-Guerrero MA, de la Gala MDCÁ, Charles J, Quéreux G, Nardin C, Tur RY, Dalle S, Beylot-Barry M, Ladwa R, McGrath M, Brungs D, Harris D, Shue H, Tazbirkova A, Fourie S, Malan DR, Oliviero J, Wilcoxen LN, Gray WG, Clingan P. Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years. J Am Acad Dermatol. 2025 Sep 29. doi: 10.1016/j.jaad.2025.09.009. IF: 11.8.

SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer. Voronova AK, Grigoriou A, Bernatowicz K, Simonetti S, Serna G, Roson N, Escobar M, Vieito M, Nuciforo P, Toledo R, Garralda E, Fieremans E, Novikov DS, Palombo M, Perez-Lopez R, Grussu F. Med Image Anal. 2025 May;102:103531. IF: 11.8.

MYC-driven gliosis impairs neuron-glia communication in amyotrophic lateral sclerosis. Fioretti PV, Barbieri A, Migazzi A, Bressan D, Grassano M, Donini L, Roccuzzo M, Torrieri MC, Conci F, Ferracci E, Invernizzi S, Bowden KM, Bacchetti F, Cappelli S, Peroni D, Belli R, Pancher M, Mugoni V, Scarduelli G, Gianesello M, Pasetto L, Canarutto G, Carra S, Soldano A, Bisio A, Robbiati S, Valentini C, Nardella C, Piazza S, D'Agostino VG, Quattrone A, Sleiman S, Whitfield JR, Soucek L, Vignoli B, Viero G, Tiberi L, Zippo A, Demichelis F, Bonetto V, Milanese M, Buratti E, Verde F, Ticozzi N, Calvo A, Ratti A, Shaw PJ, Terenzio M, Chiacchiera F, Pennuto M, Basso M. Brain. 2025 Sep 26:awaf360. doi: 10.1093/brain/awaf360. IF: 11.7.

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz-Beya M, Vives S, Zamora L, Sampol A, Coll R, Salamero O, Cervera M, Garcia A, Vall-Llovera F, Garcia-Avila S, Bargay J, Ortin X, Iranzo E, Guijarro F, Pratcorona M, Nomdedeu JF, Esteve J, Sierra J. Blood Cancer J. 2025 Jan 11;15(1):4. IF: 11.6.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study. Pérez-Lamas L, Segura Diaz A, García Delgado R, Álvarez-Larrán A, Senin MA, Mora E, Fox ML, Pastor Galan I, Azaceta G, Garrido Paniagua S, Pérez Lopez R, Trejos Carvajal DM, Angona A, Albo López C, Lorente Alegre P, Vara M, Vera Goñi JA, De Miguel Llorente D, Fernández Rodríguez Á, Marín Sanchez A, Hernando Megido A, Gómez Casares MT, Stuckey R, Carreño-Tarragona G, De Las Heras Rodriguez N, Xicoy B, Pérez Encinas M, Mata Serna R, Núñez Martin-Buitrago L, Ferrer Marín F, Amer Salas N, Guillén Rienda C, Velez P, Lamarca Eraso L, Martín S, Luts Khoroz I, De Cabo López E, Gil A, Martín-Consuegra Ramos S, Marco De Lucas F, Otero Martinez-Fornes MJ, Martín Mateos ML, Arquero T, Cabezudo Pérez E, López Gómez LA, Martínez Hellin Á, Tejedor A, Herrera de Pablo E, Mata Vazquez MI, Castillo Valero I, Fernández MJ, Aguilar C, Santaliestra M, García Menchon A, Navas Elorza B, Duran MA, Pérez Sala M, Hernández Santamaría T, Muñoz Jarreño MÁ, Dávila-Valls J, Torres Jiménez W, Gonzálvez Fernández JA, Torres Mantilla HA, Cobo Rodríguez T, Abuin Blanco A, Pérez F, Osorio Prendes S, Beneit Villena P, Peralta R, Herrera F, Cañamero Giro E, Jiménez Bárcenas R, Gasior Kabat M, González De Villambrosia S, Tercero-Mora Rodriguez MT, Menéndez Cuevas M, Cuevas Ruiz B, Fonseca-Santos M, Garcés Piquer S, De La Puerta R, Lorenzo Vizcaya Á, Hernández Boluda JC, García Gutiérrez V. Blood Cancer J. 2025 Apr 17;15(1):67. IF: 11.6.

The SOX11:SMARCA4 complex is a driver of oncogenic transcriptional programs in mantle cell lymphoma. De Bolòs A, Carreras-Caballé M, Sureda-Gómez M, Rodríguez ML, Charalampopoulou S, Albero R, Maiques-Diaz A, Playa-Albinyana H, Clot G, López C, Colomer D, Martin-Subero JI, Campo E, Reverter D, Villanueva J, Amador V. Blood Cancer J. 2025 Jul 30;15(1):127. IF: 11.6.

Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma. Winkelmann M, Raj SS, Jain MD, Iacoboni G, Müller F, Hansmann L, Corona M, Luna A, Jhaveri K, Shah GL, Scordo M, Mohammad T, Dean EA, Sheikh GT, Kunz WG, Tix T, Bücklein VL, Bedmutha A, Leithner D, von Bergwelt-Baildon M, Boardman AP, Palomba ML, Park JH, Salles G, Perales MA, Schöder H, Subklewe M, Barba P, Locke FL, Shouval R, Rejeski K. Blood Cancer J. 2025 Aug 26;15(1):144. IF: 11.6.

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop. de Jager VD, Giacomini P, Fairley JA, Toledo RA, Patton SJ, Joosse SA, Koch C, Deans ZC; ELBS ctDNA Workshop Group; Pantel K, Heitzer E, Schuuring E. EBioMedicine. 2025 Apr;114:105636. IF: 10.8.

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J. Cell Rep Med. 2025 Feb 18;6(2):101937. IF: 10.6.

Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Champiat S, Garralda E, Galvao V, Cassier PA, Gomez-Roca C, Korakis I, Grell P, Naing A, LoRusso P, Mikyskova R, Podzimkova N, Reinis M, Ouali K, Schoenenberger A, Kiemle-Kallee J, Tillmanns S, Sachse R, Moebius U, Spisek R, Bechard D, Jelinkova LP, Adkins I, Marabelle A. Cell Rep Med. 2025 Feb 18;6(2):101967. IF: 10.6.

A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer. Balaguer-Montero M, Marcos Morales A, Ligero M, Zatse C, Leiva D, Atlagich LM, Staikoglou N, Viaplana C, Monreal C, Mateo J, Hernando J, García-Álvarez A, Salvà F, Capdevila J, Elez E, Dienstmann R, Garralda E, Perez-Lopez R. Cell Rep Med. 2025 Apr 15;6(4):102032. IF: 10.6.

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. Xu Y, Yang JC, Zhao Y, Doucet L, Zhou J, Wang Y, Planchard D, Fan Y, Jin B, Han Z, Greillier L, Mazieres J, Sun M, Hu Y, Song X, Ding C, Wu L, Tang K, Liang L, Yao Y, Cheng Y, He Y, Ferreira BP, Ghiringhelli F, Felip E, Bosch-Barrera J, Liu A, Yu Y, Dong X, Gao J, Camidge DR, Nian W, Zhou C, Yang R, John T, Gao B, Bazhenova L, Nagasaka M, Wang J, Ren X, Xu F, Li W, Zhao D, Wang H, Sun S, Huang J, Zhu X, Zheng L, Jänne PA, Wang M. Cell Rep Med. 2025 May 20;6(5):102121. IF: 10.6.

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Van Laethem JL, Geboes K, Borbath I, Macarulla Mercade T, Lambert A, Cassier P, Prenen H, Mitry E, Blanc JF, Pilla L, Feliu J, Rodriguez Garrote M, Pazo-Cid RA, Gallego I, Smith KE, Nordbladh K, Jimenez DG, Ellmark P, Pico de Coaña Y, Ambarkhane SV, Beatty GL, O'Reilly EM. Cell Rep Med. 2025 Oct 21;6(10):102407. IF: 10.6.

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction. Bernatowicz K, Amat R, Prior O, Frigola J, Ligero M, Grussu F, Zatse C, Serna G, Nuciforo P, Toledo R, Escobar M, Garralda E, Felip E, Perez-Lopez R. J Immunother Cancer. 2025 Jan 11;13(1):e009140. IF: 10.6.

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Eigentler T, Thomas I, Samoylenko I, Erdmann M, Heinzerling L, Ochsenreither S, Krauss J, Oberoi A, Robert C, Lebbe C, Martin-Liberal J, Koch L, Richtig E, Terheyden P, Weishaupt C, Mohr P, Semiletova Y, Perez CL, Brossart P, Bauernfeind FG, Fluck M, Poltoratskiy A, Sekacheva M, Soria A, Schmitt-Bormann B, Gonzalez M, Heß J, Wengenmayer P, Seibel T, Koch SD, Quintini G, Codó P, Falk M, Schönborn-Kellenberger O, Gnad-Vogt U. J Immunother Cancer. 2025 Feb 4;13(2):e009352. IF: 10.6.

Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors. Taieb J, Ambrosini M, Alouani E, Lonardi S, Sinicrope FA, Decraecker M, Boileve A, Hafliger E, Mazard T, Pernot S, Parent P, Ros J, Overman MJ, Jayachandran P, Nasca V, Salvatore L, Guimbaud R, Cremolini C, Tougeron D, Pietrantonio F. J Immunother Cancer. 2025 Jan 4;13(1):e010424. IF: 10.6.

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors. Nasca V, Zhao J, Ros J, Lonardi S, Zwart K, Cohen R, Fakih M, Jayachandran P, Roodhart JML, Derksen J, Intini R, Bergamo F, Mazzoli G, Ghelardi F, Ligero M, Jonnagaddala J, Hawkins N, Ward RL, Wankhede D, Brenner H, Hoffmeister M, Vitellaro M, Salvatore L, Gallois C, Laurent-Puig P, Cremolini C, Overman MJ, Taieb J, Tougeron D, Andre T, Kather JN, Sundar R, Carmona J, Elez E, Koopman M, Pietrantonio F. J Immunother Cancer. 2025 Feb 10;13(2):e010598. IF: 10.6.

First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Maio M, Moreno V, Martin-Liberal J, Opdam F, Hansen A, Bauer TM, Le Tourneau C, Italiano A, Rischin D, Ellis C, Turner D, Yadavilli S, Zhou H, Hirschfeld S, Ballas M, Diaz-Padilla I, Angevin E. J Immunother Cancer. 2025 Aug 11;13(8):e011475. IF: 10.6.

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study. Ghiringhelli F, Lawrence YR, Felip E, Zer A, Greillier L, Greystoke A, Pardo N, Al-Sakaff N, Helms HJ, Prizant H, Pintoffl J, Lim FL, Lim SM, Cho BC. J Immunother Cancer. 2025 Aug 4;13(8):e011892. IF: 10.6.

Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer. Yu H, Magoulopoulou A, Amini RM, Chatzinikolaou MP, Horie M, Lindberg A, Mezheyeuski A, Backman M, Metousis A, Brunnström H, Marincevic M, Botling J, Mattsson JSM, Kärre K, Leandersson K, Nilsson M, Strell C, Micke P. J Immunother Cancer. 2025 Aug 27;13(8):e012089. IF: 10.6.

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response. Navarro-Garcia D, Grussu F, Zatse C, Klümper N, Macarro C, Hernando-Calvo A, Sanz M, Vieito M, Braña I, Mirallas O, Alonso G, Galvao V, Pretelli G, Lostes J, Oberoi A, Toledo R, Nuciforo P, Garralda E, Perez-Lopez R. J Immunother Cancer. 2025 Dec 21;13(12):e012143. IF: 10.6.

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer. Even C, Harrington KJ, Massarelli E, Laban S, Fayette J, Oliva M, Klein Hesselink M, Visscher S, Fury MG, Wiekmeijer AS, Licitra L, Melichar B, Devriese LA, Braña I, Jankowska P, Posner M, Glisson B, Kong A, Hooftman L, Melief CJM MD, Ferrarotto R. J Immunother Cancer. 2025 Sep 8;13(9):e012555. IF: 10.6.

Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis. Jimenez-Labaig P, Mirallas O, Martin-Quesada AI, Rullan A, Trapani D, Amaral T, Felip E, Tabernero J, Harrington KJ. J Immunother Cancer. 2025 Nov 28;13(11):e013072. IF: 10.6.

The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee. Coukos G, Donia M, Gastman BR, Goff SL, Gros A, Harari A, Hernandez S, Ito F, Maker AV, Mullinax JE, Murthy P, Pai SI, Prabhakaran S, Restifo NP, Silver NL, Marincola Smith P, Turcotte S, Wagner PL, Yang JC, Lotze MT. J Immunother Cancer. 2025 Nov 29;13(11):e013420. IF: 10.6.

EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases. Bregni G, Adams R, Bale R, Bali MA, Bargellini I, Blomqvist L, Brown G, Cremolini C, Demetter P, Denecke T, Dohan A, Dopazo C, Elez E, Evrard S, Feakins R, Guckenberger M, Guren MG, Hawkins M, Hoorens A, Huguet E, Intven M, Koessler T, Kunz WG, Lordick F, Lucidi V, Mahnken AH, Malik H, Martinive P, Mauer M, Romero AM, Nagtegaal I, Orsi F, Oyen WJ, Pellerin O, Rengo M, Ricke J, Ricoeur A, Riddell A, Ronot M, Scorsetti M, Seligmann J, Sempoux C, Sheahan K, Stättner S, Svrcek M, Taieb J, West N, Wyrwicz L, Zech CJ, Moehler M, Sclafani F. Cancer Treat Rev. 2025 May;136:102926. IF: 10.5.

Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy. Zhao X, Hao Q, Alsina M, Acosta D, Castet F, Terán E, Cano KV, Saurí T, Macías I, Yoshikawa T, Castro S, Shoji H, Lordick F, Shen Z, Tian TV, Macarulla T. Cancer Treat Rev. 2025 Dec;141:103041. IF: 10.5.

Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis. Escudero A, Bellet M, Saura C, Aguilera A, Papakonstantinou A, Tolosa P, García-Sáenz JÁ, Moreno F, López de Sá A, Schettini F, Seguí E, Gonzalez-Rodriguez M, Navarro V, Ferrero-Cafiero JM, González X, Hernando C, Matikas A, Prat A, Oliveira M, Pascual T, Villacampa G. Cancer Treat Rev. 2025 Dec 3. doi:10.1016/j.ctrv.2025.103063. IF: 10.5.

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study. Fiallo-Suárez DV, Stuckey R, Bilbao-Sieyro C, Tapia Torres M, Pérez-Ortíz L, Fernández F, Borsani O, Rumi E, Ianotto JC, Lekovic D, Ferrer-Marín F, Cuevas B, Kanduła Z, Gasior M, Álvarez-Larrán A, Lewandowski K, Senin A, Drozd-Sokołowska J, Sobas MA, Santoro M, Foncillas MA, Hernández-Boluda JC, Angona A, Carreño Gomez-Tarragona G, Mata-Vázquez MI, Fox ML, Del Orbe R, Vélez Tenza P, Vallansot R, Lemes-Castellano A, Gómez-Casares MT; Polish Acute Leukemia Group (PALG) and MPN Spanish Group (GEMFIN). Am J Hematol. 2025 Oct 17. doi: 10.1002/ajh.70105. IF: 10.3.

Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial. Röth A, Barcellini W, Ademokun C, Jang J, Lozano ML, Ferreiras DV, Pascual-Izquierdo C, Chitnis S, Matviykiv S, Vitaliti A, Chen C, Katsanou V, Chawla R, Al-Samkari H. Am J Hematol. 2025 Dec 9. doi: 10.1002/ajh.70147. IF: 10.3.

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Muñoz-Couselo E, Burris HA 3rd, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. Clin Cancer Res. 2025 Jun 3;31(11):2097-2107. IF: 10.2.

Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01). Biagioni C, Fimereli D, Irrthum A, Guerrero-Zotano A, Piccart M, Cameron D, Caballero C, Raimbault A, Martins-Branco D, Romagnoli D, Agostinetto E, Venet D, Llinas-Bertran A, Seoane JA, Zoppoli G, Vivancos A, Vingiani A, Oliveira M, Curigliano G, Crestani T, Sotiriou C, Nili Gal-Yam E, Hilbers FS, Aftimos P, Benelli M. Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01). Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-2707. IF: 10.2.

Addition of ipatasertib to dual anti-HER2 maintenance therapy in HER2-positive metastatic breast tumors with PIK3CA mutations: the phase 1b SOLTI-1507 IPATHER trial. Oliveira M, Ciruelos E, Villacampa G, Morales S, Salvador Bofill J, Quiroga V, Gavilá J, Cortegoso A, Vega E, Henao F, Servitja S, Tolosa P, Chillara S, Bergamino M, Salvador F, Paes Dias M, Ferrero-Cafiero JM, Gonzalez Farre X, Pascual T, Saura C. Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-229. IF: 10.2.

Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer. Sanfeliu E, Martínez-Romero A, Marín-Aguilera M, Cobo S, González-Farré B, Hernandez-Illan E, Jares P, Puig-Butillé JA, Muñoz M, Gómez-Bravo R, Tapia M, Tebar C, Saura C, Escrivà-de-Romaní S, Soberino J, Cortés J, Morales S, Amillano K, Paré L, Villagrasa P, Buckingham W, Pardo F, Parker JS, Brasó-Maristany F, Ciruelos E, Sánchez-Bayona R, Martinez-Sáez O, Cejalvo JM, Prat A. Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-3123. IF: 10.2.

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL). Hodson DJ, Shouse G, Shin HJ, Salar A, Bobillo S, Ribrag V, Macpherson NA, Cordoba R, Kim JS, Guidez S, Herrera AF, Morschhauser F, Colton D, Izuzquiza M, Sambamurthy N, Munugalavadla V, Vicente S, Gorgun G, Chen R, Younes A, Wang ML. Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-2239. IF: 10.2.

Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma. Pant S, Park JO, Su WC, Loriot Y, Carranza O, Corassa M, Doi T, Qin S, Tabernero J, Prenen H, Folprecht G, Winter H, Dal Molin GZ, Shen L, Qian J, Liao H, Thomas S, Sweiti H, Triantos S, Feng YH. Clin Cancer Res. 2025 Dec 29. doi: 10.1158/1078-0432.CCR-25-2264. IF: 10.2.

MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response. Wan J, Saatcioglu HD, Ellis H, Aguado-Fraile E, Xu Q, Kondo H, Manguso RT, Gritti I, Norden BL, Noble C, Corcoran RB, Lubner SJ, Javle M, Abou-Alfa GK, Cleary JM, Kelley RK, Borad MJ, Macarulla T, Oh DY, Daigle S, Gliser C, Pandya S, Choe S, Tron AE, Bardeesy N. Clin Cancer Res. 2025 Dec 29. doi: 10.1158/1078-0432.CCR-25-3284. IF: 10.2.

Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial. Ciruelos E, Pascual T, Villacampa G, Pernas S, Sanchez-Bayona R, Ponce J, Cantos B, Escrivá-de-Romaní S, Perelló A, Sanfeliu E, Galvan P, Montaño A, Martínez E, Lopez A, Mele M, de la Haba J, Cortés J, Mulero-Sánchez A, Ferrero-Cafiero JM, Oliveira M, Villanueva L, Gonzalez X, Villagrasa P, Prat A. Clin Cancer Res. 2025 Dec 3. doi: 10.1158/1078-0432.CCR-25-2882. IF: 10.2.

First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors. El-Khoueiry A, Saavedra O, Thomas J, Livings C, Garralda E, Hintzen G, Kohlhas L, Vanosmael D, Koch J, Rajkovic E, Ravenstijn P, Nuciforo P, Fehniger TA, Foster M, Berrien-Elliott MM, Wingert S, Stäble S, Morales-Espinosa D, Rivas D, Emig M, Lopez J. Clin Cancer Res. 2025 Apr 1;31(7):1257-1267. IF: 10.2.

lacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial. Vidal M, Falato C, Pascual T, Sanchez-Bayona R, Muñoz-Mateu M, Cebrecos I, Gonzalez-Farré X, Cortadellas T, Margelí Vila M, Luna MA, Siso C, Amillano K, Galván P, Bergamino MA, Ferrero-Cafiero JM, Salvador F, Espinosa Guerrero A, Pare L, Sanfeliu E, Prat A, Bellet M. Clin Cancer Res. 2025 Apr 1;31(7):1223-1232. IF: 10.2.

A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma. Pal SK, Bernard-Tessier A, Grell P, Gao X, Kotecha RR, Picus J, de Braud F, Takahashi S, Wong A, Suárez C, Otero JA, Kundamal N, Yang X, Sharaby S, Roy M, Barzaghi-Rinaudo P, Tannir NM. Clin Cancer Res. 2025 May 15;31(10):1847-1855. IF: 10.2.

Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.Guiu S, Balmaña J, Lemercier P, Follana P, Gonçalves A, Bigot F, Frenel JS, Brain E, Mailliez A, Chakiba Brugere C, Curtit E, Derbel O, Dalenc F, Derquin F, Duhoux F, Canon JL, Pimentel I, Chevalier LM, Buisson A, Guyonneau C, Lemonnier J, Delaloge S, Bachelot T. Clin Cancer Res. 2025 Nov 14;31(22):4633-4643. IF: 10.2.

Phase I Clinical Trial of the Bifunctional EGFR/TGF-ß Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors. Hernando-Calvo A, Carvajal RD, Paik PK, Morris VK, Zandberg DP, Kaczmar JM, Bohr DN, Reiners RD, Gharakhani E, Salazar RL, Lizotte PH, Ivanova EV, Bedard PL, Hanna GJ. Clin Cancer Res. 2025 Nov 14;31(22):4623-4632. IF: 10.2.

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations. Harding JJ, Oh DY, Mercade TM, Goyal L, Varkaris A, Palmieri LJ, Ikeda M, Kondo S, Bai LY, Ueno M, Chen LT, Papadopoulos KP, Shroff RT, Kizilbash SH, Hollebecque A, Adeva J, Cosman R, Yokota T, Park JO, Turk A, Liao CY, Satoh T, Borad MJ, El-Khoueiry A, Azad N, Jaeckle KA, Loong HH, Yong WP, Bender MH, Varughese SC, Sachdeva D, Radtke DB, Gueorguieva I, Szpurka AM, Chen HR, Liu H, Xu X, Rodon J. Clin Cancer Res. 2025 Dec 1;31(23):4920-4932. IF: 10.2.

A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study. Alsina M, Villacampa G, de Andrea C, Vivancos A, Ponz-Sarvise M, Arrazubi V, Jimenez-Fonseca P, Diez M, Sanz-Garcia E, Martínez E, Guardeño R, Calvo M, Bugés C, Longo F, Navarro V, García-Galea E, Gros A, Ochoa MC, Lopez-Janeiro A, Sanchez-Gregorio S, Herrero C, Labiano I, Vila-Casadesús M, López D, Alexandru R, Muñoz S, Tabernero J, Melero I. Clin Cancer Res. 2025 Jul 15;31(14):2890-2898. IF: 10.2.

Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I. Clin Cancer Res. 2025 Oct 15;31(20):4244-4254. IF: 10.2.

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors. Cortés J, Priego A, Garralda E, Rojas K, Lord SR, Goetze TO, Kuemmel S, Crabb SJ, Parra-Guillen ZP, Borggren M, Karlsson I, Lindahl D, Mårtensson L, Oldham R, Ropenga A, Teige I, Wallin J, Frendeus B, McAllister A. Clin Cancer Res. 2025 Dec 1;31(23):4953-4963. IF: 10.2.

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. Juric D, Song K, Johnson RM, Accordino MK, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE, Oliveira M, Saura C, Schmid P, Turner NC, Varga A, Gendreau S, Hwang MS, Kuang Z, Lau JT, Lin E, Pham T, Maddalo D, Rees MG, Ronan MM, Roth JA, Martin S, Sodir NM, Sokol ES, Whitfield ZJ, Wong A, Yauch RL, Aimi J, Cheeti S, Fredrickson J, Hilz S, Hafner M, Hutchinson KE, Jin Y, Peters U, Zingg D, Royer-Joo S, Shankar N, Schutzman JL, Jhaveri KL, Dey A. Clin Cancer Res. 2025 Oct 27. doi: 10.1158/1078-0432.CCR-25-1459. IF: 10.2.

The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma. García-Vicente R, Rodríguez-García A, Ancos-Pintado R, Arroyo A, Ortega-Hernández A, Bragado-García I, Castellano E, Ortiz-Ruiz A, Navarro-Aguadero MÁ, Modrego J, Leivas A, García-Villalba R, Tomás-Barberán FA, Sánchez-Pina JM, Alonso R, Cedena MT, Hernández-Sánchez M, Carpio C, Barba P, Carbonell D, Kwon M, Bastos-Oreiro M, Martín García-Sancho A, Jiménez-Ubieto A, Valeri A, Gómez-Garre D, Martínez-López J, Linares M. Clin Cancer Res. 2025 Nov 13. doi: 10.1158/1078-0432.CCR-25-1676. IF: 10.2.

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). Capdevila J, Hernando J, Molina-Cerrillo J, Benavent Viñuales M, Garcia-Carbonero R, Teulé A, Custodio A, Jimenez-Fonseca P, López C, Hierro C, Carmona-Bayonas A, Alonso V, Llanos M, Sevilla I, García-Álvarez A, Alonso-Gordoa T, Gallego Jiménez I, Antón-Pascual B, Modrego Sánchez A, Grande E. Clin Cancer Res. 2025 Nov 14;31(22):4655-4663. IF: 10.2.

Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers. Salem ME, Puccini A, Mauer E, André T, George TJ, Tabernero J, Sinicrope FA, Tie J, Kopetz S, Van Cutsem E, Lonardi S, Overman MJ, Foureau D. Clin Cancer Res. 2026 Jan 16;32(2):417-427. IF: 10.2.

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors. Melero I, Tabernero J, Steeghs N, Robbrecht DGJ, Peters S, Rizvi NA, O'Reilly EM, Calvo E, Eefsen RL, Leighl N, Cervantes A, Hafez N, Habigt C, Andersson E, Dejardin D, Rossmann E, Martinez Quetglas I, Babitzki G, Duarte J, Adessi C, Boetsch C, Evers S, Charo J, Teichgräber V, Lassen U. Clin Cancer Res. 2025 Nov 18. doi: 10.1158/1078-0432.CCR-25-2440. IF: 10.2.

Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation. Pretelli G, Garralda E. Clin Cancer Res. 2025 Dec 1;31(23):4866-4868. IF: 10.2.

MITF regulates autophagy and extracellular vesicle cargo in gastrointestinal stromal tumors. Proaño-Pérez E, Serrano-Candelas E, Guerrero M, Gómez-Peregrina D, Llorens C, Soriano B, Gámez-Valero A, Herrero-Lorenzo M, Martí E, Serrano C, Martin M. Mol Biomed. 2025 Oct 31;6(1):92. IF: 10.1.

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols. Ursino M, Villacampa G, Rekowski J, Dimairo M, Solovyeva O, Ashby D, Berlin J, Boix O, Calvert M, Chan AW, Coschi CH, Evans TRJ, Garrett-Mayer E, Golub RM, Guo C, Hayward KS, Hopewell S, Isaacs JD, Ivy SP, Jaki T, Kholmanskikh O, Kightley A, Lee S, Liu R, Mander A, Marshall LV, Matcham J, Patel D, Peck R, Rantell KR, Richards DP, Rouhifard M, Seymour L, Tanaka Y, Weir CJ, de Bono J, Yap C. EClinicalMedicine. 2025 Jan 10;79:102988. IF: 10.0.

Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study. Tibau A, Cliff ERS, Romano A, Borrell M, Molto C, Kesselheim AS. EClinicalMedicine. 2025 May 31;84:103088. IF: 10.0.

Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis. Papakonstantinou A, Villacampa G, Navarro V, Oliveira M, Valachis A, Pascual T, Matikas A. EClinicalMedicine. 2025 Feb 17;81:103116. IF: 10.0.

Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. Camacho-Arteaga L, Iacoboni G, Kwon M, Bailén R, Hernani R, Benzaquén A, López-Corral L, Pérez-López E, Leguízamo-Martínez LM, Calvo-Orteu M, Guerreiro M, Balaguer-Rosello A, Alonso-Martínez C, Vidal X, Barba P, Agustí A. JAMA Netw Open. 2025 Feb 3;8(2):e2461683. IF: 9.7.

Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial. Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sánchez-Hernández A, Dakhil S, Camidge DR, Pillet M, Brown M, Paliompeis C, Dowson A, Cooper ZA, Kumar R, Herbst RS. JAMA Netw Open. 2025 Jul 1;8(7):e2518440. IF: 9.7.

Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA. Tibau A, Hwang TJ, Romano A, Borrell M, Gich I, Molto C, Kesselheim AS. JAMA Netw Open. 2025 Mar 3;8(3):e252026. IF: 9.7.

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials. Jänne PA, Planchard D, Goto K, Smit EF, de Langen AJ, Goto Y, Ninomiya K, Kubo T, Pérol M, Felip E, Hayashi H, Nakagawa K, Shimizu J, Nagasaka M, Pereira K, Taguchi A, Ali A, Karnoub M, Yonemochi R, Leung D, Li BT. JAMA Netw Open. 2025 Nov 3;8(11):e2543107. IF: 9.7.

Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination. Martin-Martin N, Garcia-Longarte S, Corres-Mendizabal J, Lazcano U, Astobiza I, Bozal-Basterra L, Herranz N, van Splunder H, Carlevaris O, Pujana-Vaquerizo M, Blasco MT, Aransay AM, Rosino A, Tudela J, Jimenez D, Martinez A, Salca A, Santos-Martín A, Rey S, Ugalde-Olano A, Gonzalo D, Graupera M, Gomis RR, Mateo J, Unda M, Gonzalez-Billalabeitia E, Loizaga-Iriarte A, Mendizabal I, Carracedo A. Genome Biol. 2025 Jun 3;26(1):154. IF: 9.4.

Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study. Albiges L, Gross-Goupil M, Barthélémy P, Bamias A, Bedke J, Bex A, Fontes-Sousa M, Grünwald V, Melichar B, Pickering L, Porta C, Procopio G, Rottey S, Schmidinger M, Suárez C, Velasco G, Escudier B. Eur Urol Oncol. 2025 Dec;8(6):1474-1485. IF: 9.3.

Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial. Carles J, Tombal B, Hussain M, Saad F, Fizazi K, Montesa Pino Á, Méndez-Vidal MJ, Rodriguez-Vida A, Castellano D, Borrega P, Adorjan P, Moretones C, Dissanayake M, Smith MR. Eur Urol Oncol. 2025 Nov 4. doi: 10.1016/j.euo.2025.10.001. IF: 9.3.

Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis. Zurita AJ, Tidwell RS, Chapin BF, Harris DR, Zhang M, Pisters LL, Aparicio A, Araujo JC, Arce-Gallego S, Zhu K, Lozano ML, Pagliaro L, Mateo J, Logothetis C, Troncoso P, Davis JW. Eur Urol Oncol. 2025 Aug;8(4):1010-1019. IF: 9.3.

PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes. Rescigno P, Fenor de la Maza MD, Tovey H, Villacampa G, Cafferty F, Burnett S, Stiles M, Gurel B, Tunariu N, Carreira S, Figueiredo I, Beije N, Flohr P, Hall E, Hill A, Mahmud M, Perna C, Sarvadikar A, Sharp A, Abramovich K, Aversa C, Bertran C, Bianchini D, Carmichael J, Chandran K, Crespo M, Cross E, Curcean A, Ferreira A, Grochot R, Guo C, Hamilton L, Harden L, Hunt J, Longoria O, Martos L, Miranda S, Riisnaes R, Vadgama S, Westaby D, Wilkinson J, Yap C, de Bono JS. Eur Urol Oncol. 2025 Aug;8(4):1059-1069. IF: 9.3.

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109). Agostinetto E, Pfeiler G, Hlauschek D, Mayer EL, Lambertini M, de Azambuja E, Bellet-Ezquerra M, Meisel JL, Rubovszky G, Zdenkowski N, Novik Y, Ruiz-Borrego M, Gelmon KA, Mamounas EP, Iwata H, Lu DR, Soelkner L, Fesl C, Gnant M, DeMichele A. ESMO Open. 2025 Jan;10(1):104096. IF: 8.3.

Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer. Angelats L, Paré L, Rubio-Perez C, Sanfeliu E, González A, Seguí E, Villacampa G, Marín-Aguilera M, Pernas S, Conte B, Albarrán-Fernández V, Martínez-Sáez O, Aguirre Á, Galván P, Fernandez-Martinez A, Cobo S, Rey M, Martínez-Romero A, Walbaum B, Schettini F, Vidal M, Buckingham W, Muñoz M, Adamo B, Agrawal Y, Guedan S, Pascual T, Agudo J, Grzelak M, Borcherding N, Heyn H, Vivancos A, Parker JS, Villagrasa P, Perou CM, Prat A, Brasó-Maristany F. ESMO Open. 2025 Jan;10(1):104109. IF: 8.3.

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2. Stintzing S, Tabernero J, Satoh T, Dasari A, Lonardi S, Eng C, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero AF, Yao JC, Kasper S, Arnold D, Basic E, Granold M, Petschulies M, Wu L, Chung YC, Chen L, Yang Z, Van Cutsem E. ESMO Open. 2025 Mar;10(3):104297. IF: 8.3.

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series. Hardy C, Thorne E, O'Connor M, Élez E, Kamposioras K, Punie K, Oing C, Murali K, Haanen JBAG, Lim KHJ, Banerjee S; ESMO Resilience Task Force. ESMO Open. 2025 Mar;10(3):104298. IF: 8.3.

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors. Schram AM, Boni V, Adjei AA, Olszanski AJ, Vieito M, Francis JH, Kurman M, Ahsan JM, Tomkinson B, Garralda E. ESMO Open. 2025 Mar;10(3):104300. IF: 8.3.

Genomic profiling unlocks new treatment opportunities for ampullary carcinoma. Fabregat-Franco C, Castet F, Castillo G, Salcedo M, Sierra A, López-Valbuena D, Pando E, Tian TV, Macarulla T. ESMO Open. 2025 May;10(5):104480. IF: 8.3.

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers. Lynce F, Martínez-Sáez O, Walbaum B, Brasó-Maristany F, Waks AG, Villagrasa P, Villacampa Javierre G, Sanfeliu E, Galván P, Paré L, Anderson LM, Perou CM, Parker JS, Vivancos A, DiLullo MK, Pernas S, Winer EP, Overmoyer B, Mittendorf EA, Bueno-Muiño C, Martín M, Prat A, Tolaney SM. ESMO Open. 2025 Feb;10(2):104100. IF: 8.3.

Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project. Dienstmann R, Ruiz-García E, Alsina M, Ruiz-Pace F, Groen-van Schooten TS, Martínez-Ciarpaglini C, Fernández-Figueroa EA, Herrera-Goepfert R, Díaz-Romero C, Lino-Silva L, Hernandez-Guerrero AI, Valdez-Reyes NM, León-Takahashi A, Falcón-Martínez JC, Pouw RE, Romero S, Villagrasa R, Cabeza-Segura M, Alarcón-Molero L, Jimenez-Martí E, Miralles A, Boggino H, Gauna C, Pereira R, Lezcano H, Cantero D, Vivancos A, Matito J, Martin A, Gómez M, Castillo E, Vila M, Ferreira RM, Barros R, Santos-Antunes J, Mendes-Rocha M, Costa A, Riquelme E, Roa JC, Latorre G, Freile B, Caro L, Esteso F, O'Connor J, Riquelme A, Owen G, Garrido M, Diez-García M, Figueiredo C, Caballero C, Lordick F, Farrés J, Derks S, Carneiro F, Cervantes A, Fleitas T. ESMO Open. 2025 Mar;10(3):104482. IF: 8.3.

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. Chiang AC, Olmedo Garcia ME, Carlisle JW, Dowlati A, Reguart N, Felip E, Jost PJ, Steeghs N, Stec R, Gadgeel SM, Loong HH, Jiang W, Hamidi A, Parkes A, Paz-Ares L. ESMO Open. 2025 Apr;10(4):104538. IF: 8.3.

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies. Janku F, Tan DSP, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Razak A, Kan R, Reiners R, Mataraza J, Szpakowski S, Subramanian K, Chen X, Lai C, Bedard PL. ESMO Open. 2025 Jun;10(6):105051. IF: 8.3.

Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative. Taieb J, Seligmann J, Modest D, Girault C, Rivera F, Mahillo E, Osterlund P, Pfeiffer P, Malka D, Louvet C, Siebenhuner AR, Morf C, de la Fouchardiere C, Monard L, Koopman M, Vink G, Borbath I, Dewever L, Adams R, Reinacher-Schick A, Pietrantonio F, Lonardi S, Aparicio T, Cremolini C; ENGIC members. ESMO Open. 2025 May;10(5):105055. IF: 8.3.

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA. Carbone DP, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Felip E, Cheng Y, Juan-Vidal O, Alexandru A, Mizutani H, Reinmuth N, Lu S, Reck M, John T, Scherpereel A, De Marchi P, Aoyama T, Sathyanarayana P, Grootendorst DJ, Hu N, Ip V, Hung YH, Paz-Ares LG. ESMO Open. 2025 Jun;10(6):105123. IF: 8.3.

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer. Nag S, Ray Coquard I, Gupta S, Pathak A, Li N, Mulya Sari R, Harano K, Kim GM, Ang SF, Que FV, Chay WY, Lai HC, Ativitavas T, Tangjitgamol S, Lai CH, Heong VYM, Contreras Tolentino J, Ngu MR, Yun J, Yunokawa M, Hanafi WLH, Li J, Smyth E, Yoshino T, Mehta J, Pentheroudakis G, Maheshwari A, Cervantes A, Basade M, Oaknin A. ESMO Open. 2025 Jun;10(6):105125. IF: 8.3.

Development and implementation of novel liquid biopsy NGS panels via the OncNGS precommercial procurement (PCP) initiative. Raicevic Toungouz G, Alessandrello R, Giacomini P, Kamal M, Gausachs M, Mazzarella L, Sujobert P, Frigè G, Alay A, Planchon JM, Blau O, Mias Carballal MR, Antoine-Poirel H, Nadal E, Bullinger L, Hebrant A, Servant N, D'Haene N, Aftimos P, Silkenstedt E, Michalík A, Dupain C, Delcourt T, Huet S, Van Campenhout C, Cordero D, Castellano Garcia JM, Codony C, Krol A, Gonzalo J, Van Damme N, Delnord M, Carbone R, Trapani V, Van Garsse S, Van Den Bulcke M. ESMO Open. 2025 Jun;10(6):105127. IF: 8.3.

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). Gambardella V, Accordino MK, Bedard PL, Cervantes A, Hamilton E, Italiano A, Kalinsky K, Krop IE, Oliveira M, Saura C, Schmid P, Turner NC, Varga A, Fernandez-Saranillo A, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman JL, Juric D, Jhaveri KL. ESMO Open. 2025 Jul;10(7):105303. IF: 8.3.

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavila J, Schmid P, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Di Cosimo S, Anton A, Cottu P, Shimizu E, Fernandez M, Sampayo-Cordero M, Cortés J; PARSIFAL-LONG Steering Committee and Trial Investigators. ESMO Open. 2025 Jul;10(7):105309. IF: 8.3.

Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers. Perachino M, Blondeaux E, Delucchi V, Bernstein Molho R, Frank S, Paluch-Shimon S, Linn S, Di Meglio A, Peccatori F, Moore HCF, Parokonnaya A, Renaud T, Rodriguez Wallberg KA, Partridge AH, Pogoda K, Ferrari A, Wildiers H, Toss A, Rousset-Jablonski C, Kim HJ, Varela M, Cordoba O, Tanase Damian C, Marhold M, Fabi A, Graff SL, Rodriguez-Hernandez A, Okano M, Duchnowska R, Luna Pais H, Di Rocco R, Azim HA Jr, Mariamidze E, Kourie HR, Arecco L, Carrasco E, Agostinetto E, Balmana J, Saura C, Lambertini M. ESMO Open. 2025 Aug;10(8):105513. IF: 8.3.

Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches. de Grandis MC, Baraibar I, Prior O, Balaguer-Montero M, Salvà F, Ros J, Rodríguez-Castells M, Tabernero J, Lonardi S, Perez-Lopez R, Élez E. ESMO Open. 2025 Aug;10(8):105520. IF: 8.3.

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial. Melisi D, Macarulla T, De La Fouchardière C, Pazo Cid RA, Chandana SR, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Maxwell F, Zhang L, Benzaghou F, O'Reilly EM, Wainberg ZA. ESMO Open. 2025 Aug;10(8):105534. IF: 8.3.

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial. Pascual T, Villacampa G, Oliveira M, Escrivá-de-Romaní S, Pernas S, Paré L, Adamo B, Martínez E, Cortés J, Perelló A, Galan M, Melé M, Villanueva L, Gonzalez-Rodriguez M, Tolosa P, González-Farré B, Galván P, Canes J, Nuciforo P, Ferrero-Cafiero JM, González-Farré X, Villagrasa P, Prat A, Ciruelos E. ESMO Open. 2025 Sep;10(9):105572. IF: 8.3.

Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe. Kyriazoglou A, Zając A, Valverde C, Czarnecka AM, Błoński P, Romagosa C, Seliga KA, Koulouridi A, Mala A, Wągrodzki M, Silva TM, Witczak M, Ługowska I, Rosińska M, Álvarez R, Aguirre M, Tysarowski A, Kokkali S, Georgoulias V, Serrano C, Rutkowski P, Boukovinas I. ESMO Open. 2025 Sep;10(9):105577. IF: 8.3.

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study. Martelli V, Vidal J, Gibert J, Fernández-Rodríguez MC, Linares J, García-Alfonso P, Páez D, Alonso V, Gomez-España MA, Guix M, Santos C, Duran G, Élez E, Garcia-Carbonero R, Ferreiro R, Pineda E, Sastre J, Cano MT, Manzano JL, Losa F, Aranda E, Rivera F, Sibilio A, Toledo R, Tabernero J, Salazar R, Bellosillo B, Montagut C; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). ESMO Open. 2025 Sep;10(9):105760. IF: 8.3.

Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer. Morganti S, Kusmick RJ, Hughes ME, Brasó-Maristany F, Smith K, Tarantino P, Vega-Leon R, Grinda T, Pardo F, Dvir K, Suggs GL, Buck S, Skeffington M, Garrido-Castro AC, Parsons HA, Sammons SL, Prat A, Lin NU, Tolaney SM, Giordano A. ESMO Open. 2025 Oct;10(10):105828. IF: 8.3.

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial. Seguí E, Brasó-Maristany F, Pascual T, Sanfeliu E, Victoria I, Saura C, Hierro C, López-González A, Izarzugaza Y, Ciruelos E, Gavilá J, Racca F, Cejalvo JM, Amillano K, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Conte B, Walbaum B, Indacochea A, Castillo O, Blasco P, Pardo F, Aguirre Á, Sirenko V, González X, Galván P, Vivancos A, Ferrero-Cafiero JM, Mulero-Sánchez A, Salvador F, Villacampa G, Mesía R, Cervantes A, Prat A, Tabernero J. ESMO Open. 2025 Oct;10(10):105838. IF: 8.3.

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study. Metges JP, Kato K, Sun JM, Shen L, Enzinger PC, Adenis A, Doi T, Kojima T, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Alsina M, Buchschacher GL Jr, Hara H, Tsuji A, Wu J, Shah S, Bhagia P, Shah MA. ESMO Open. 2025 Dec;10(12):105854. IF: 8.3.

Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer. Yee D, Iwata H, LoRusso P, Oliveira M, Gonçalves A, Stradella A, Vidal M, Sablin MP, Hardebeck MC, Fukuyama Y, Forman N, Puig M, Lorence RM. ESMO Open. 2025 Nov;10(11):105863. IF: 8.3.

Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial. García-Mosquera JJ, Pérez-García JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escrivá-de-Romaní S, Calvo Martínez L, Gebhart G, Kerrou K, Gion M, Antonarelli G, Santasusagna Canal S, Rodríguez-Morato J, Mina L, Sampayo-Cordero M, Llombart-Cussac A, Cortés J. ESMO Open. 2025 Nov;10(11):105875. IF: 8.3.

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors. Dienstmann R, Vivancos A, Nuciforo P, Aguilar S, Ruiz-Pace F, Viaplana C, Gonzalez J, Fite B, Pedrola A, Elez E, Saura C, Felip E, Macarulla T, Capdevila J, Fariñas-Madrid L, Carles J, Mateo J, Muñoz-Cosuelo E, Balmaña J, Braña I, Garralda E, Tabernero J. ESMO Open. 2025 Nov;10(11):105888. IF: 8.3.

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. Elez E, Siena S, Sartore-Bianchi A, Ros J, Ciardello F, Martinelli E, Steeghs N, Huijberts S, Cervantes A, Roselló S, Tejpar S, Wilmsen B, Salazar R, Santos C, de Schaetzen G, Muñoz S, Bernards R, Moreno V, García-Galera E, Alemany R, Gros A, Bardelli A, Arena S, Piris A, Chavarría E, Dienstmann R, Tabernero J. ESMO Open. 2025 Dec;10(12):105892. IF: 8.3.

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey. Turinetto M, Marchetti C, Scandurra G, Colombo N, Cormio G, Cecere S, Pellegrini D, De Angelis C, Abeni C, Petrella MC, Ferrero A, Camnasio C, Villa F, Mammoliti S, Giordano M, Valabrega G, DeStefanis M, Cirigliano G, Boccia S, Distefano M, Chiusolo P, Perri MT, Lombardo V, Caruso G, Loizzi V, Coppola E, Barberi V, Lamia MR, Fagotti A, Pignata S. ESMO Open. 2025 Dec;10(12):105903. IF: 8.3.

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial. Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R, Klümpen HJ, Cremer B, Sevilla I, Eriksson B, Tabaksblat E, Metges JP, Reed NS, Schrader J, Navarro V, Valentí V, Hernando J, Colao AM, Vestermark L, Carnaghi C, Knigge UP, Jimenez-Fonseca P, Benavent M, de Vos-Geelen J, Venerito M, Von Werder A, Jann H, Rinke A, Smith D, Hörsch D, Starling N, Ruszniewski P, Baudin E, Caroli-Bosc FX, Manzano JL, Martín M, Scarpa A, Lawlor RT, Ragulan C, Ps H, Sadanandam A, Carmona-Bayonas A, Salazar R. ESMO Open. 2025 Dec;10(12):105922. IF: 8.3.

Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer. Karta J, Meyers M, Rodriguez F, Koncina E, Gilson C, Klein E, Gabola M, Benzarti M, Pérez Escriva P, Molina Tijeras JA, Correia Tavares Bernardino C, Ponath F, Carpentier A, Pujabet MA, Schmoetten M, Tsenkova M, Saoud P, Gaigneaux A, Ternes D, Alonso L, Zügel N, Willemssen E, Koppes P, Léonard D, Casanova LP, Haan S, Mittelbronn M, Meiser J, Pozdeev VI, Vogel J, Nuciforo PG, Wilmes P, Letellier E. EMBO J. 2025 Oct;44(19):5375-5393. IF: 8.3.

Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity. He B, Wood KH, Li ZJ, Ermer JA, Li J, Bastow ER, Sakaram S, Darcy PK, Spalding LJ, Redfern CT, Canes J, Oliveira M, Prat A, Cortes J, Thompson EW, Littlefield BA, Redfern A, Ganss R. EMBO Mol Med. 2025 May;17(5):1071-1100. IF: 8.3.

NEDDylation Regulates CD8+ T-cell Metabolism and Antitumor Immunity. Jiménez-Lasheras B, Velasco-Beltrán P, Egia-Mendikute L, Pérez-Gutiérrez L, Lee SY, de Blas A, García-Del Río A, Zanetti SR, Antoñana-Vildosola A, Barreira-Manrique A, Bosch A, Etxaniz-Díaz de Durana J, Prieto-Fernández E, Serrano-Maciá M, Goikoetxea-Usandizaga N, Azkargorta M, Elortza F, Gruber T, Peer S, Baier G, Woodhoo A, Martínez-Chantar ML, Palazon A. Cancer Immunol Res. 2025 Jul 2;13(7):1004-1021. IF: 8.2.

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts. Òdena A, Monserrat L, Brasó-Maristany F, García-Galea E, Casals E, Molina C, Herencia-Ropero A, Pedretti F, Domènech H, Guzmán M, Rodríguez O, Grueso J, Esteve-Codina A, Dienstmann R, Chandarlapaty S, Fan PD, Suto F, Oliveira M, Prat A, Serra V. NPJ Precis Oncol. 2025 Nov 21;9(1):393. IF: 8.0.

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer. Arce-Gallego S, Esquefa V, Domenech H, Salca A, Aguilar D, Casals T, Mir G, Simonetti S, Oliveira A, de Llobet L, Neeb A, Brandariz J, Anselmino N, Casanova-Salas I, Herranz N, Serra V, de Bono JS, Mateo J. NPJ Precis Oncol. 2025 Nov 26;9(1):407. IF: 8.0.

Collaborative framework on responsible AI in LLM-driven CDSS for precision oncology leveraging real-world patient data. Mathes S, Ferber D, Dreyer T, Borm KJ, Modersohn L, Willem T, Dirven R, Vibert J, Kreutzfeldt S, Perez-Lopez R, Prelaj A, Strand F, Baird RD, Boeker M, Kather JN, Tschochohei M, Lammert J. NPJ Precis Oncol. 2025 Dec 4;10(1):15. IF: 8.0.

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma. Muñoz Couselo E, Berking C, Baurain JF, Martelli S, Arntz R, Savoia P. J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e788-e790. IF: 8.0.

Multimodal data integration in early-stage breast cancer. Llinas-Bertran A, Butjosa-Espín M, Barberi V, Seoane JA. Breast. 2025 Apr;80:103892. IF: 7.9.

Identifying germline pathogenic variants in breast cancer using tumor sequencing. Cruellas M, Papakonstantinou A, López-Fernández A, Castillo E, Matito J, Gómez M, Rezqallah A, Vega S, Navarro V, Torres M, Moles-Fernández A, Saura C, Vivancos A, Balmaña J, Oliveira M. Breast. 2025 Jun;81:104439. IF: 7.9.

Integrating genetic polymorphisms and clinical data to develop predictive models for skin toxicity in breast cancer radiation therapy. Aguado-Flor E, Reyes VM, Navarro V, Mollà M, Aguado-Barrera ME, Altabas M, Azria D, Baten A, Bourgier C, Bultijnck R, Chang-Claude J, De Santis MC, Dunning AM, Duran-Lozano L, Elliott RM, Farcy Jacquet MP, Giandini C, Giraldo A, Green S, Lambrecht M, Lopez-Pleguezuelos C, Monten C, Rancati T, Rattay T, Rosenstein BS, De Ruysscher D, Diez O, Seibold P, Sperk E, Symonds RP, Stobart H, Vega A, Veldeman L, Villacampa G, Webb AJ, Weltens C, Zunino P, Talbot CJ, West CM, Giralt J, Gutiérrez-Enríquez S; REQUITE consortium. Breast. 2025 Aug;82:104506. IF: 7.9.

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer. Li M, Panet F, Barberi V, Salgado R, Oliveira M, Loi S. Breast. 2025 Oct;83:104545. IF: 7.9.

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial. Demeestere I, Niman SM, Partridge AH, Diego DS, Kammler R, Ruggeri M, Colleoni M, Shimizu C, Saura C, Gelmon KA, Saetersdal AB, Kroep JR, Mailliez A, Amant F, Ruız-Borrego M, Lee JE, Kataoka A, Walshe JM, Takei J, Borstnar S, Borges VF, Saunders C, Susnjar S, Bjelic-Radisic V, Cardoso F, Meisel JL, Kawwass JF, Spanic T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr, Peccatori FA; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. Breast. 2025 Oct;83:104547. IF: 7.9.

Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Serna Á, Navarro V, Iacoboni G, López L, Sancho JM, González-Barca E, López-García A, Córdoba R, Sáez A, Jiménez-Ubieto A, Ferrero A, García T, Sánchez Á, García C, Bosch M, Cabirta A, Jiménez M, Marín-Niebla A, Bosch F, Abrisqueta P. Haematologica. 2025 Jan 1;110(1):173-178. IF: 7.9.

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Montesinos P, Barba P, Diaz-Beya M, Hermosin L, Maluquer C, Gonzalez-Campos J, Bernal T, Arriaga MS, Zamora L, Pratcorona M, Martino R, Larrayoz MJ, Artola T, Torrent A, Vall-Llovera F, Tormo M, Gil C, Novo A, Martinez-Sanchez P, Ribera J, Queipo MP, Gonzalez-Martinez T, Cabrero M, Cladera A, Cervera J, Orfao A, Ribera JM, Genesca E. Haematologica. 2025 Jan 1;110(1):206-211. IF: 7.9.

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia. Medina-Gil D, Palomo L, Navarro V, Lázaro G, Martín-Mur B, Hernández C, Castells O, Sánchez B, Muñoz-Torres PM, Pagès C, Pujadas G, Esteve-Codina A, Cabirta A, Ferrà C, Alcoceba M, Terol MJ, Andreu R, Martí M, Abrisqueta P, Bosch F, Crespo M. Haematologica. 2025 Aug 1;110(8):1758-1773. IF: 7.9.

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study. Rodríguez-Veiga R, Gil C, Sobas M, Torres-Miñana L, Botella C, De la Serna J, Bernal T, Salamero O, Otero C, Navarro-Vicente I, De Miguel C, Garrido A, Vives S, Bergua J, Pérez-Encinas M, Algarra L, González-Campos J, Gómez MDMC, Prates MV, Benavente C, Tormo M, Cervera M, Fazio P, Amutio ME, García R, Pomares H, Vidriales B, Serrano J, Amigo ML, Rubio V, Almela Á, Barrios M, Sossa-Melo CL, Paluszewska M, Novo A, Gromek T, Rodríguez-Macías G, Oleksiuk J, Lloret-Madrid P, Montesinos P. Haematologica. 2025 Nov 13. doi: 10.3324/haematol.2025.288112. IF: 7.9.

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review. Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P. Haematologica. 2025 Nov 20. doi: 10.3324/haematol.2025.288654. IF: 7.9.

Model of selective neurodegeneration driven by a Ccp1 mutation leads to atypical microglia with an increased response to pathological stimuli. Pérez-Boyero D, de la Mata A, Castillo-Sanchez J, Reverte I, Yanguas-Casás N, Ávila-Zarza C, Valero J, Alonso JR, Arevalo MA, Ragozzino D, Weruaga E, Díaz D. Brain Behav Immun. 2025 Dec 29. doi: 10.1016/j.bbi.2025.106248. IF: 7.6.

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm DL, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T. NPJ Breast Cancer. 2025 Mar 7;11(1):23. IF: 7.6.

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab. Sánchez-Bayona R, Martínez-Sáez O, Romero-Romero D, Seguí E, Carcelero E, Tolosa P, Soberino J, Alva M, Pascual T, Lema L, Garcia-Fructuoso I, Cobos-Fernandez MA, Rey M, Manso L, Aguirre A, Madariaga A, Sirenko V, González-Deza C, Blasco P, Mayhua A, Castillo O, Galván P, Sanfeliu E, Villacampa G, Buckingham W, Marín-Aguilera M, Paré L, Villagrasa P, Perou CM, Maues J, Brasó-Maristany F, Ciruelos E, Prat A. NPJ Breast Cancer. 2025 Apr 25;11(1):37. IF: 7.6.

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial. Albanell J,Pozo AG,Arteaga CL,Bellet M,Rojo F,González A,Bellosillo B,Serra V,Gener P,Guerrero JA,Shimizu E,Mancino M,Rodríguez J,Mina L,Pérez JM,Cortés J,Llombart A. NPJ Breast Cancer. 2025. 11. (1):p. 59-59. IF: 7.6.

Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes. Pudlarz T, Turpin A, Tissera NS, Hilmi M, Antoun L, Castet F, Lopez-Valbuena D, Rousseau A, Delaye M, Gelli M, Italiano A, Valéry M, Tarabay A, Boige V, Malka D, García-Galea E, Castillo G, Tian TV, Hollebecque A, Smolenschi C, Ducreux M, Macarulla T, Boilève A. JHEP Rep. 2025 Aug 11;7(11):101550. IF: 7.5.

Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAFV600E-induced growth arrest in melanocytes. McGrail K, Granado-Martínez P, Orsenigo R, Caratù G, Nieto P, Heyn H, Ferrer B, Hernández-Losa J, Muñoz-Couselo E, García-Patos V, Recio JA. Oncogene. 2025 Jun;44(21):1592-1608. IF: 7.3.

PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression. Sanchis P, Sabater A, Lechuga J, Rada J, Seniuk R, Pascual G, Gatti M, Bizzotto J, Shepherd PDA, Yang J, Cotignola J, Vazquez E, Mateo J, Valacco P, Labanca E, Logothetis C, Gueron G, Anselmino N. Oncogene. 2025 Oct;44(38):3568-3579. IF: 7.3.

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis. McWilliam A, Marshall D, Kerns SL, Barnett GC, Vega A, Kapouranis T, Aguado Barrera ME, Avuzzi B, Azria D, Chang-Claude J, Choudhury A, Coedo Costa C, Dunning A, Farcy-Jacquet MP, Faivre-Finn C, Gutiérrez-Enríquez S, Fuentes-Ríos O, Gómez Caamaño A, Lambrecht M, López Pleguezuelos C, Rancati T, Rattay T, de Ruysscher D, Seibold P, Sperk E, Talbot C, Webb A, Veldeman L, Rosenstein BS, West CML; REQUITE Consortium. J Natl Cancer Inst. 2025 May 1;117(5):1018-1026. IF: 7.2.

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer. Stecklein SR, Martín M, Villacampa G, Del Monte-Millan M, Yoder R, Pathak H, Cobo S, Brasó-Maristany F, Álvarez EL, Echavarría I, Bueno-Muiño C, Jerez Y, Cebollero M, Bueno O, García-Saenz JÁ, Moreno F, Gómez HL, Massarrah T, Herrero B, Paré L, Marín-Aguilera M, Buckingham W, López-Tarruella S, Villagrasa P, Godwin AK, Salgado R, Prat A, Sharma P. J Natl Cancer Inst. 2025 July 2. doi.org/10.1093/jnci/djaf162. IF: 7.2.

A randomized study of 2 risk assessment models for individualized breast cancer risk estimation. López-Fernández A, Duran-Lozano L, Villacampa G, Pardo M, Pérez E, Darder E, Vallmajó A, Alfonso R, Cruellas M, Roqué A, Cartró M, Bareas A, Carrasco E, Rezqallah A, Jimenez-Macedo AR, Torres-Esquius S, Torres M, Lopez C, Espinosa M, Teulé A, Munté E, Tuset N, Diez O, Feliubadaló L, Lázaro C, Llort G, Carver T, Ficorella L, Mavaddat N, Mercadé A, Antoniou AC, Brunet J, Ramon Y Cajal T, Balmaña J. J Natl Cancer Inst. 2025 Aug 1;117(8):1593-1604. IF: 7.2.

The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population. Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. J Natl Cancer Inst. 2025 Oct 1;117(10):2029-2043. IF: 7.2.

Breastfeeding after breast cancer in young BRCA carriers. Blondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, Linn S, Kim HJ, Agostinetto E, Paluch-Shimon S, Cortesi L, Di Meglio A, Balmana J, Yerushalmi R, Rodriguez-Wallberg KA, Renaud T, Cui W, Moore HCF, Wong SM, Pogoda K, Lustberg M, Phillips KA, Han S, Puglisi F, Vernieri C, Bajpai J, Sonnenblick A, Rousset-Jablonski C, De Marchis L, De Giorgi U, Bianchini G, Texeira L, Duhoux FP, Villarreal-Garza C, Sini V, Fruscio R, Del Mastro L, Demeestere I, Azim HA Jr, Peccatori FA, Partridge AH, Lambertini M. J Natl Cancer Inst. 2025 Nov 1;117(11):2229-2239. IF: 7.2.

Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Maćkowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS. Eur J Cancer. 2025 Feb 5;216:115146. IF: 7.1.

Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study. Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E. Eur J Cancer. 2025 Feb 25;217:115219. IF: 7.1.

Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study. Sobrero A, Dasari A, Aquino J, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Price T, Yu Z, Geiger A, Chen L, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C. Eur J Cancer. 2025 Mar 11;218:115268. IF: 7.1.

Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis. Villacampa G, Eminowicz G, Navarro V, Carità L, García-Illescas D, Oaknin A, Pérez-Fidalgo JA. Eur J Cancer. 2025 May 2;220:115329. IF: 7.1.

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. Qi C, Shen L, Andre T, Chung HC, Cannon TL, Garralda E, Italiano A, Rieke DT, Liu T, Burcoveanu DI, Neu N, Mussi CE, Xu RH, Hong DS, Drilon A, Berlin J. Eur J Cancer. 2025 May 2;220:115338. IF: 7.1.

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study. Weichenthal M, Ellebaek E, Mangana J, Asher N, Gavrilova I, Kandolf L, Ugurel S, Hausschild A, Meier F, Leiter U, Livingstone E, Gebhardt C, Gutzmer R, Ruhlmann CH, Mahncke-Guldbrandt L, Haslund CA, Kopec S, Teterycz P, Bender M, Poudroux W, Muñoz-Couselo E, Berciano-Guerrero MA, Shalamanova G, DePalo DK, Brozić JM, Chiarion-Sileni V, Arance A, Ziogas D, Robert C, van de Velde AO, Gassama AA, Shapira R, BenBetzalel G, Grynberg S, Ramelyte E, Bertoldo F, DelPrete V, Gaudy-Marqueste C, Mohr P, Dummer R, Ascierto PA, Gogas H, Espinosa E, Lebbé C, Rutkowski P, Haanen J, Schadendorf D, Svane IM; EUMelaReg Consortium Members. Eur J Cancer. 2025 May 2;220:115339. IF: 7.1.

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. Tahara M, Greil R, Rischin D, Harrington KJ, Burtness B, de Castro G, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Lin J, Gumuscu B, Lerman N, Soulières D. Eur J Cancer. 2025 May 15;221:115395. IF: 7.1.

Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. Bedard PL, Jhaveri KL, Accordino MK, Cervantes PA, Gambardella V, Hamilton E, Italiano PA, Kalinsky PK, Krop PIE, Oliveira M, Schmid PP, Saura C, Turner PN, Varga A, Cheeti S, Dey A, Hilz S, Hutchinson KE, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman JL, Aimi J, Song K, Juric D. Eur J Cancer. 2025 May 15;221:115397. IF: 7.1.

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study. Magaton IM, Blondeaux E, Hamy AS, Linn S, Bernstein-Molho R, Peccatori FA, Ferrari A, Carrasco E, Paluch-Shimon S, Agostinetto E, Venturelli M, Luis IMV, Rodriguez-Wallberg KA, Kim HJ, Sorouri K, Renaud T, Moore HCF, Cui W, Bajpa J, Rousset-Jablonski C, De Marchis L, Yerushalmi R, Wong SM, Han S, Phillips KA, Pogoda K, Puglisi F, Chirco A, Duhoux FP, Meattini I, Villarreal-Garza C, Vernieri C, Bruzzone M, Demeestere I, Azim HA Jr, Partridge AH, Lambertini M. Eur J Cancer. 2025 Jun 3;222:115434. IF: 7.1.

Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations. Morfouace M, Bielle F, Razis E, Estrade F, Rubio A, Bautista F, de Rojas T, Vieito M, Meade S, Sanson M, Marques AC, Preusser M, Hatcher H, Balasubramanian GP, Pineda E, D'Hondt L, Duerinck J, Michotte A, Mawrin C, Ribalta T, Marucci G, Golfinopoulos V, Pfister SM, Jones DT, McCabe MG. Eur J Cancer. 2025 Jun 18;223:115493. IF: 7.1.

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study. Mandalà M, Amaral T, Rutkowski P, Sergi MC, Rasch ML, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Dirven I, Tucci M, Guida M, Spagnolo F, Rossi E, Queirolo P, Quaglino P, Depenni R, Placzke J, Giacomo AMD, Del Vecchio M, Indini A, Silva IPD, Menzies AM, Hong A, Lorigan P, Long GV, Robert C, Ascierto PA. Eur J Cancer. 2025 Jul 25;225:115567. IF: 7.1.

Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study. Grünwald V, Bex A, Rottey S, Suárez C, Procopio G, Velasco G, Melichar B, Bedke J, Pickering L, Fontes-Sousa M, Schmidinger M, Bamias A, Gross-Goupil M, Porta C, Barthélémy P, Escudier B, Albiges L. Eur J Cancer. 2025 Jul 25;225:115569. IF: 7.1.

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Lebreton C, Konecny GE, McNeish IA, Scott CL, Maloney L, Goble S, Lin KK, Coleman RL. Eur J Cancer. 2025 Jul 25;225:115584. IF: 7.1.

Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop. Glasmacher A, Garralda E, Gwaltney C, Rupalla K, Li C, Weber H. Eur J Cancer. 2025 Aug 26;226:115593. IF: 7.1.

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial. Taieb J, Modest DP, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Gravalos C, Bragagnoli AC, Barboux V, Roby L, Amellal N, Prager GW. Eur J Cancer. 2025 Sep 9;227:115644. IF: 7.1.

Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Gallois C, Ambrosini M, Lonardi S, Alouani E, Guimbaud R, Overman MJ, Sinicrope F, Mazard T, Decraecker M, Ros J, Elez E, Pernot S, Cremolini C, Boilève A, Parent P, Jayachandran P, Dutherage M, Mercier M, Flecchia C, Fakih M, Sclafani F, Pietrantonio F, Taieb J, Tougeron D. Eur J Cancer. 2025 Sep 9;227:115645. IF: 7.1.

Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab. Pirrone C, Malapelle U, Pepe F, Lo Prinzi F, Nichetti F, Saborowski A, Antonuzzo L, Camera S, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Grandis C, Lavacchi D, Persano M, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, De Cobelli F, Ratti F, Daniel F, Tesini G, Masi G, Vogel A, Lonardi S, Rimini M, Fornaro L, Rimassa L, Casadei-Gardini A. Eur J Cancer. 2025 Nov 17;230:116035. IF: 7.1.

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Chong EA, Penuel E, Napier EB, Lundberg RK, Budde LE, Shadman M, Matasar MJ, Bartlett NL, Flinn IW, Bosch F, Fay K, Goy A, Kumar A, Nastoupil LJ, Wei MC, Wu M, Yin S, Fraietta JA, Chong ER, Schuster SJ. Blood Adv. 2025 Feb 25;9(4):696-703. IF: 7.1.

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular. Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes J, Azaceta G, Ibáñez M, Chen T, Notario C, Amer N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo J, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M. Blood Adv. 2025 Jan 14;9(1):39-53. IF: 7.1.

Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers. Magno G, Rejeski K, Rappa G, Stock S, Holzem A, Landwehr M, Seib M, Kutsch N, Mammadova J, Mayer S, Aumann S, Van Ham J, Ringelstein-Harlev S, Velazquez GF, Wurm-Kuczera R, Scholz JK, Greenbaum U, Raj SS, Shouval R, Müller F, Chapuy B, Schmid C, Beyar-Katz O, Vergote VKJ, Poeck H, Dong N, Holtick U, Ram R, Pabst T, Shumilov E, Lenz G, Iacoboni G, Barba P, Bücklein V, Subklewe M. Blood Adv. 2025 Oct 22. doi: 10.1182/bloodadvances.2025017766. IF: 7.1.

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders. Serna Á, Navarro V, Jiménez M, Iraola-Truchuelo J, Bosch M, García C, Falcó A, Albasanz A, Ruiz-Camps I, Andrés C, Antón A, Esperalba J, Ferrero A, García T, Carpio C, Crespo M, Iacoboni G, Marín-Niebla A, Bosch F, Abrisqueta P. Blood Adv. 2025 Aug 26;9(16):4180-4189. IF: 7.1.

Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study. Bento L, Gutiérrez A, Martínez C, Ortí Verdet MC, Sorribes M, Caballero AC, Peña M, Pérez A, Jiménez-Ubieto A, Medina L, Bastos-Oreiro M, Caldas-González PF, Navarro B, Salcedo I, Abrisqueta P, Español I, Cornago J, Martín-Moro F, García L, Gómez P, Varela MR, Puente M, Zanabili J, Zudaire T, Zeberio I, Del Campo R, González L, González P, Blázquez C, Rovira J, Sitges M, Franch-Sarto M, Cabero A, Mussetti A, Montoro J, Sampol A, Sureda A, Caballero D, Martín García-Sancho A. Blood Adv. 2025 Jul 8;9(13):3281-3292. IF: 7.1.

The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential. Verdú-Bou M, Baptista MJ, Ribeiro ML, Méndez-López A, Profitós-Pelejà N, Frontzek F, Roué G, Mate JL, Pellicer M, Abrisqueta P, Castellví J, Bastos-Oreiro M, Menárguez J, Alcoceba M, González-Barca E, Climent F, Salar A, Sancho JM, Staiger AM, Ott G, Anagnostopoulos I, Esteller M, Lenz G, Tapia G, Navarro JT. Blood Adv. 2025 Jun 24;9(12):2953-2967. IF: 7.1.

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS. DeZern AE, Thepot S, de Botton S, Patriarca A, Deeren D, Torregrossa-Diaz JM, Marconi G, Bernal T, Bergua Burgues J, Xicoy B, Jonášová A, Zeidan AM, Dimicoli-Salazar S, Simand C, Valcarcel D, Diez Campelo M, Chai-Ho W, Saini L, Garnier A, Geissler K, Ofran Y, Nagy Z, Krishnamurthy P, Lübbert M, Basak G, Carraway HE, Sallman DA, Borate U, Santini V, Campbell V, Fenaux P, Braun T, Lanza F, Zaucha JM, Roth DA, Paul S, Roy P, Kelly MJ, Volkert A, Chisholm J, Malak TA, Klimek VM, Cluzeau T. Blood Adv. 2025 Aug 26;9(16):4090-4099. IF: 7.1.

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGvHD biomarkers. Caballero-Velázquez T, Delgado Serrano J, López-Corral L, Ferra-Coll C, García-Calderón CB, Valcárcel D, García-Cadenas I, Pérez López E, Jiménez Lorenzo MJ, Martín-Domínguez FM, Jiménez-León MLR, Orti G, Escamilla Gómez V, Blázquez-Goñi C, Cabero Martínez A, Andrade Ruiz H, Menéndez-Pedregal E, Sánchez-Guijo F, Pérez Simón JA. Blood Adv. 2025 Nov 11;9(21):5528-5538. IF: 7.1.

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO. Gutierrez A, Zeberio I, Peñalver FJ, Martinez-Barranco P, Perez S, Morillo D, Martin X, Nicolas C, Ferrero A, Jimenez-Ubieto A, Bastos-Oreiro M, Davila-Valls J, Calle MV, Perez M, Rodriguez G, Alonso A, Garcia-Noblejas A, Sanchez Argüello D, Knight T, Fernandez Á, Lopez J, Perez De Oteyza J, González de Villambrosia S, Perez E, Marin A, Navarro MB, Fernandez R, Gomez P, Hueso JA, Peñarrubia Ponce MJ, Bravo P, Garcia-Belmonte D, De La Nuez H, Nistal S, Abrisqueta P, Ibañez F, Palomera L, Donato E, Provencio A, Infante MS, Gonzalez-Barca E. Blood Adv. 2025 Oct 14;9(19):4924-4935. IF: 7.1.

New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Geethakumari PR, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse C, Turtle CJ, Vallurupalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror M. Blood Adv. 2025 Aug 18. doi: 10.1182/bloodadvances.2024015599. IF: 7.1.

Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia. Cabrera-Serrano AJ, Sánchez-Maldonado JM, Rodríguez-Sevilla JJ, Reyes-Zurita FJ, Collado R, Puiggros A, Cornejo-Calvo E, García-Martín P, Ter Horst R, Benavente Y, Jerez A, Landi S, Espinet B, Maffei R, López-Nevot MÁ, Ramos-Campoy S, González-Olmedo C, Chen-Liang TH, Moreno V, Jannus F, Marcos-Gragera R, Carretero-Fernández M, Sampaio-Marques B, Gámez I, García-Álvarez M, Camp NJ, Dierssen-Sotos T, Kamaso J, Pérez EM, Norman AD, Luppi M, Li Y, Alcoceba M, Campa D, de San José S, Marasca R, Ludovico P, Clay-Gilmour A, Canzian F, Ibañez M, Netea MG, McKay J, Casabonne D, Berndt SI, Slager SL, Sainz J. Blood Adv. 2025 Dec 9;9(23):6076-6089. IF: 7.1.

A lncRNA-mediated metabolic rewiring of cell senescence. Grossi E, Marchese FP, González J, Goñi E, Fernández-Justel JM, Amadoz A, Herranz N, Puchades-Carrasco L, Montes M, Huarte M. Cell Rep. 2025 Jun 24;44(6):115747. IF: 6.9.

Mex3a-dependent post-transcriptional silencing ensures olfactory receptor diversity and axon guidance specificity. Duffié R, Shayya H, Escamilla Del Arenal M, Wang M, Kahiapo J, Ugurbil A, Keskin A, Clowney F, Bashkirova EV, Pourmorady AD, Schieren I, Avila HI, Berchowitz LE, Barriga FM, Batlle E, Jovanovic M, Lomvardas S. Cell Rep. 2025 Aug 26;44(8):115979. IF: 6.9.

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. Giuntini F, González-Larreategui Í, Herencia-Ropero A, Casacuberta-Serra S, Zacarías-Fluck MF, Arnal M, Pedretti F, Martínez-Martín S, Thabussot H, Cano VC, Grueso J, Foradada L, Serrano E, López-Estévez S, Rodriguez O, Guzman M, Rodriguez-Hernandez A, Brasó-Maristany F, Llop-Guevara A, Balmaña J, Nonell L, Prat A, Serra V, Beaulieu ME, Whitfield JR, Massó-Vallés D, Soucek L. Cell Rep. 2025 Dec 23;44(12):116604. IF: 6.9.

Sinonasal Sarcomas Management: An International Consensus Statement. Vinciguerra A, Caspani F, Valentini M, Camarda AM, Provenzano S, Wang EW, Meço C, Ferrari M, Surda P, Harrabi S, Campos FAB, Broto JM, Guadagnolo BA, Navarria P, Hosni A, Hindi N, Italiano A, Trifiletti DM, Kasper B, Verillaud B, Schreiber A, Castelnuovo P, Nicolai P, Dallan I, Chacon M, Su SY, Thariat J, Valverde C, Lechner M, Blay JY, Fiore MR, Eloy JA, Brahmi M, Palmer JN, Oliden VC, Greto D, Lugowska I, Tos APD, van Zele T, Psaltis AJ, Casali PG, Dufresne A, Sangalli C, Georgalas C, Orlandi E, Wormald PJ, Herman P, Carrau R, Hanna EY, Licitra L, Turri-Zanoni M, Battaglia P. Int Forum Allergy Rh. 2025 Sep 30. doi: 10.1002/alr.70038. IF: 6.8.

Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence. Groen-van Schooten TS, Cabeza-Segura M, Ferreira RM, Martínez-Ciarpaglini C, Barros R, Santos-Antunes J, Costa A, Fernández-Figueroa EA, Lino-Silva L, Hernandez-Guerrero AI, Ruiz-García E, Caballero C, Boggino H, Gauna C, Cantero D, Freile B, Esteso F, O Connor J, Riquelme A, Owen G, Riquelme E, Roa JC, Latorre G, Garrido M, Ruiz-Pace F, Diez García M, Alsina M, Lordick F, Farrés J, Carbonell-Asins JA, Villagrasa R, Pereira R, Pouw RE, Jimenez-Martí E, Miralles A, Dientsmann R, Figueiredo C, Carneiro F, Cervantes A, Derks S, Fleitas T. Br J Cancer. 2025 May;132(9):783-792. IF: 6.8.

Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis. Mateos L, Jiménez-Fonseca P, Gallego J, Lecumberri A, Custodio A, Martínez de Castro E, Hernández San Gil R, Fernández Montes A, Limón ML, Vidal-Tocino R, Cano JM, López Robles J, Gil M, Acosta Eyzaguirre D, Marín Zafra G, Mérida-García AJ, Francisco Fernández A, Ribera Fernández P, Hierro C, Riesco MC, García Araque M, Ruiz Martín M, Pimentel P, Visa L, Cerdá P, Granja M, Rupérez Blanco AB, Gutiérrez L, Carmona-Bayonas A. Br J Cancer. 2025 Nov 26. doi: 10.1038/s41416-025-03264-2. IF: 6.8.

DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer. Rodríguez-Lloveras H, Zafon C, Iglesias C, Marcos-Ruiz J, Gil J, Rueda-Pujol A, González L, Mayor R, Klein Hesselink EN, van Hemel BM, Carrato C, Perelló-Fabregat C, Hernández-Losa J, Somoza R, Pluvinet R, Sánchez-Herrero JF, Sumoy L, Seoane J, Riesco-Eizaguirre G, Montero-Conde C, Robledo M, Hernando J, Capdevila J, Reverter JL, Puig-Domingo M, Links TP, Jordà M. Thyroid. 2025 May;35(5):494-507. IF: 6.7.

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer. Elisei R, Wirth LJ, Capdevila J, Hoff AO, Tahara M, Sherman EJ, Hu MI, Ge MH, Wadsley J, Vaisman F, Kopeckova K, Krajewska J, Olvera D, Churchill C, Maeda P, Gilligan AM, Lin Y, Payakachat N, Robinson B, Hadoux J, Brose MS. Thyroid. 2025 Oct;35(10):1162-1172. IF: 6.7.

Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial. Gomà C, Mollà M, Oses G, Sanfeliu E, Rodríguez-Hernández A, González-Farré B, Galván P, Sirenko V, Castillo O, Blasco P, Llop-Guevara A, Serra V, Ganau S, Úbeda B, Bargalló X, Cases C, Latorre-Musoll A, Martínez-Sáez O, Garcia-Fructuoso I, Gómez-Bravo R, Schettini F, Adamo B, Pascual T, Vidal M, Muñoz M, Laplana M, Cebrecos I, Mension E, Prat A, Brasó-Maristany F. Int J Radiat Oncol Biol Phys. 2025 Aug 5. doi: 10.1016/j.ijrobp.2025.07.1443. IF: 6.5.

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). Sierra Rodero B, Martínez-Toledo C, Nadal E, Molina-Alejandre M, García Campelo R, Gil-González Á, Massuti B, García-Grande A, Dómine M, Insa A, de Castro Carpeño J, Huidobro Vence G, Majem M, Martinez-Marti A, Megias D, Lobato D, Collazo-Lorduy A, Calvo V, Provencio M, Cruz-Bermúdez A. Oncoimmunology. 2025 Dec;14(1):2513109. IF: 6.3.

Swarm learning with weak supervision enables automatic breast cancer detection in magnetic resonance imaging. Saldanha OL, Zhu J, Müller-Franzes G, Carrero ZI, Payne NR, Escudero Sánchez L, Varoutas PC, Kyathanahally S, Laleh NG, Pfeiffer K, Ligero M, Behner J, Abdullah KA, Apostolakos G, Kolofousi C, Kleanthous A, Kalogeropoulos M, Rossi C, Nowakowska S, Athanasiou A, Perez-Lopez R, Mann R, Veldhuis W, Camps J, Schulz V, Wenzel M, Morozov S, Ciritsis A, Kuhl C, Gilbert FJ, Truhn D, Kather JN. Commun Med (Lond). 2025 Feb 6;5(1):38. IF: 6.3.

Expanding screening through the use of liquid biopsy for early cancer detection. Perachino M, Ortiz C, Carmona J, Saura C, Vivancos A. Commun Med (Lond). 2025 May 10;5(1):167. IF: 6.3.

Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI. Grussu F, Grigoriou A, Bernatowicz K, Palombo M, Casanova-Salas I, Navarro-Garcia D, Barba I, Simonetti S, Serna G, Macarro C, Voronova AK, Garay V, Corral JF, Vidorreta M, García-Polo García P, Merino X, Mast R, Rosón N, Escobar M, Vieito M, Toledo R, Nuciforo P, Mateo J, Garralda E, Perez-Lopez R. Commun Med (Lond). 2025 Nov 20;5(1):535. IF: 6.3.

Syndecan-3 positively regulates the pro-inflammatory function of macrophages. Lee SY, Prieto-Fernández E, Egia-Mendikute L, Antoñana-Vildosola A, Velasco-Beltrán P, Bosch A, Jimenez-Lasheras B, de Blas A, Etxaniz-Diaz de Durana J, Valdaliso-Díez E, Bozal-Basterra L, Ercilla A, Martin JE, Carracedo A, Gros A, Aransay AM, Palazón A, Pérez-Gutiérrez L. Cell Mol Life Sci. 2025 Apr 7;82(1):145. IF: 6.2.

The risk of a second primary cancer in PTEN Hamartoma Tumor Syndrome (PHTS). Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, de Jong MM, Links TP, Brems H, Aerden M, Brunet J, Lleuger-Pujol R, Hüneburg R, Aretz S, Colas C, Villy MC, Woodward ER, Evans DG, Bosch DGM, Donze SH, Foretová L, Blatnik A, Leter EM, Tischkowitz M, Jahn A, de Putter R, Dupont J, Briskemyr S, Steinke-Lange V, Baldassarri M, Anastasiadou VC, Irmejs A, Oliveira C, van der Post RS, Mensenkamp AR, Tesi B, Mu N, Benusiglio PR, Gerasimenko A, Innella G, Turchetti D, Houdayer C, Branchaud M, Høberg Vetti H, Tveit Haavind M, Balmaña J, Torres M, Genuardi M, Panfili A, Jørgensen K, Mæhle L, Hoogerbrugge N, Vos JR. Genet Med. 2025 Oct;27(10):101467. IF: 6.2.

Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Ngeow J, Chiang J, Astiazaran-Symonds E, Balmaña J, Cass I, Kommoss FKF, Foulkes WD, James PA, Katcher A, Klugman S, Livinski AA, Mak JS, Voian N, Wick MJ, Tischkowitz M, Pal T, Stewart DR, Hanson H; ACMG Professional Practice and Guidelines Committee. Electronic address: documents@acmg.net. Genet Med. 2025 Nov;27(11):101557. IF: 6.2.

A bottom-up approach to find lead compounds in expansive chemical spaces. Serrano-Morrás Á, Bertran-Mostazo A, Miñarro-Lleonar M, Comajuncosa-Creus A, Cabello A, Labranya C, Escudero C, Tian TV, Khutorianska I, Radchenko DS, Moroz YS, Defelipe L, Ruiz-Carrillo D, Garcia-Alai M, Schmidt R, Rarey M, Aloy P, Galdeano C, Juárez-Jiménez J, Barril X. Commun Chem. 2025 Aug 1;8(1):225. IF: 6.2.

Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care. Salas MQ, Solano MT, Baile González M, Acera Gómez M, Fox L, Pérez Artigas MDM, Santamaría A, Quintela González MDC, Sánchez Salinas A, Salmerón Camacho JM, Illana Álvaro V, Abdallahi-Lefdil Z, Cornago Navascues J, Pardo L, Fernández-Luis S, Vega Suárez LP, Villar S, Beorlegui-Murillo P, Esquirol A, Izquierdo García I, Rodríguez González S, Mussetti A, Lavilla E, Lopez-Marín J, Filaferro S, Cedillo Á, Bento L, Sureda A. Front Immunol. 2025 Jan 7;15:1512154. IF: 5.9.

Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC. Pinto FR, Cascos E, Pérez-López E, Baile-González M, Martín Rodríguez C, Pascual Cascón MJ, Luque M, Esquirol A, Calvo CM, Peña-Muñóz F, Fernando IH, Oiartzabal Ormtegi I, Sáez Marín AJ, Fernández-Luis S, Domínguez-García JJ, Fernández SV, López Lorenzo JL, Girón MFS, Pinedo LG, García L, González-Rodriguez AP, Torrado T, Filaferro S, Basalobre P, López-García A, Ortí G, Jurado Chacón M, Queralt Salas M. Front Immunol. 2025 May 1;16:1571678. IF: 5.9.

Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies. Catani G, Morchón-Araujo D, Mirallas O, Sánchez-Pérez V, Nuciforo P, Villacampa G, Dienstmann R, Vivancos A, Garralda E, Hernando-Calvo A. Front Immunol. 2025 Oct 22;16:1664443. IF: 5.9.

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence. Mora E, Fox ML, Lemes A, Velasco B, Hernández-Rivas JM. Front Immunol. 2025 Nov 14;16:1704077. IF: 5.9.

Targeted Next-Generation Sequencing in Succinate Dehydrogenase-Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway. Cicala CM, Matito J, Quindos M, Gómez-Peregrina D, Romero-Lozano P, Fernández-Suárez P, Valverde C, González M, Landolfi S, Pérez-Albert P, Gros L, Vivancos A, Serrano C. JCO Precis Oncol. 2025 Jan;9:e2400497. IF: 5.8.

Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations. Aldea M, Orillard E, Bernard-Tessier A, Cerbone L, Llacer C, Koster KL, Roubaud G, De Giorgi U, Joly F, Cherifi F, Rochand A, Omlin A, Beltran H, Morales-Barrera R, Annonay M, Bianchini D, de Bono J, Castro E, Baciarello G, Gillessen S, Thiery-Vuillemin A, Fizazi K. JCO Precis Oncol. 2025 Aug;9:e2500310. IF: 5.8.

Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challenges. Jiménez-Labaig P, Lorini L, Gurizzan C, Kinloch E, Burton S, Forster MD, Metcalf R, Ferrarotto R, Bossi P, O Leary B, Hanna G, Felip E, Garcia IB, Harrington KJ. Crit Rev Oncol Hematol. 2025 Jul;211:104747. IF: 5.6.

Balancing risks and benefits of immune checkpoint inhibitors in patients with pre-existing immune-mediated inflammatory diseases: A comprehensive review. de Torres CS, Trallero-Araguas E, Marmolejo D, Hermida JMU, Mejía ND, Baselga PM, Geng-Cahuayme AAA, Catalan L, González M, Morales-Barrera R, Carles J, Gallardo E, Suárez C. Crit Rev Oncol Hematol. 2025 Dec;216:105000. IF: 5.6.

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]). DeMichele A, Dueck AC, Hlauschek D, Martin M, Burstein H, Pfeiler G, Zdenkowski N, Wolff A, Bellet-Ezquerra M, Winer E, Balic M, Miller K, Colleoni M, Lake D, Rubovsky G, Cameron D, Balko J, Singer CF, Nowecki Z, Iwata H, Wolmark N, Parraga KA, Rugo H, Steger GG, Traina T, Werutsky G, Czajkowska D, Metzger O, El-Abed S, Theall KP, Lu RD, O'Brien P, Fesl C, Mayer E, Gnant M. Breast Cancer Res. 2025 Jan 23;27(1):12. IF: 5.6.

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study. Dent R, Cortés J, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Holgado E, Foukakis T, Kümmel S, Yearley J, Wang A, Nebozhyn M, Huang L, Cristescu R, Jelinic P, Karantza V, Schmid P. Breast Cancer Res. 2025 Mar 11;27(1):35. IF: 5.6.

The SeqSplice multiplexed minigene splicing assay for characterization and quantitation of variant-induced BRCA1 and BRCA2 splice isoforms. Canson DM, Parsons MT, Moir-Meyer G, Dumenil T, Montalban G, Lin E, McVeigh TP, Davidson AL, Bouckaert SM, Trau M, Korbie D, Spurdle AB. Genome Res. 2025 Sep 2;35(9):2104-2115. IF: 5.5.

Discovery and characterisation of VPRBP/DCAF1 kinase inhibitor analogues as microtubular destabilising agents with potent anti-myeloma activity. Susanto O, Gruber E, Wun CM, Franich RL, Ma X, Sabouri-Thompson Z, Porter ZJ, Murray HC, Cluse LA, Maher B, Brasacchio D, Martin BP, Fraser PJ, Nikolic I, Mir Arnau G, Sandow JJ, Simpson KJ, Verrills NM, Johnstone RW, Thompson PE, Kats LM, Shortt J. Mol Cancer Ther. 2025 Nov 4. doi: 10.1158/1535-7163.MCT-25-0306. IF: 5.5.

Mosperafenib, a novel paradox breaker BRAF inhibitor with potent preclinical activity in BRAF mutated colorectal cancer. Renner F, Eckmann J, Handl C, Wichmann J, Schnetzler G, Kratochwil NA, Keshelava N, Ros J, Élez E, Vergés J, Chicote I, Martínez-Quintanilla J, Palmer HG, Pettazzoni P. Mol Cancer Ther. 2025 Dec 4. doi: 10.1158/1535-7163.MCT-25-0562. IF: 5.5.

Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer. Brandariz J, de Llobet L, Esquefa V, Aguilar D, Salca A, Arce-Gallego S, Cresta Morgado P, Sole A, Agundez L, Mir G, Castro N, Casals T, Oliveira A, Casanova-Salas I, Malumbres M, Carles J, Morellá-Aucejo Á, Bernardos A, Martínez-Máñez R, Mateo J, Herranz N. Mol Cancer Ther. 2025 Dec 2;24(12):1959-1976. IF: 5.5.

Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth. Guerrero M, Proaño-Pérez E, Serrano-Candelas E, García-Valverde A, Carrillo-Rodríguez B, Rosell J, Serrano C, Martin M. Mol Ther Oncol. 2025 Apr 14;33(2):200983. IF: 5.3.

Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia. López A, Charbonnier D, Vela P, Díez B, Río P, Sánchez R, Alberquilla O, Martín-Antonio B, Minguillón J, Esquinas E, García-Escudero R, Errazquin R, Del Marro S, Pascual A, Lorz C, Juarranz Á, Barahona A, Balmaña J, Maher J, Bueren JA, Casado JA. Mol Ther Oncol. 2025 Sep 22;33(4):201060. IF: 5.3.

Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial. de Leeuw ALMP, Hoebers FJP, Giralt J, Tao Y, Terhaard CHJ, Lee LW, Friesland S, Steenbakkers RJHM, Tans L, Kayembe MT, van Kranen SR, Bartelink H, Rasch CRN, Sonke JJ, Hamming-Vrieze O. Radiother Oncol. 2025 Sep;210:111044. IF: 5.3.

Unveiling regions associated with acute and late breast side-effects from breast radiotherapy using voxel-wise image-based data mining analysis. Jaikuna T, Wilson F, Anandadas C, Azria D, Chang-Claude J, De Santis MC, Gutiérrez-Enríquez S, van Herk M, Hoskin P, Kotzki L, Lambrecht M, Lingard Z, Seibold P, Seoane A, Sperk E, Symonds R, Talbot CJ, Rancati T, Rattay T, Reyes V, Rosenstein BS, de Ruysscher D, Vega A, Veldeman L, Webb A, West CM, Vasquez Osorio E, Aznar MC. Radiother Oncol. 2025 Oct 25. doi: 10.1016/j.radonc.2025.111230. IF: 5.3.

Footprints of Worldwide Adaptation in Structured Populations of Drosophila melanogaster Through the Expanded DEST 2.0 Genomic Resource. Nunez JCB, Coronado-Zamora M, Gautier M, Kapun M, Steindl S, Ometto L, Hoedjes K, Beets J, Wiberg RAW, Mazzeo GR, Bass DJ, Radionov D, Kozeretska I, Zinchenko M, Protsenko O, Serga SV, Amor-Jimenez C, Casillas S, Sánchez-Gracia A, Patenkovic A, Glaser-Schmitt A, Barbadilla A, Buendia-Ruíz AJ, Bertelli AC, Kiss B, Önder BS, Matrín BR, Wertheim B, Deschamps C, Arboleda-Bustos CE, Tinedo C, Feller C, Schlötterer C, Lawler C, Fricke C, Vieira CP, Vieira C, Obbard DJ, Orengo DJ, Vela D, Amat E, Loreto E, Kerdaffrec E, Mitchell ED, Puerma E, Staubach F, Camus MF, Colinet H, Hrcek J, Sørensen JG, Abbott J, Torro J, Parsch J, Vieira J, Olmo JL, Khfif K, Wojciechowski K, Madi-Ravazzi L, Kankare M, Schou MF, Ladoukakis ED, Gómez-Julián MJ, Espinosa-Jimenez ML, Garcia Guerreiro MP, Parakatselaki ME, Savic Veselinovic M, Tanaskovic M, Stamenkovic-Radak M, Paris M, Pascual M, Ritchie MG, Rera M, Jelić M, Ansari MH, Rakic M, Merenciano M, Hernandes N, Gora N, Rode N, Rota-Stabelli O, Sepulveda P, Gibert P, Carazo P, Kohlmeier P, Erickson PA, Vitalis R, Torres JR, Guirao-Rico S, Ramos-Onsins SE, Castillo S, Paulo TF, Tyukmaeva V, Alonso Z, Alatortsev VE, Pasyukova E, Mukha DV, Petrov DA, Schmidt P, Flatt T, Bergland AO, Gonzalez J. Mol Biol Evol. 2025 Jul 30;42(8):msaf132. IF: 5.3.

Iron Deficiency Is Associated With Impaired Myocardial Reperfusion in ST-Segment-Elevation Myocardial Infarction: Influence of the Definition Used. Barrabés JA, Inserte J, Castellote L, Buera I, Milà L, Sambola A, Uribarri A, Vidal M, Aluja D, Delgado-Tomás S, Tobías-Castillo PE, Calvo-Barceló M, Guala A, Rodríguez-Palomares JF, Del Blanco BG, Beneítez D, Ferreira-González I. J Am Heart Assoc. 2025 Jun 3;14(11):e040845. IF: 5.3.

Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis. López-Pereira P, Romero Domínguez S, Martin-Moro F, Caballero AC, López García A, de la Cruz Benito B, Franch Sarto M, de la Cruz Vicente F, López Marín J, Pinzón Marino S, Jiménez-Ubieto A, Cabirta A, Gutiérrez NC, Lis Chulvi MJ, Puyuelo A, Muntañola Prat A, Penedo Coello A, García-Lerma E, Mercadal Vilchez S. Bone Marrow Transplant. 2025 Nov 27. doi: 10.1038/s41409-025-02772-2. IF: 5.2.

Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee. Ortí G, Dachy G, Graham CE, Peric Z, Alarcon A, Del Bufalo F, Doglio M, Henter JI, Roddie C, Stewart O, Van de Donk WCJ, Velasco R, Aljurf M, Ruggeri A, Onida F, Sánchez-Ortega I, Yakoub-Agha I, Penack O. Bone Marrow Transplant. 2025 Jun;60(6):751-758. IF: 5.2.

Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy. Torrent A, Morgades M, Iacoboni G, Reguera JL, Kwon M, López Corral L, Hernani R, Ortiz-Maldonado V, Sanz J, Caballero Gonzalez AC, Guerra L, Sánchez Pina JM, Mussetti A, Garcia-Sancho AM, Bastos-Oreiro M, Delgado J, Carpio C, Sancho JM, Pérez-Martinez A, Barba P. Bone Marrow Transplant. 2025 Dec;60(12):1675-1678. IF: 5.2.

External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy. Jimenez-Fonseca P, Álvarez-Escola C, Ballester Navarro I, Hernando Cubero J, González Fernández L, Mangas Cruz MÁ, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Molina J, Jimeno Maté R, Aller J, Romero MDCT, Cardenas Salas J, Gutiérrez-Buey G, Egaña Zunzunegui N, Navarro M, Lecumberri MJ, Valdés N, Carmona-Bayonas A. Eur J Endocrinol. 2025 Jul 31;193(2):320-328. IF: 5.2.

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index. Persano M, Rimini M, Salani F, Prinzi FL, Nichetti F, Saborowski A, Antonuzzo L, Passeri L, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Corallo S, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Fornaro L, De Rosa A, Lanzetta I, Balsano R, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Tesini G, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Ferrara M, Himmelsbach V, Landriscina M, Djaballah SA, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Liver Int. 2025 Jul;45(7):e70181. IF: 5.2.

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study. Niger M, Rimini M, Castet F, Melzer A, Rizzato MD, Pressiani T, Lavacchi D, Aprile G, Angela T, Saladino T, Silvia N, Cito P, Pastorino A, Terán-Brage E, Sciortino C, Camera S, Pircher C, Persano M, Mazzaferro V, Foti S, Vega KS, Ettrich TJ, Antonuzzo L, Rimassa L, Lonardi S, Perkhofer L, Macarulla T, Pietrantonio F, Casadei-Gardini A. Liver Int. 2025 Sep;45(9):e70295. IF: 5.2.

Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers. Rimini M, Fornaro L, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Pircher C, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Lamarca A, Landriscina M, Fimkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Pinto CMS, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Changhoon Y, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan S, Warmington E, Lancianese A, Bekaii-Saab T, Lavacchi D, Kang M, Lonardi S, Vogel A, Prete AA, Bozzarelli S, Salani F, Persano M, Masi G, Balsano R, Niger M, Camera S, Passeri L, Ferrara M, Satake T, Rimassa L, Casadei-Gardini A. Liver Int. 2025 Dec;45(12):e70428. IF: 5.2.

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients. El-Deiry WS, Bresson C, Wunder F, Carneiro BA, Dizon DS, Warner JL, Graff SL, Azzoli CG, Wong ET, Cheng L, Mani SA, Safran HP, Williams C, Meissner T, Solomon B, Rubin E, Porgador A, Berchem G, Saintigny P, Onn A, Bar J, Berger R, Gantenbein M, Chen Z, Souza CP, Reis RMV, Sekacheva M, Cervantes A, Dahut WL, Annunziata CM, Gober K, Musallam KM, Al-Shamsi HO, Abu-Gheida I, Salazar R, Limaye S, Aref AT, Reddel RR, Homsi MUA, Rouf A, Dermime S, Suwaidi JA, Vlad C, Buiga R, Omari AA, Abdel-Razeq H, Oñate-Ocaña LF, Nielsen FC, Graham L, Rueter J, Joshua AM, Girda E, Libutti S, Riedlinger G, Salem ME, Farhangfar CJ, Mesa RA, Faltas BM, Elemento O, Pramesh CS, Sengar M, Aoyama S, Ikeda S, Berindan-Neagoe I, Gaddipati H, Kulkarni M, Auzias E, Gerogianni M, Wolikow N, Istolainen S, Schlafrig P, Frankel NZ, Ferraro AR, Palma J, Gimenez AP, Hernando-Calvo A, Felip E, Tsimberidou AM, Herbst RS, Tabernero J, Schilsky RL, Liu J, Lussier Y, Raynaud J, Batist G, Magidi S, Kurzrock R. Oncotarget. 2025 Mar 12;16:140-162. IF: 5.168.

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment. Hernando A,Kurzrock R,Gonzalez NS,Magidi S,Bresson C,Wunder F,Pretelli G,Casado AM,El WS. Oncotarget. 2025. 16. p. 456-466. IF: 5.168.

Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression. Martínez-Ciarpaglini C, Barros R, Caballero C, Boggino H, Alarcón-Molero L, Peleteiro B, Ruiz-García E, Fernandez-Figueroa E, Herrera-Goepfert R, Díaz-Romero C, Ferreira R, Groen-van Schooten TS, Gauna C, Pereira R, Cantero D, Lezcano H, Esteso F, O Connor J, Riquelme A, Owen GI, Garrido M, Roa JC, Ruiz-Pace F, Vivancos A, Diez-García M, Alsina M, Matito J, Martin A, Gómez M, Castillo E, Vila M, Santos-Antunes J, Costa A, Lordick F, Farrés J, Palomar-De Lucas B, Cabeza-Segura M, Villagrasa R, Jimenez-Martí E, Miralles-Marco A, Dienstmann R, Derks S, Figueiredo C, Cervantes A, Carneiro F, Fleitas-Kanonnikoff T. Gastric Cancer. 2025 Mar;28(2):160-173. IF: 5.1.

Histology-informed microstructural diffusion simulations for MRI cancer characterisation-the Histo-µSim framework. Grigoriou A, Macarro C, Palombo M, Navarro-Garcia D, Voronova AK, Bernatowicz K, Barba I, Escriche A, Greco E, Abad M, Simonetti S, Serna G, Mast R, Merino X, Roson N, Escobar M, Vieito M, Nuciforo P, Toledo R, Garralda E, Sala-Llonch R, Fieremans E, Novikov DS, Perez-Lopez R, Grussu F. Commun Biol. 2025 Nov 26;8(1):1695. IF: 5.1.

Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry. Carmona-Bayonas A, Álvarez-Escolá C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MÁ, Garcia-Centeno R, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Alonso Gordoa T, López C, Hanzu F, Martínez-Trufero J, Febrero B, Saiz-López P, Blanco Carrera C, Ramón Y Cajal T, Veiguela B, Gressani O, Valdés N, Jimenez-Fonseca P. J Clin Endocrinol Metab. 2025 Oct 16;110(11):3155-3167. IF: 5.1.

Emerging Immunotherapy Targets in Early Drug Development. Morchón-Araujo D, Catani G, Mirallas O, Pretelli G, Sánchez-Pérez V, Vieito M, Braña I, Pujol-Borrell R, Garralda E, Hernando-Calvo A. Int J Mol Sci. 2025 Jun 4;26(11):5394. IF: 4.9.

Specific Instability of HLA-A*03:01 Expression in HEK-293 Cells. Area-Navarro M, Pastor-Moreno A, Scholz E, Cerqueira A, Tirado-Herranz A, Marcilla M, Canals F, Juan M, Palacio JR, Alvarez I. Int J Mol Sci. 2025 Nov 24;26(23):11357. IF: 4.9.

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer. Barnes DR, Tyrer JP, Dennis J, Leslie G, Bolla MK, Lush M, Aeilts AM, Aittomäki K, Andrieu N, Andrulis IL, Anton-Culver H, Arason A, Arun BK, Balmaña J, Bandera EV, Barkardottir RB, Berger LPV, Berrington de Gonzalez A, Berthet P, Białkowska K, Bjørge L, Blanco AM, Blok MJ, Bobolis KA, Bogdanova NV, Brenton JD, Butz H, Buys SS, Caligo MA, Campbell I, Castillo C, Claes KBM, Colonna SV, Cook LS, Daly MB, Dansonka-Mieszkowska A, de la Hoya M, deFazio A, DePersia A, Ding YC, Doherty JA, Domchek SM, Dörk T, Einbeigi Z, Engel C, Evans DG, Foretova L, Fortner RT, Fostira F, Foti MC, Friedman E, Frone MN, Ganz PA, Gentry-Maharaj A, Glendon G, Godwin AK, González-Neira A, Greene MH, Gronwald J, Guerrieri-Gonzaga A, Hamann U, Hansen TVO, Harris HR, Hauke J, Heitz F, Hogervorst FBL, Hooning MJ, Hopper JL, Huff CD, Huntsman DG, Imyanitov EN, Izatt L, Jakubowska A, James PA, Janavicius R, John EM, Kar S, Karlan BY, Kennedy CJ, Kiemeney LALM, Konstantopoulou I, Kupryjanczyk J, Laitman Y, Lavie O, Lawrenson K, Lester J, Lesueur F, Lopez-Pleguezuelos C, Mai PL, Manoukian S, May T, McNeish IA, Menon U, Milne RL, Modugno F, Mongiovi JM, Montagna M, Moysich KB, Neuhausen SL, Nielsen FC, Noguès C, Oláh E, Olopade OI, Osorio A, Papi L, Pathak H, Pearce CL, Pedersen IS, Peixoto A, Pejovic T, Peng PC, Peshkin BN, Peterlongo P, Powell CB, Prokofyeva D, Pujana MA, Radice P, Rashid MU, Rennert G, Richenberg G, Sandler DP, Sasamoto N, Setiawan VW, Sharma P, Sieh W, Singer CF, Snape K, Sokolenko AP, Soucy P, Southey MC, Stoppa-Lyonnet D, Sutphen R, Sutter C, Tan YY, Teixeira MR, Terry KL, Thomsen LCV, Tischkowitz M, Toland AE, Van Gorp T, Vega A, Velez Edwards DR, Webb PM, Weitzel JN, Wentzensen N, Whittemore AS, Winham SJ, Wu AH, Yadav S, Yu Y, Ziogas A, Berchuck A, Couch FJ, Goode EL, Goodman MT, Monteiro AN, Offit K, Ramus SJ, Risch HA, Schildkraut JM, Thomassen M, Simard J, Easton DF, Jones MR, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. NPJ Genom Med. 2025 Nov 20;10(1):73. IF: 4.8.

VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol. Salazar J, Arranz MJ, Martin-Broto J, Serra M, Palmerini E, Martínez-García J, Juan-Ribelles A, Andion M, Martinez-Trufero J, Gutiérrez G, Echebarria-Barona A, Vaz-Salgado MA, Regueiro A, Alvarez R, Valverde C, Luna P, Blay P, Sebio A. Pharmaceuticals (Basel). 2025 Dec 5;18(12):1855. IF: 4.8.

Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study. Rimini M, Fornaro L, Prinzi FL, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Corallo S, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Vitiello F, Himmelsbach V, Landriscina M, Djaballah SA, Tesini G, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Int J Cancer. 2025 Sep 15;157(6):1246-1259. IF: 4.7.

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population. Prinzi FL, Salani F, Camera S, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Polito MG, Di Giacomo E, Farinea G, Bartalini L, Grelli G, De Rosa A, Lavacchi D, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Bekaii-Saab T, Fornaro L, Masi G, Vogel A, Lonardi S, Rimini M, Rimassa L, Casadei-Gardini A. Int J Cancer. 2025 Nov 15;157(10):2092-2102. IF: 4.7.

ESR Essentials: diffusion-weighted MRI-practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology. Palombo M, Bodini B, Grussu F, Le Bihan D, Nilsson M, Perez-Lopez R, Oei EHG, Schoots IG, Smits M, Jelescu IO. Eur Radiol. 2025 Oct 2. doi: 10.1007/s00330-025-12033-x. IF: 4.7.

ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer. Woo S, Russo L, Withey SJ, Dehghanpour A, García-Figueiras R, Schoots IG, Petralia G, Lakhani A, Penzkofer T, Pecoraro M, Wu CJ, Walz J, Eiber M, Fendler WP, Gillessen S, Perez-Lopez R, Lecouvet FE, Barwick TD, Padhani AR; ESUR Prostate MRI Working Group. Eur Radiol. 2025 Nov 5. doi: 10.1007/s00330-025-12089-9. IF: 4.7.

Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V. Int J Gynecol Cancer. 2025 Sep;35(9):101812. IF: 4.7.

An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study). Gallego A, Madariaga A, Estévez-García P, Albertí F, Carbó A, Palacio I, Churruca C, Gálvez F, Ortega ME, Murata P, Manzano A, Masvidal M, Martín-Lorente C, Hernando B, Lozano I, Cueva JF, García-Illescas D, Gost E, Mendiola M, Redondo A. Int J Gynecol Cancer. 2025 Jul;35(7):101903. IF: 4.7.

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S. Int J Gynecol Cancer. 2025 Nov;35(11):101832. IF: 4.7.

Spanish consensus on the diagnosis and management of adrenocortical carcinoma. Araujo-Castro M, Álvarez-Escola C, Casteràs A, Carmona-Bayonas A, Chiara MD, Hanzu FA, Hernando J, Vercher-Conejero JL, Rodríguez-Fraile M, Gómez Dos Santos V, Jimenez-Fonseca P, Giraldo A, Valdés N, Vidal O, Del Olmo-García M, Capdevila J. Endocr Relat Cancer. 2025 Apr 24;32(5):e250034. IF: 4.6.

Lenvatinib as salvage therapy in advanced and progressive GI-NET. Mathew A, Capdevila J, Unger N, Fendler W, Theurer S, Weber F, Fuhrer D, Lahner H. Endocr Relat Cancer. 2025 Aug 20;32(8):e250165. IF: 4.6.

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs. López-Garza A, James D, Creagh E, Murray JT. Mol Oncol. 2025 Nov;19(11):3427-3444. IF: 4.5.

Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities. Ringborg U, von Braun J, Celis J, Berns A, Baumann M, Albreht T, Abou-Zeid N, Bagnato V, Brandts C, Chen CJ, di Pietro M, Dosanjh M, Dubois T, Eggermont A, Eggert A, Ernberg I, Faithfull S, Förner J, Fröhling S, Heitor M, Hood L, Jiang W, Jönsson B, Kannan R, Leptin M, Li S, Lindgren P, Lowy D, Ma J, Markham A, Nagy P, Oberst S, Parker MI, Rodin D, Ryan K, Schüz J, Sullivan R, Tabernero J, Turkson P, Várhelyi O, Varmus H, Wang C, Weiderpass E, Wilking N. Mol Oncol. 2025 Dec 15. doi: 10.1002/1878-0261.70179. IF: 4.5.

Transcriptional network analysis of PTEN-protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication. Rondon-Lorefice I, Lopez JI, Ugalde-Olano A, Zufiaurre M, Astobiza I, Martin-Martin N, Bozal-Basterra L, Garcia-Longarte S, Zabala-Letona A, Rey S, Santos-Martin A, Unda M, Loizaga-Iriarte A, Graupera M, Nuciforo P, Carracedo A, Mendizabal I. Mol Oncol. 2025 Nov 17. doi: 10.1002/1878-0261.70164. IF: 4.5.

Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials. Gil-Bernabé S, García-DeLaFuente L, García-Álvarez A, García-Rostán G, Capdevila J, Hernando J. Am J Med Genet C Semin Med Genet. 2025 Sep;199(3):228-238. IF: 4.4.

Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Luan D, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Elsawy M, Ganguly S, Geethakumari PR, Greenbaum U, Hashmi H, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, Mead E, McGuirk JP, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Riedell PA, Saber W, Mirza AS, Magalhaes-Silverman M, Shpall EJ, Sorror M, Wudhikarn K, Turtle CJ, Moskop A, Pasquini MC. Transplant Cell Ther. 2025 Jul;31(7):419-433. IF: 4.4.

EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study. Peña M, Martinez DF, López-Corral L, Martín-López AÁ, Sanchez-Salinas M, Benzaquén A, Hernani R, Sanz J, Balaguer A, Perera M, Torrent A, Pérez-Martínez A, Filaferro S, Balsalobre P, Barba P, Mussetti A. Transplant Cell Ther. 2025 Oct 25. doi: 10.1016/j.jtct.2025.10.017. IF: 4.4.

TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer. Jones DR, Opitz I, Harpole D, Yanagawa J, Lim E, Tsutani Y, Tan DSW, Dacic S, Ganti AK, Bodla S, Batig A, Lyfar P, Forcina A, Felip E. J Thorac Cardiovasc Surg. 2025 Sep 19. doi: 10.1016/j.jtcvs.2025.09.017. IF: 4.4.

Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT). Gridelli C, Mok T, Jänne P, Passaro A, Felip E, Ramalingam SS, Attili I, de Marinis F. Lung Cancer. 2025 Mar;201:108100. IF: 4.4.

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer. Bosch-Barrera J, Estévez-García P, Martín-Martorell P, Sabatier R, Nadal E, Sais E, Gascón P, Oaknin A, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfón J, Domènech C, Morán T. ENDOLUNG trial, part II. Lung Cancer. 2025 Mar;201:108105. IF: 4.4.

Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma. Nadal E, Martín-Martorell P, Benítez JC, Sala MÁ, Cedrés S, Álvarez C, Dómine M, Sais E, Saigí M, López R, Vilà L, Massutí B, García-Campelo R, Mesas-Ruiz A, Insa A, Plans-Marín S, Hijazo-Pechero S, Muñoz-Pinedo C, Brenes J, Provencio M; Spanish Lung Cancer Group. Lung Cancer. 2025 May;203:108545. IF: 4.4.

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial. Guckenberger M, Opitz I, Dellaporta T, Curioni-Fontecedro A, Frauenfelder T, Ribi K, Cerciello F, Sullivan I, Hendriks L, Dorta M, Callejo A, Aerts J, Addeo A, Dingemans AC, Pasello G, Provencio M, de Marinis F, Mederos-Alfonso N, Roschitzki-Voser H, Ruepp B, Haberecker M, Kammler R, Dafni U, Peters S, Stahel R; ETOP 14-18 CHESS collaborators. Lung Cancer. 2025 Jun;204:108553. IF: 4.4.

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts. Pronsati N, Liu G, Bauer TM, Felip E, Goto Y, Green G, Grizzard M, Hamel M, Mazieres J, Mok T, Snow S, Solomon BJ, Stratmann J, Culver K. Lung Cancer. 2025 Aug;206:108662. IF: 4.4.

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. Dingemans AC, Syrigos K, Livi L, Paulus A, Kim SW, Chen Y, Felip E, Griesinger F, Ohashi K, Zalcman G, Hughes BGM, Sørensen JB, Blais N, Ferreira CGM, Lindsay CR, Dziadziuszko R, Ward PJ, Obiozor CC, Wang Y, Peters S. Lung Cancer. 2025 Sep;207:108683. IF: 4.4.

Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse. Martinez-Recio S, Molina-Pérez MA, Muñoz-Couselo E, Sevillano-Tripero AR, Aya F, Arance A, Orrillo M, Martin-Liberal J, Fernandez-Morales L, Lesta R, Quindós-Varela M, Nieva M, Vidal J, Martinez-Perez D, Barba A, Majem M. Cancers (Basel). 2025 Jan 5;17(1):143. IF: 4.4.

Head and Neck Cancer in Fanconi Anemia: Report of 11 Cases and a Systematic Review. de Pablo García-Cuenca A, Rofín-Fontanet P, Lorente-Guerrero J, Balmaña-Gelpí J, Carrasco-López E, Temprana-Salvador J, Granado-Carrasco R, Braña-García I, Vaquero-Martínez P, Pujol-Pina R, Bescós-Atín C. Cancers (Basel). 2025 Jan 22;17(3):349. IF: 4.4.

Naloxegol for the Treatment of Opioid-Induced Constipation in Patients with Cancer Pain: A Pooled Analysis of Real-World Data. Sabaté JM, Beato-Zambrano C, Cobo M, Lemaire A, Montesarchio V, Serna-Montros J, Namane R, Martín Baccarelli S, Rico-Villademoros F. Cancers (Basel). 2025 Mar 3;17(5):865. IF: 4.4.

BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives. Cedres S, Valdivia A, Priano I, Rocha P, Iranzo P, Pardo N, Martinez-Marti A, Felip E. Cancers (Basel). 2025 May 6;17(9):1581. IF: 4.4.

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications. Lundberg AS, Geuijen CAW, Hill S, Lammerts van Bueren JJ, Fumagalli A, de Kruif J, Silverman PB, Tabernero J. Cancers (Basel). 2025 May 14;17(10):1665. IF: 4.4.

Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation. Lema L, Pérez-García JM, Blanch S, Balmaña J, García-Sáenz JÁ, Vegas EF, Jiménez B, de la Haba J, Campolier M, Shimizu E, Alcalá-López D, Sampayo-Cordero M, Cortés J, Llombart-Cussac A. Cancers (Basel). 2025 May 22;17(11):1744. IF: 4.4.

DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. Statz-Geary K, Elliott A, Bialick S, Serrano C, von Mehren M, Oberley M, Espejo-Freire AP, Barreto Coelho P, Costa PA, D'Amato GZ, Jonczak E, Trent JC, Montgomery E, Lombard D, Rosenberg A, Dhir A. Cancers (Basel). 2025 Jun 12;17(12):1962. IF: 4.4.

Insights on Oligometastatic Non-Small-Cell Lung Cancer. Valdivia A, Mascaro-Baselga P, Salva-de Torres C, Geng-Cahuayme A, Torresan S, Yaringaño J, Priano I, Iranzo P, Pardo N, Masfarre L, Mirallas O, Farfan K, Cedres S, Rocha P, Martinez-Marti A, Felip E. Cancers (Basel). 2025 Jul 24;17(15):2451. IF: 4.4.

Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation. Torrent-Rodríguez A, Cascos E, Garcés VN, Pérez-López E, Baile-González M, Rodríguez CM, Cascón MJP, Luque M, Esquirol A, Calvo CM, Peña-Muñoz F, Fernando IH, Ormtegi IO, Marín AJS, Fernández-Luis S, Domínguez-García JJ, Fernández SV, Lorenzo JLL, de Sanmamed Girón MF, Pinedo LG, García-Maño L, González-Rodriguez AP, Torrado T, Filaferro S, Basalobre P, Ortí G, Rovira M, Chacón MJ, Salas MQ; GETH-TC. Cancers (Basel). 2025 Sep 26;17(19):3128. IF: 4.4.

Consensus on the Management of the Clinical Challenges of Venous Thromboembolism in Special Situations. Marzo C, Solanich T, Tassies D, Pina E, Rebollo MA, Gallardo E, Serradell S, Merino M, Carrasco M, Tugues A. Thromb Haemost. 2025 Oct;125(10):944-959. IF: 4.3.

Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus. Ryška A, Capdevila J, Dettmer MS, Elisei R, Führer D, Hadoux J, Jarząb B, Locati LD, Newbold K, Tallini G, Uccella S, Wirth L, Singh R, Simon IM, Camacho P, Fugazzola L. Eur Thyroid J. 2025 Jul 7;14(4):e250024. IF: 4.3.

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma. Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K, Hamidi A, Chesney J. Oncologist. 2025 Mar 10;30(3):oyae203. IF: 4.2.

A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. Calvo E, Doger B, Carles J, Peer A, Sarid D, Eigl BJ, Avadhani A, Yao D, Lin V, Wu S, Jaiprasart P, Loffredo J, Tamegnon M, Xu W, Xie H, Hansen AR. Oncologist. 2025 Jan 17;30(1):oyae313. IF: 4.2.

Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study. Del Olmo-García M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, Gomez M, Palma Milla S, Suarez L, Bellver M, Alonso V, Serrano R, Valdés N, Melian M, Febrero B, Sampedro-Nuñez MA, Biarnes J, Díaz-Pérez JÁ, Molina-Cerrillo J, Lopez C, Martínez Olmos MÁ, Merino-Torres JF, Capdevila J, Argente Pla M; NUTRIGETNE Group. Oncologist. 2025 Feb 6;30(2):oyae343. IF: 4.2.

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. Eng C, Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Yang Z, Guevara F, Schelman W, Pallai R, Tabernero J. Oncologist. 2025 Mar 10;30(3):oyae360. IF: 4.2.

Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation. Nuñez Hernández I, Gómez Palmero C, Delgado JR, Nuño A, Sala González MÁ, González Ageitos A, Aguilar H, Ayala de Miguel P, Condori E, Díaz Beveridge R, Martínez García J, Marquina G, Varela-Pose V, Veas Rodríguez J, Serrano C. Oncologist. 2025 May 8;30(5):oyaf062. IF: 4.2.

First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer. Nasca V, Tinè G, Taieb J, Lonardi S, Boursi B, Margalit O, Salvatore L, Cohen R, Ros J, Ambrosini M, Zwart K, Roodhart J, Jayachandran P, Overman MJ, Elez ME, Cremolini C, Tougeron D, Koopman M, André T, Miceli R, Pietrantonio F. Oncologist. 2025 Sep 1;30(9):oyaf255. IF: 4.2.

Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results. Spanggaard I, Matrana M, Rocha Lima C, Mahipal A, Vieito M, Hervieu A, Goyal L, Rodón J, Veronese ML, Oliveira N, Li X, Schaffer M, Kesari S. Oncologist. 2025 Nov 11;30(11):oyaf272. IF: 4.2.

Fertility preservation practices and gastrointestinal oncologist in Europe: a pan-European study. Ben-Aharon I, Goshen-Lago T, Puccini A, Alsina M, Arnold D, van Laarhoven H, Elme A, Buffart T, Fokter-Dovnik N, Sokop T, Obermanova R, Lordick F, Papamichael D, Sclafani F, Elez E, Taieb J. Oncologist. 2025 Nov 11;30(11):oyaf350. IF: 4.2.

Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain. Álvarez-Gallego R, Pazo-Cid R, López de San Vicente B, Macarulla T, Martinez E, Garicano F, Hernández I, Granja M, Ghanem I, Martinez J, Ribera P, Diaz R, Martin Valadés JI, Angeles MC, Cubillo A. Ther Adv Med Oncol. 2025 Jan 8;17:17588359241309828. IF: 4.2.

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, Graff SL, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G. Ther Adv Med Oncol. 2025 Apr 17;17:17588359251327992. IF: 4.2.

Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Adv Ther. 2025 May;42(5):2015-2018. IF: 4.1.

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression = 1%: A Retrospective Analysis of RATIONALE-305. Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH. Adv Ther. 2025 May;42(5):2248-2268. IF: 4.1.

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial. Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Pozharskaya V, Rose S, Keeperman K, Lai Y, Kalsekar S, Aggarwal B, Miteva D, Valcárcel D, Fenaux P, Shortt J, Della Porta MG, Platzbecker U. Adv Ther. 2025 Jul;42(7):3576-3589. IF: 4.1.

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. Chopra D, Lan Z, Waterhouse DM, Wolf J, Felip E, Moradian H, Karim N, Obiozor C, Stollenwerk B. Adv Ther. 2025 Sep;42(9):4300-4317. IF: 4.1.

A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer. De Cock E, Oskar S, Lourdudoss C, Eiras R, Pietanza MC, Arunachalam A, Alves G, Martinengo GL, Felip E. Adv Ther. 2025 Dec;42(12):6175-6189. IF: 4.1.

Tislelizumab plus Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up. Cruz-Correa M, Oh DY, Kato K, Tabernero J, Bai Y, Shi J, Lee KW, Hirano H, Spigel D, Wyrwicz L, Pazo Cid R, Cubillo Gracián A, Xu Y, Sheng T, Yang S, Xu RH, Moehler M. Adv Ther. 2025 Nov 18. doi: 10.1007/s12325-025-03415-0. IF: 4.1.

High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density. Corvigno S, Fernebro J, Karlsson JS, Mezheieusky A, Martín-Bernabé A, De La Fuente LM, Westbom-Fremer S, Carlson JW, Klein C, Kannisto P, Hedenfalk I, Malander S, Östman A, Dahlstrand H. Gynecol Oncol. 2025 Feb;193:148-155. IF: 4.1.

Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial. Lorusso D, Oaknin A, Borges GS, Damian F, Ottevanger N, Van Gorp T, Paiva CE, Kroep JR, Kim YM, Kim HS, Lee JK, Denys H, Lalisang R, De Melo AC, Redondo A, Reyners AKL, Mora P, Closset C, Melief CJM, Hooftman L, Jamil S, Boersma L, Yoo SY, Seebach F, Lowy I, Fury MG, Mathias M, Colombo N. Gynecol Oncol. 2025 May;196:28-35. IF: 4.1.

Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial. Poveda A, Lheureux S, Colombo N, Cibula D, Elstrand M, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Rubio Pérez MJ, Ledermann J, Romero I, Özgören O, Barnicle A, Marshall H, Bashir Z, Škof E. Gynecol Oncol. 2025 Jun;197:74-82. IF: 4.1.

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma. Whittle JR, Vieito M, Rohrberg K, Rodriguez-Ruiz ME, Castanon E, Mellinghoff IK, Van Linde M, Cloughesy T, Reardon DA, Chong RA, Rosenthal M, Wick A, Waldhauer I, Henkel N, Romagnoli B, Wolowski V, Dey S, Heil F, Heichinger C, Flinn N, Gou JP, Smith L, Prince F, Derks M, Roller A, Schiff C, Schneider M, Mason W. Neurooncol Adv. 2025 Jul 18;7(1):vdaf160. IF: 4.1.

White paper on best practices for translational research in neuroendocrine neoplasms. Cros J, Casanovas O, Castaño JP, Dayton T, Alvarez AG, Gibert B, Simbolo M, Vandamme T, Cives M, Marinoni I; ENETS Basic and Translational Research Group (BTRG). J Neuroendocrinol. 2025 Oct;37(10):e70072. IF: 4.1.

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Sanborn RE, Zhou C, Tang KJ, Cho BC, Cheng S, Popat S, Ono A, Lu S, Majem M, Aguilar A, Del Rosario Garcia Campelo M, Hayashi H, Lee KY, Lee SH, Delmonte A, Alatorre-Alexander J, Richardson G, Santos V, Dooms C, Sabari JK, Shu CA, Girard N, Mansfield AS, Park K, Xia Y, Bhattacharya A, Buyukkaramikli N, Perualila N, Diels J, Acharya S, Chandler C, Proskorovsky I, Dearden L, Wortman-Vayn H, Mahadevia PJ, Knoblauch RE, Agrawal T, Baig M, Felip E. Target Oncol. 2025 Nov;20(6):979-989. IF: 4.0.

T-Cell Redirecting Strategies in Large B-Cell Lymphoma and Follicular Lymphoma. Iacoboni G. Hematol Oncol. 2025 Jun;43 Suppl 2:e70068. IF: 3.9.

MIA40 circumvents the folding constraints imposed by TRIAP1 function. Pujols J, Fornt-Suñé M, Gil-García M, Bartolomé-Nafría A, Canals F, Cerofolini L, Teilum K, Banci L, Esperante SA, Ventura S. J Biol Chem. 2025 Mar;301(3):108268. IF: 3.9.

A reduction in effective population size has not relaxed purifying selection in the human population of Eivissa (Balearic Islands). Aizpurua-Iraola J, Marí-Cardona E, Barber-Olives M, Comas D, Calafell F. Sci Rep. 2025 Jan 3;15(1):660. IF: 3.9.

Evaluation of magnetic resonance spectroscopy total sodium concentration measures, and associations with microstructure and physical impairment in cervical myelopathy. Solanky BS, Prados F, Tur C, Grussu F, Al-Ahmad S, Yang X, Bianchi A, Kanber B, Russo A, Russo V, Choi D, Panicker JN, Wheeler-Kingshott CAMG. Sci Rep. 2025 Feb 27;15(1):7014. IF: 3.9.

A probabilistic model of bilateral lymphatic spread in head and neck cancer. Ludwig R, Pérez Haas Y, Benavente S, Balermpas P, Unkelbach J. Sci Rep. 2025 May 25;15(1):18152. IF: 3.9.

A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis. Mozas P, Ould Ammar R, Chartier L, Nastoupil L, Bachy E, Bezsera SM, Barnes J, Bijou F, Goy A, Zerazhi H, Cartron G, Ojeda-Uribe M, Choquet S, Joly B, Cheminant M, Martín García-Sancho A, Eradat H, Gressin R, Abrisqueta P, Parcelier A, Rodríguez Salazar MJ, Bonnet C, Johnson NA, López-Guillermo A, Morschhauser F. Br J Haematol. 2025 May;206(5):1380-1389. IF: 3.9.

A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS. Searle E, Cluzeau T, O'Nions J, Recher C, Gyan E, Morillo D, Esteve J, Kulasekararaj A, Raffoux E, Walter HS, Pigneux A, Valcárcel D, Daskalakis N, Bussolari J, Pietsch EC, Kuduk S, Bush T, Zhang X, Philippar U, Oluwasanjo A, Bradford K, Miller J, Van Bogaert C, Curtis M, Chang SY, Guttke C, Gaj S, Pearson R, Murphy J, van Dijck W, Alfonso Piérola A. Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20224. IF: 3.9.

Validation of prognostic scores in patients with HIV-related diffuse large B-cell lymphoma: The value of peripheral blood parameters-A study from the Spanish Lymphoma Group GELTAMO. Huguet M, Morgades M, Rivas-Delgado A, Bastos-Oreiro M, Córdoba R, Salar A, de la Cruz-Vicente F, Alcoceba M, Ferrer-Lores B, Jiménez-Ubieto A, Gutiérrez A, Infante M, Huerga S, Abrisqueta P, Cruz D, Montalbán C, Muntañola A, Villambrosia SG, Ribera JM, Navarro JT. Br J Haematol. 2025 Dec 23. doi: 10.1111/bjh.70287. IF: 3.9.

A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial. Carpio C, de la Cruz-Vicente F, García-Sanz R, Zeberio I, Barrenetxea C, Domingo-Domenech E, Bastos M, Rubio Martinez A, Gómez-Prieto P, Rodriguez A, Casanova M, Cladera-Serra A, Nuñez Cespedes J, Martínez C, Moreno-Velázquez M, Garcia-Galea E, Abrisqueta P, Bosch F. Br J Haematol. 2025 Oct;207(4):1348-1356. IF: 3.9.

Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study. Tolosa-Ridao C, González MB, Gómez MA, Fox L, Pérez Artigas MDM, Santamaría A, Quintela González MDC, Salinas AS, Salmerón Camacho JM, Illana Álvaro V, Abdallahi-Lefdil Z, Navascues JC, Pardo L, Fernández-Luis S, Vega Suárez LP, Villar S, Beorlegui-Murillo P, Esquirol A, Izquierdo García I, Ribes-Amorós J, Lavilla E, Lopez-Marín J, Basalobre P, Filaferro S, Cedillo Á, Bento L, Sureda A, Salas MQ. Br J Haematol. 2025 Oct;207(4):1504-1516. IF: 3.9.

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy. Vilaseca A, Ariño H, Iacoboni G, Feijóo S, Zabalza A, Fissolo N, Arévalo MJ, Carpio C, Sánchez M, Tintoré M, Comabella M, Montalban X, Barba P, Vidal-Jordana Á. Eur J Neurol. 2025 Aug;32(8):e70305. IF: 3.9.

The immune response to SARS-CoV-2 in COVID-19 as a recall response susceptible to immune imprinting: A prospective cohort study. Alvarez-Sierra D, Martínez-Gallo M, Sánchez-Montalvá A, Fernández-Sanmartín M, Colobran R, Espinosa-Pereiro J, Poyatos-Canton E, Zurera-Egea C, Sánchez-Pla A, Violan C, Parra R, Alzayat H, Vivancos A, Morandeira-Rego F, Urban-Vargas B, Martínez-Cáceres E, Hernández-González M, Bas-Minguet J, Katsikis PD, Teniente-Serra A, Pujol-Borrell R. Clin Immunol. 2025 Mar;272:110429. IF: 3.8.

Degree of Food Processing and Incidence of Obesity-Related Cancers in the "Seguimiento Universidad de Navarra" Project. Cobo Díez MJ, Vázquez-Ruiz Z, Huybrechts I, Martin-Moreno JM, González IG, Martínez-González MÁ, Bes-Rastrollo M, Toledo E. J Nutr. 2025 Nov;155(11):3987-3996. IF: 3.8.

UpSMART: five years of digital innovation in cancer clinical research-achievements, challenges, and recommendations. O'Regan P, Butt F, Carter L, Graham DM, Le Blanc A, Hoskins R, Stephenson L, Patil A, Shabbir M, Eken D, Singh S, Villa A, Agnelli L, Damian S, Grave C, Pretelli G, Garralda E, Frost H, de Braud F, Freitas A, Dive C, Unsworth H. Front Digit Health. 2025 Nov 27;7:1708067. IF: 3.8.

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc. Takekuma M, Nishio S, Yamaguchi S, Yunokawa M, Nishio H, Nishino K, Kurosaki A, Minobe S, Villacampa G, Oaknin A, Okamoto A. J Gynecol Oncol. 2025 Nov;36(6):e116. IF: 3.7.

Development and Preclinical Evaluation of a Zirconium-89-Labeled Immunoconjugate for Positron Emission Tomography Imaging of Leukemia Inhibitory Factor in Glioblastoma. Betancourt Fernández E, Baguña Torres J, Iurlaro R, Cuartas I, Ortega Pijeira MS, Rodríguez Fernández S, Velasco-Vila S, Seoane J, Herance JR. ACS Pharmacol Transl Sci. 2025 Oct 7;8(11):3886-3895. IF: 3.7.

Best practices in sample management and molecular profiling of cholangiocarcinoma: a practical guide. Castet F, Salcedo MT, Nuciforo P, Aguilar S, Vivancos A. Expert Rev Mol Diagn. 2025 Aug;25(8):479-494. IF: 3.6.

Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial. Olawaiye AB, Gladieff L, O'Malley DM, Kim J, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim B, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balazs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Creva H, de Carvalho AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagameri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Obstet Gynecol Surv. 2025. 80(10): 636-638. IF: 3.6.

Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis. Perachino M, Blondeaux E, Molinelli C, Ruelle T, Giannubilo I, Arecco L, Nardin S, Razeti MG, Borea R, Favero D, Lanzavecchia C, Chiappe E, Tomasello L, Mariamidze E, Jankovic K, Stana M, Ottonello S, Scavone G, de Moura Leite L, Spinaci S, Saura C, Lambertini M. Eur J Clin Invest. 2025 Jun;55(6):e70001. IF: 3.6.

Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients. Toledano-Fonseca M, Cano-Osuna MT, Élez E, Soto-Alsar J, Páez D, Fernández-Montes A, Graña B, Salud A, Yubero A, Macías I, Quintero G, López-López C, Fernández-Rodríguez T, García-Ortiz MV, Sastre J, García-Alfonso P, Rodríguez-Ariza A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Eur J Clin Invest. 2025 Aug 1. doi: 10.1111/eci.70103. IF: 3.6.

The Sense of Smell (SoS) Atlas: Its Creation and First Application to Investigate COVID-19 Related Anosmia With a Comprehensive Quantitative MRI Protocol. Gaviraghi M, Lupi E, Grosso E, Fusari A, Baiguera M, Monteverdi A, Battiston M, Grussu F, Kanber B, Prados Carrasco F, Samson RS, Makaronidis J, Yiannakas MC, Zandi MS, Batterham RL, D'Angelo E, Palesi F, Gandini Wheeler-Kingshott CAM. J Magn Reson Imaging. 2025 Oct 3. doi: 10.1002/jmri.70128. IF: 3.5.

Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement. Ospina-Serrano AV, González-Larriba JL, Nadal E, Trancho FH, Bosch-Barrera J, Calvo V, Bolufer-Nadal S, Campo-Cañaveral de la Cruz JL, Macía-Vidueira I, Álvarez-Kindelán A, Del Barco-Morillo E, Bernabé-Caro R, Casal-Rubio J, Cilleruelo-Ramos Á, Cobo-Dols M, Dómine-Gómez M, Figueroa-Almánzar S, Insa-Mollá A, Jarabo-Sarceda JR, Jiménez-Maestre U, López-Castro R, Majem M, Martinez-Marti A, Martínez Téllez E, Sánchez-Lorente D, López-Valcárcel M, Couñago F, Garcia-Campelo R, de Castro J, Massutí-Sureda B, Provencio M. Transl Lung Cancer Res. 2025 Sep 30;14(9):3299-3322. IF: 3.5.

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5. Gazzah A, Ricordel C, Italiano A, Cho BC, Calvo E, Kim DW, Helissey C, Kim JS, Villar MV, Ghiringhelli F, Moreno V, Cousin S, Paz-Ares L, Fagniez N, Chadjaa M, Bauchet AL, Soufflet C, Masson N, Barlesi F. JTO Clin Res Rep. 2025 May 15;6(10):100844. IF: 3.5.

Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis. Lee JM, Brunelli A, Cummings AL, Felip E, Shu CA, Solomon BJ, Tsuboi M, Wakelee H, Saqi A, Wu YL, Li PC, Gitlitz BJ. JTO Clin Res Rep. 2025 Jun 19;6(9):100866. IF: 3.5.

Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial. Reinmuth N, Couraud S, Paz-Ares L, Garassino MC, Baijal S, Daniel D, Garrido P, Kato T, Percent I, Rittmeyer A, Parra HS, Mekan S, Patel M, Radford M, Zhang E, Pelligra CG, Guo S, Felip E. JTO Clin Res Rep. 2025 Oct 30;7(2):100929. IF: 3.5.

A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A. BMC Cancer. 2025 Apr 4;25(1):613. IF: 3.4.

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC). Aroldi F, Elez E, André T, Perkins G, Prenen H, Popovici V, Gallagher P, Houlden J, Collins L, Roberts C, Rolfo C, Di Nicolantonio F, Grayson M, Boyd R, Bettens K, Delfavero J, Coyle V, Lawler M, Khawaja H, Laurent-Puig P, Salto-Tellez M, Maughan TS, Tabernero J, Adams R, Jones R, Hennessy BT, Bardelli A, Peeters M, Middleton MR, Wilson RH, Van Schaeybroeck S; MErCuRIC Trial Consortium. BMC Cancer. 2025 Apr 10;25(1):658. IF: 3.4.

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer. Taieb J, Fakih M, Liposits G, Prager GW, Van Cutsem E, Ciardiello F, Amellal N, Calleja E, Liu M, Roby L, Tabernero J, André T. Front Oncol. 2025 Jan 16;14:1506075. IF: 3.3.

Precision Oncology: A Global Perspective on Implementation and Policy Development. Horgan D, Tanner M, Aggarwal C, Thomas D, Grover S, Basel-Salmon L, Dienstmann R, Tan TJY, Park WY, Abu Rasheed HM, Siu LL, Ma B, Ortiz-López R, Van den Bulcke M, Taucher SC, Ferris A, Starling N, Malapelle U, Longshore J, Saldaña HAB, Subbiah V. JCO Glob Oncol. 2025 Jan;11:e2400416. IF: 3.3.

Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial. Soria A, Sanchez Mauriño P, Serrano Domingo JJ, García Galindo R, Sequero S, Gutiérrez Sanz L, Crespo G, Díaz-Beveridge R, Puértolas T, López P, Fra Rodríguez J, López Castro R, Aguayo C, Valdivia J, Cunquero-Tomás AJ, Benítez G, Ayala de Miguel P, Espinosa E, Muñoz-Couselo E, Campos B, García Sánchez L, Cerezuela-Fuentes P. Front Oncol. 2025 Feb 26;15:1466185. IF: 3.3.

Mapping MAGE-A4 expression in solid cancers for targeted therapies. Habigt C, Rottey S, Spanggaard I, Lopez JS, Garralda E, Calvo E, Bechter O, Desai J, Galot R, Gandhi L, Heil F, Rieder N, Dimitrov I, Quetglas IM, Heichinger C, Keshelava N, Roller A. Front Oncol. 2025 Mar 13;15:1484182. IF: 3.3.

Part I: consensus statements and expert recommendations for HER2-negative early breast cancer in the Asia-Pacific region: diagnosis and risk assessment. Lee SC, Park YH, Singer CF, Balmaña J, Dent RA, Tan VK, Mulansari NA, Yusof MM, Que FVF, Lu YS, Parinyanitikul N, Pham CP, Taib NA, Kong SY, Antill Y, Kim HJ. Front Oncol. 2025 Jun 23;15:1507836. IF: 3.3.

Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management. Park YH, Lee SC, Singer CF, Balmaña J, Dent RA, Tan VK, Mulansari NA, Yusof MM, Que FVF, Lu YS, Parinyanitikul N, Pham CP, Taib NA, Kong SY, Antill Y, Kim HJ. Front Oncol. 2025 Jun 23;15:1507840. IF: 3.3.

European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study. Saura C, Wildiers H, Bianchini G, García-Saenz JÁ, Allignol A, Logue A, Lucerna M, Stamenitis S, De Laurentiis M. Front Oncol. 2025 Oct 14;15:1650981. IF: 3.3.

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib. Tomasini P, Juan-Vidal O, Califano R, Lin CC, Hulo P, Dooms C, Fang J, Blasco A, Kowalski D, Salinas J, Babu G, Mun TL, Bearz A, Surmont V, Baldotto C, Sharma R, Arrieta O, Stencel K, Card C, Zer A, Massarelli E, Fang B, Mashru S, Schuchard J, Sermon J, Diels J, Chu PL, Withelder M, Bauml JM, Shah S, Baig M, Felip E. Clin Lung Cancer. 2025 Dec 20. doi: 10.1016/j.cllc.2025.12.005. IF: 3.3.

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. Munoz-Couselo E, Soria Rivas A, Sandhu S, Long GV, Sanmamed MF, Spreafico A, Buchbinder E, Sznol M, Prenen H, Fedenko A, Milhem M, Arance Fernandez AM, Grob JJ, Demidov L, Robert C, Habigt C, Evers S, Sleiman N, Dejardin D, Ardeshir C, Martin N, Boetsch C, Charo J, Teichgräber V, Kraxner A, Keshelava N, Bechter O. Cancer Res Commun. 2025 Feb 1;5(2):358-368. IF: 3.3.

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors. Gambardella V, Ong M, Rodriguez-Ruiz ME, Machiels JP, Sanmamed MF, Galvao V, Spreafico A, Renouf DJ, Luen SJ, Galot R, Doger de Spéville B, Calvo E, Naing A, Curdt S, Kolben TM, Rossmann E, Tanos T, Smart K, Amann M, Xie Y, Xu L, Gomez Alcaide E, Städler N, Justies N, Boetsch C, Karanikas V, Schnetzler G, Rohrberg KS. Cancer Res Commun. 2025 Mar 1;5(3):422-432. IF: 3.3.

Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer. Yaeger R, Martini JF, Pasquina L, Tunquist B, Zhang X, Kaiser F, Pantoja Galicia N, Deng S, Gong S, Guo C, Kiely J, Ng TV, Ferrier G, Tabernero J, Kopetz S. Cancer Res Commun. 2025 Sep 1;5(9):1566-1573. IF: 3.3.

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors. Powderly J, Imbimbo M, Italiano A, Martin-Romano P, McKean M, Macarulla T, Castañón Alvarez E, Carneiro BA, Mager R, Barnhart V, Eck S, Murtomaki E, Loembé AB, He Y, Cooper ZA, Tu E, Fan C, Boyer Chamard A, Paturel C, Fraenkel PG, Hollebecque A. Cancer Res Commun. 2025 Sep 1;5(9):1690-1700. IF: 3.3.

Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival. Canale M, Urbini M, Petracci E, Angeli D, Tedaldi G, Priano I, Cravero P, Flospergher M, Andrikou K, Bennati C, Tassinari D, Dubini A, Rossi G, Panzacchi R, Valli M, Bronte G, Crinò L, Delmonte A, Ulivi P. Lung Cancer (Auckl). 2025 Feb 20;16:11-23. IF: 3.3.

Comparative Analysis of Ultrasonography and MicroCT Imaging for Organ Size Evaluation in Mice. Jimenez Catalan JJ, Ferrer Clotas M, Camara Serrano JA. J Imaging. 2025 Jun 18;11(6):200. IF: 3.3.

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1). Cercek A, Bachet JB, Capdevila J, Starling N, Chen E, Salvatore L, Bando H, O'Donnell S, Harfst L, Szijgyarto Z, Heinemann V. Clin Colorectal Cancer. 2025 Jun;24(2):325-330. IF: 3.2.

Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma. Iacoboni G, Morschhauser F. Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):482-488. IF: 3.2.

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5. Gazzah A, Ricordel C, Italiano A, Cho BC, Calvo E, Kim DW, Helissey C, Kim JS, Villar MV, Ghiringhelli F, Moreno V, Cousin S, Paz-Ares L, Fagniez N, Chadjaa M, Bauchet AL, Soufflet C, Masson N, Barlesi F. JTO Clin Res Rep. 2025 May 15;6(10):100844. IF: 3.2.

Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review. Macarulla T, Neuzillet C, Prager GW, Rimassa L, Bridgewater J. Oncol Ther. 2025 Dec;13(4):939-962. IF: 3.2.

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment. Espín R, Medina-Jover F, Sigüenza-Andrade J, Farran-Matas S, Mateo F, Figueras A, Sanz RT, Vicent GP, Shabbir A, Ruiz-Auladell L, Racionero-Andrés E, García I, Baiges A, Franco-Luzón L, Martínez-Tebar A, Pardo-Cea MA, Martínez-Iniesta M, Wang XC, Cuyàs E, Menendez JA, Lopez-Cerda M, Muñoz P, Richaud I, Raya A, Fabregat I, Villanueva A, Serrat X, Cerón J, Alemany M, Guix I, Herencia-Ropero A, Serra V, Krishnan R, Mekhail K, Hakem R, Bruna J, Barcellos-Hoff MH, Viñals F, Aytes Á, Pujana MA. NAR Cancer. 2025 Mar 7;7(1):zcaf007. IF: 3.2.

Short- and long-term mortality in critically ill patients with solid cancer. The Vall d'Hebron Intensive Care Unit-Vall d'Hebron Institute of Oncology Cohort: a retrospective study. Díaz-Lagares C, García-Roche A, Pacheco A, Ros J, Plata-Menchaca EP, Albasanz A, Pérez D, Saoudi N, Ruiz-Camps I, Élez E, Ferrer R. Med Intensiva (Engl Ed). 2025 Nov;49(11):502176. IF: 3.1.

Comparison of immunohistochemical HER2 low detection in breast cancer using two antibodies assays in an interlaboratory study. da Silva LM, Rodrigues AM, da Cunha DB, Duarte V, Pereira EM, Koyama FC, Ferrari BL, Dienstmann R. Virchows Arch. 2025 Jul 26. doi: 10.1007/s00428-025-041872. IF: 3.1.

Considerations and recommendations from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 3-Ex vivo imaging: Data processing, comparisons with microscopy, and tractography. Schilling KG, Howard AFD, Grussu F, Ianus A, Hansen B, Barrett RLC, Aggarwal M, Michielse S, Nasrallah F, Syeda W, Wang N, Veraart J, Roebroeck A, Bagdasarian AF, Eichner C, Sepehrband F, Zimmermann J, Soustelle L, Bowman C, Tendler BC, Hertanu A, Jeurissen B, Verhoye M, Frydman L, van de Looij Y, Hike D, Dunn JF, Miller K, Landman BA, Shemesh N, Anderson A, McKinnon E, Farquharson S, Dell'Acqua F, Pierpaoli C, Drobnjak I, Leemans A, Harkins KD, Descoteaux M, Xu D, Huang H, Santin MD, Grant SC, Obenaus A, Kim GS, Wu D, Le Bihan D, Blackband SJ, Ciobanu L, Fieremans E, Bai R, Leergaard TB, Zhang J, Dyrby TB, Johnson GA, Cohen-Adad J, Budde MD, Jelescu IO. Magn Reson Med. 2025 Jun;93(6):2561-2582. IF: 3.0.

Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 1: In vivo small-animal imaging. Jelescu IO, Grussu F, Ianus A, Hansen B, Barrett RLC, Aggarwal M, Michielse S, Nasrallah F, Syeda W, Wang N, Veraart J, Roebroeck A, Bagdasarian AF, Eichner C, Sepehrband F, Zimmermann J, Soustelle L, Bowman C, Tendler BC, Hertanu A, Jeurissen B, Verhoye M, Frydman L, van de Looij Y, Hike D, Dunn JF, Miller K, Landman BA, Shemesh N, Anderson A, McKinnon E, Farquharson S, Dell'Acqua F, Pierpaoli C, Drobnjak I, Leemans A, Harkins KD, Descoteaux M, Xu D, Huang H, Santin MD, Grant SC, Obenaus A, Kim GS, Wu D, Le Bihan D, Blackband SJ, Ciobanu L, Fieremans E, Bai R, Leergaard TB, Zhang J, Dyrby TB, Johnson GA, Cohen-Adad J, Budde MD, Schilling KG. Magn Reson Med. 2025 Jun;93(6):2507-2534. IF: 3.0.

Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2-Ex vivo imaging: Added value and acquisition. Schilling KG, Grussu F, Ianus A, Hansen B, Howard AFD, Barrett RLC, Aggarwal M, Michielse S, Nasrallah F, Syeda W, Wang N, Veraart J, Roebroeck A, Bagdasarian AF, Eichner C, Sepehrband F, Zimmermann J, Soustelle L, Bowman C, Tendler BC, Hertanu A, Jeurissen B, Verhoye M, Frydman L, van de Looij Y, Hike D, Dunn JF, Miller K, Landman BA, Shemesh N, Anderson A, McKinnon E, Farquharson S, Dell'Acqua F, Pierpaoli C, Drobnjak I, Leemans A, Harkins KD, Descoteaux M, Xu D, Huang H, Santin MD, Grant SC, Obenaus A, Kim GS, Wu D, Le Bihan D, Blackband SJ, Ciobanu L, Fieremans E, Bai R, Leergaard TB, Zhang J, Dyrby TB, Johnson GA, Cohen-Adad J, Budde MD, Jelescu IO. Magn Reson Med. 2025 Jun;93(6):2535-2560. IF: 3.0.

Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer. Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton MJ, Pfeiler G, Gelmon K, Balko JM, Egle D, Zoppoli G, Traina T, Jimenez MM, Novoa SA, Haddad T, Chan A, Ring A, Wolff A, Symmans WF, Ponce Lorenzo J, Sabanathan D, Burstein HJ, Nowecki ZI, Pristauz-Telsnigg G, Brufsky A, Bellet-Ezquerra M, Foukakis T, Novik Y, Rubovszky G, Singer CF, Muehlbacher K, Filho OM, Goulioti T, Law E, Partridge AH, Carey LA, Zoroufy A, Hlauschek D, Fesl C, Mayer EL, Gnant M. Breast Cancer Res Treat. 2025 Jun;211(2):385-397. IF: 3.0.

Impact of Family History of Haemophilia on Diagnosis, Management and Outcomes in Severe Haemophilia. Mendoza A, Rivas I, Hidalgo OB, Cid AR, Olivieri M, Ranta S, Labarque V, Andersson NG, de Kovel M, Álvarez-Román MT. Haemophilia. 2025 Jul;31(4):679-686. IF: 3.0.

Smoking Adversely Affects Survival of Metastatic Lung Carcinoid Patients: Analysis of a Large International Audit and Prognostic Models for Metastasis-Free Survival and Overall Survival. Clarke A, Cunningham A, Garcia-Alvarez A, Spurgeon L, Morgan R, Carmona Alonso A, Hernando J, Capdevila J, Backen A, Campana LG, Manoharan P, Verma A, Lord GM, Chaturvedi A, Mansoor W, Valpione S. Neuroendocrinology. 2025;115(9):757-769. IF: 2.8.

Clinical Actionability of Genes in Gastrointestinal Tumors. Saoudi Gonzalez N, Patelli G, Crisafulli G. Genes (Basel). 2025 Sep 25;16(10):1130. IF: 2.8.

Competencies for bioinformatics core facility scientists: extension of the ISCB competency framework for bioinformatics. Lloret-Llinares M, Carvajal-López P, Downing T, Gogol M, Ho Sui S, Nonell L, Paladin L, Reid AJ, Pomann GM, Brooksbank C. Bioinform Adv. 2025 Sep 16;5(1):vbaf206. IF: 2.8.

First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. Johnson M, Hong D, Braña I, Schöffski P, Galvao V, Rangwala F, Ma B, Hernandez R, Kamat A, Kato K, Schreiber TH, Pandite L, Siu LL. Invest New Drugs. 2025 Apr;43(2):284-292. IF: 2.7.

Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes. Bakaloudi DR, Talukder R, Enright T, Leary JB, Makrakis D, Diamantopoulos LN, Hobeika C, Thomas VM, Swami U, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Latchford C, Jindal T, Koshkin VS, Murgić J, Miletić M, Frobe A, Johnson J, Zakharia Y, Alva A, Nguyen CB, Hui G, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Barrera RM, Marmolejo D, McKay RR, Stewart TF, Barata P, Epstein IB, Bellmunt J, Yu EY, Raychaudhuri R, Nadal R, Vakar-Lopez F, Gupta S, Wright JL, Khaki AR, Grivas P. Clin Genitourin Cancer. 2025 Aug;23(4):102356. IF: 2.7.

Emerging treatments for sarcoma: from 2024 onward. Gómez-Puerto D, Cicala CM, Valverde C, Serrano C. Expert Opin Emerg Drugs. 2025 Feb 3. doi: 10.1080/14728214.2025.2460525. IF: 2.7.

Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study. Suárez C, Reig Torras Ò, Morales Barrera R, Rodríguez Sánchez Á, Anguera Palacios G, Manshino AMB, Fernández Núñez N, Méndez Vidal MJ, García Carbonero I, Fernández Calvo O, Gironés Sarrió R, Crespo Herrero G, Afonso Afonso J, Juan Fita MJ, Gumà Padró J, Lázaro Quintela M, Rodriguez-Vida A, Hernández Pérez C, Medina Colmenero A, Collado Martín R, Garcías de España C, Molins Palau C, Martínez Ortega E, Gallardo E; SPRWEC Study investigators. Clin Genitourin Cancer. 2025 Oct;23(5):102402. IF: 2.7.

DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models. Camarillo R, Prados-Carvajal R, Cruz-García A, Rodríguez-Real G, Herencia-Ropero A, Serra V, Jimeno S, Huertas P. DNA Repair (Amst). 2025 Aug;152:103866. IF: 2.7.

Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease. Cicala CM, Bauer S, Heinrich MC, Serrano C. Hematol Oncol Clin North Am. 2025 Aug;39(4):773-784. IF: 2.7.

Leiomyosarcoma Therapeutic Approaches and Future Directions. Haddox CL, Papke DJ Jr, Serrano C. Hematol Oncol Clin North Am. 2025 Aug;39(4):785-804. IF: 2.7.

Age-stratified analysis of health-related quality of life in patients with early-stage breast cancer receiving adjuvant radiation therapy and endocrine therapy. Li K, Chadha M, Moshier E, Rosenstein BS; REQUITE consortium. J Geriatr Oncol. 2025 Mar;16(2):102195. IF: 2.7.

Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Future Oncol. 2025 Mar;21(6):637-652. IF: 2.6.

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, Liu M, Bhatt A, Wang Z, Nandoskar P, Suarez C. Future Oncol. 2025 Mar;21(7):787-794. IF: 2.6.

A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Jin Leei W, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM. Future Oncol. 2025 Mar;21(7):765-774. IF: 2.6.

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases. Marhold M, Vaz Batista M, Blancas I, Morales C, Saura-Manich C, Saavedra C, Ruíz-Borrego M, Cortez P, Slebe F, Campolier M, Santos JC, Guerrero-Martínez JA, Jiménez-Cortegana C, Rottenmanner B, Forstner H, Bartsch R, Preusser M. Future Oncol. 2025 Apr;21(9):1065-1073.IF: 2.6.

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. Future Oncol. 2025 Apr;21(9):1033-1044. IF: 2.6.

Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA. Felip E, Cho BC, Lu S, Şendur MAN, Gadgeel SM, Sethi S, Bauml JM, Hayashi H. Future Oncol. 2025 May;21(12):1429-1444. IF: 2.6.

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer. Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E, Karumanchi D, Garassino MC. Future Oncol. 2025 Oct;21(25):3245-3257. IF: 2.6.

The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary. Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Beyzarov E, Zhang X, Ferrier G, Zhang X, Tabernero J. Future Oncol. 2025 Jun;21(13):1541-1552. IF: 2.6.

A plain language summary of the molecular changes in the tumors of people with BRAF V600E-mutant colorectal cancer in the BEACON study. Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J. Future Oncol. 2025 Jun;21(14):1713-1723. IF: 2.6.

Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial. Loi S, Salgado R, Curigliano G, Iván Romero Díaz R, Delaloge S, Rojas García CI, Kok M, Saura C, Harbeck N, Mittendorf EA, Yardley DA, Suárez Zaizar A, Caminos FR, Ungureanu A, Reinoso-Toledo JG, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Qun Wu J, Pusztai L, McArthur H. Future Oncol. 2025 Oct;21(24):3091-3101. IF: 2.6.

Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers. Hurvitz S, Simonelli M, Yarza R, Berz D, Kitano S, Del Conte G, Acosta Eyzaguirre D, Doger de Speville Uribe BG, Maier D, Erzen D, Aykut Yazgili S, Curigliano G, Deng T, Yan M, Zhang Q, Wang X, Nakayama I, Shitara K. Future Oncol. 2025 Oct;21(26):3385–3393. IF: 2.6.

A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract. Powles T, Tagawa ST, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, Duran I, Morales-Barrera R, Guo J, Sternberg CN, Bellmunt J, Goebell PJ, Kovalenko M, Boateng F, Sierecki M, Wang L, Sima CS, Waldes J, Bangs R, Loriot Y, Grivas P. Future Oncol. 2025 Dec;21(28):3593-3610. IF: 2.6.

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer. Kopetz S, Tabernero J, Élez E. Future Oncol. 2025 Dec;21(28):3585-3588. IF: 2.6.

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201. Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. Future Oncol. 2025 Dec;21(30):3859-3871. IF: 2.6.

OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy. Pistilli B, Bellet Ezquerra M, Del Mastro L, Sohn J, Schmid P, Meisel J, Chan A, Zheng L, de Kermadec E, McArthur H. Future Oncol. 2025 Dec 29. doi: 10.1080/14796694.2025.2608863. IF: 2.6.

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches. Farina-Morillas M, Ollé-Monràs L, Maas SC, de Rojas-P I, Segura MF, Seoane JA. Epigenomics. 2025 Oct;17(15):1069-1081. IF: 2.6.

Revisiting Alma Ata: A Blueprint for Cancer Care. Benitez-Fuentes JD, Lastra Del Prado R, Borregon-Rivilla M, de Luna Aguilar A, Lazaro-Sanchez AD, Ferrández-Arias A, Rodríguez Payá P, Grau Mirete B, Quintanar Verduguez T, Asensio Martinez E, Iranzo P, Callejo A, Cruellas Lapeña M, Gómez Ulla J, Rodriguez-Lescure A. Cancer Control. 2025 Jan-Dec;32:10732748251363701. IF: 2.6.

Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma. Pomares AA, Merino LR, González S, Morata J, Tonda R, Arribas P, Revert J, Carrillo E, Grande C, Roncero JM, de Oteyza JP, Nicolás C, Gutierrez N, Abrisqueta P, Gutiérrez A, Ramírez-Páyer Á, Garcia-Sancho AM, González-Barca E, Montes-Moreno S; GELTAMO group (Grupo Español de Linfomas y Trasplante Autólogo de Medula Osea), Spain. PLoS One. 2025 Mar 11;20(3):e0318689. IF: 2.6.

Gender and sex differences in colorectal cancer screening, diagnosis and treatment. González-Flores E, Garcia-Carbonero R, Élez E, Redondo-Cerezo E, Safont MJ, Vera García R. Clin Transl Oncol. 2025 Jul;27(7):2825-2837. IF: 2.5.

SEOM-GEIS Spanish clinical guidelines for the management of soft-tissue sarcomas (2024). Serrano C, Arregui M, Carrasco I, Hindi N, Martínez-Trufero J, Martínez-García J, Molina Á, Paisán A, Sánchez R, Sala MÁ. Clin Transl Oncol. 2025 Apr;27(4):1460-1471. IF: 2.5.

Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects. Mur P, Pozuelo A, Tabernero J, Albanell J, Bellosillo B, Bosch F, Briones J, Brunet J, Colomer D, Domènech M, Fontanet JM, Matias-Guiu X, Salazar R, Vivanco-Hidalgo RM, Mollà M, Moreno L, Prat A, Ribera JM, Clèries R, Guarga A, Espinàs JA, Borras JM. Clin Transl Oncol. 2025 Sep 3. doi: 10.1007/s12094-025-04022-9. IF: 2.5.

SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Mezquita L, Vicente-Herrero MT, Cruz P, de la Torre MVRÍ, Hidalgo-Coloma J, García LC, Gallego O, Calvo A, Martínez K, Pérez-Altozano J, Molina R, García-Pardo M, Gutiérrez-Sainz L, Moreno-Atahonero E, Oré-Arce M, Serrano C, Terradillos-García MJ, Valero MR, Reinoso-Barbero L, Rodríguez CA, Calvo-Cerrada B; SEOM - Environmental, Occupational Cancer Working Group, the AEEMT - Functional Group on Cancer, Work. Clin Transl Oncol. 2025 Sep 16. doi: 10.1007/s12094-025-04037-2. IF: 2.5.

Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Pacheco-Barcia V, Obispo B, Tomas E, Salva de Torres C, Quintanar T, Paez D, Leon-Mateos L, Cancio H, Cortegoso A, Anido U, Quilez A, Tarazona N, Jimenez-Labaig P, Sanchez-Martinez DA, Sesma Goni A, Fernandez-Montes A, Felip E, Rodriguez C, Elez E. Clin Transl Oncol. 2025 Dec 23. doi: 10.1007/s12094-025-04171-x. IF: 2.5.

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Espinosa E, Berciano-Guerrero MÁ, Muñoz-Couselo E, Puértolas T, Manzano JL, Soria A, de Miguel PA, Crespo G, Sanz LG, Cerezuela-Fuentes P, de la Rosa CA, Majem M, Castaño AG, Berrocal A, Arroyo FRG, de la Borbolla MR, Bellido L, Martínez JM, Fernández LA, Carnicero AM, Castro RL, Rodríguez AB, Lecumberri MJ, Guzmán JCV, Balea BC, Rodríguez JF, Bautista JV, Pérez VN, Mujika K, Subias MC, Hernández B, Algarra SM, Márquez-Rodas I. Clin Transl Oncol. 2025 Nov 28. doi: 10.1007/s12094-025-04098-3. IF: 2.5.

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. Cerezuela-Fuentes P, Piñero-Madrona A, Muñoz-Couselo E, Manzano JL, Berciano-Guerrero MÁ, Majem M, Espinosa E, Soria A, Ayala de Miguel P, García Castaño A, Crespo G, Gutiérrez Sanz L, Aguado de la Rosa C, Fernández-Morales LA, Puértolas T, Fra Rodríguez J, Rodríguez de la Borbolla M, Bellido L, López Castro R, Navarro Pérez V, García Arroyo FR, Villa Guzmán JC, Campos Balea B, Hernández B, Martín Algarra S, Márquez-Rodas I. Clin Transl Oncol. 2025 Dec 20. doi: 10.1007/s12094-025-04164-w. IF: 2.5.

2025 Updated version v1.0 SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022). Montes AF, Alonso V, Aguilar EA, Élez E, Alfonso PG, Castro CG, Maurel J, García RV, Tocino RV, Urtasun JA. Clin Transl Oncol. 2025 Apr;27(4):1845-1850. IF: 2.5.

Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. Soler G, Grávalos C, Rivera F, Safont MJ, Virgili AC, Valladares-Ayerbes M, Ferreiro-Monteagudo R, Ortiz-Morales MJ, Polo-Marques E, Kornusova-Bersheva I, Soustre E, Yao W, Élez E. Clin Transl Oncol. 2025 Nov;27(11):4203-4213. IF: 2.5.

SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025). Macarulla T, Adeva J, Cano Osuna MT, Ruiz Casado A, Jiménez Gordo AM, Lamarca A, López Muñoz AM, Pazo Cid RA, Saurí T, Gallego Plazas J. Clin Transl Oncol. 2025 Aug;27(8):3293-3306. IF: 2.5.

Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensus. García-Alfonso P, Alcaide-Garcia J, Aranda Aguilar E, Elez E, Fernández Montes A, García Escobar I, Grávalos C, Matos García I, Montagut Viladot C, Santos Vivas C, Sastre J, Tarazona N, Jimenez-Fonseca P. Clin Transl Oncol. 2025 Aug 11. doi: 10.1007/s12094-025-03986-y. IF: 2.5.

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801). Ayala-de Miguel P, Muñoz-Couselo E, Gutiérrez-Sanz L, Fernández LA, Navarro-Pérez V, Berciano-Guerrero MÁ, García-Arroyo F, Aguado-de la Rosa C, Cerezuela-Fuentes P, Majem M, Campos-Balea B, Soria A, Hernández-Marín B, García-Castaño A, Martín-Algarra S, Márquez-Rodas I. Clin Transl Oncol. 2025 Jul 27. doi: 10.1007/s12094-025-04005-w. IF: 2.5.

Merkel cell carcinoma: long-term outcomes after radiotherapy treatment. Recalde Vizcay E, Navalpotro Yagüe B, Ferrandiz-Pulido C, Hernando Cubero J, Capdevila J, Peregrin Pastor B, Granado Carrasco R. Clin Transl Oncol. 2025 Jul 31. doi: 10.1007/s12094-025-04012-x. IF: 2.5.

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry. Gonzalez-Cao M, Berciano-Guerrero MÁ, Muñoz-Couselo E, Manzano JL, Cerezuela-Fuentes P, Crespo G, Soria A, de Miguel PA, Gutiérrez Sanz L, de la Rosa CA, García Castaño A, Puértolas T, Espinosa E, Medina J, Bellido L, Berrocal A, Majem M, López Castro R, Fernandez LA, Garcia F, de la Borbolla MR, Martín Algarra S, Márquez-Rodas I. Clin Transl Oncol. 2025 Aug 21. doi: 10.1007/s12094-025-04018-5. IF: 2.5.

A world map of air pollution and EGFR-mutant prevalence. Rojas L, Villacampa G, Tan DSW, Arrieta O, Zuluaga J, Cardona AF. Clin Transl Oncol. 2025 Aug 28. doi: 10.1007/s12094-025-04039-0. IF: 2.5.

SEOM-GEICO clinical guidelines on endometrial cancer (2025). Ramírez SP, Fidalgo AP, Ginesta MPB, De Juan Ferré A, Madrid LF, Martínez AG, Montosa FG, Madariaga A, Gómez TM, Gil-Martin M. Clin Transl Oncol. 2025 Dec;27(12):4368-4380. IF: 2.5.

Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis. Calle C, Elez E, Manzano JL, Moreno-Martinez ME, Pericay C, Graefenhain R, Ariznavarreta A, Lizan L. J Pharm Policy Pract. 2025 Oct 13;18(1):2567970. IF: 2.5.

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025). Garcia-Saenz JA, Lopez-Barajas IB, Echavarria I, Gonzalez CH, Vila MM, Antón FM, Pernas S, Cajal TRY, Ribelles N, Ezquerra MB. Clin Transl Oncol. 2025 Nov 3. doi: 10.1007/s12094-025-04102-w. IF: 2.5.

How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia. Hidalgo-Gómez G, Tazón-Vega B, Palacio C, Saumell S, Martínez-Morgado N, Navarro V, Murillo L, Velasco P, Murciano T, Díaz de Heredia C, Bosch F, Armengol G, Ortega M. Ann Hematol. 2025 Apr;104(4):2387-2402. IF: 2.4.

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma. Garcia-Guiñon A, Charry PA, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, Santaliestra M, Garcia-Pintos M, Gonzalez Y, Senin A, Motlló C, Abella E, Cabezudo E, Granell M, Sancho E, Herranz MJ, Seres Y, Gironella M, Soler JA, Marti-Tutusaus JM, Ben Azaiz R, Fernandez de Larrea C. Ann Hematol. 2025 Feb;104(2):1177-1186. IF: 2.4.

Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review. Abrisqueta P, Jiménez-Ubieto A, Serna Á, Zamanillo I, Kuang Y, Uyei J, Shah M, Walsh L, Thorley E, Cantos K, Rashidi E, Ma Q, Jalbert JJ, Archambault AN, Xu Y, Aggarwal S, Ambati S, Mohamed H, Hampp C, von Tresckow B. Ann Hematol. 2025 Sep;104(9):4357-4367. IF: 2.4.

Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events. Boy B, Iacoboni G, Valcárcel D, Molina C, Rodrigo-Gisbert M. Neurol Sci. 2025 Aug;46(8):4051-4055. IF: 2.4.

Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications. Bacca L, Brandariz J, Zacchi F, Zivi A, Mateo J, Labbé DP. Gene. 2025 Nov 20;972:149774. IF: 2.4.

Next questions on gastrointestinal stromal tumors: unresolved challenges and future directions. Romandini D, Sobczuk P, Cicala CM, Serrano C. Curr Opin Oncol. 2025 Jul 1;37(4):358-364. IF: 2.4.

A current update of the development of Chimeric Antigen Receptor T-cell therapy and kidney disease. León-Román J, Esteves A, Iacoboni G, Soler MJ. Curr Opin Nephrol Hypertens. 2025 Sep 1;34(5):389-396. IF: 2.4.

Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review. von Tresckow B, Abrisqueta P, Zamanillo I, Serna Á, Kuang Y, Uyei J, Shah M, Walsh L, Thorley E, Cantos K, Rashidi E, Hampp C, Jalbert JJ, Archambault AN, Xu Y, Aggarwal S, Ambati S, Mohamed H, Ma Q, Jiménez-Ubieto A. Eur J Haematol. 2025 Aug;115(2):104-116. IF: 2.3.

Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report. Llata-Ortega J, Pau-Parra A, Alonso-Martínez C, García-Roche A, Carpio C, Barba P, Murillo-Florez I, Iacoboni G. Eur J Haematol. 2025 Dec;115(6):610-613. IF: 2.3.

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia. Castellet H, Ramil G, Carricondo M, Oñate G, Garrido A, Artigas A, Pratcorona M, Salamero O, Cortés-Bullich A, Vives S, Tormo M, Mascaró M, Gallardo D, Tutusaus JMM, Garcia A, Sierra J, Esteve J, Nomdedéu J; CETLAM group. Eur J Haematol. 2025 Jun;114(6):1052-1054. IF: 2.3.

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE. Matikas A, Naume B, Wildiers H, Sonke G, Dieci MV, Karakatsanis A, Andersson A, Barnekow E, Kessler LE, Einbeigi Z, Killander F, Linderholm B, Schiza A, Valachis A, Nearchou A, Engebraaten O, Porojnicu A, Soland MH, Mannsåker B, Raj SX, Blix ES, Nordstrand CS, Lambertini M, Vernieri C, Punie K, Sotiriou C, Bergh J, Villacampa G, Zouzos A, Hellström M, Hartman J, Foukakis T. BMJ Open. 2025 Aug 27;15(8):e102626. IF: 2.3.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. Cruz-Correa M, Xu RH, Moehler M, Oh DY, Kato K, Spigel D, Arkenau HT, Tabernero J, Zimina AV, Bai Y, Shi J, Lee KW, Hirano H, Wyrwicz L, Cid RP, Xu H, Sheng T, Barnes G. Curr Med Res Opin. 2025 Jun;41(6):1007-1016. IF: 2.2.

Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy. Iskierka-Jażdżewska E, Kim WS, Cho SG, Kim TM, Jarque I, Robak T, Poon M, Prince HM, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Zhang H, Cao J, Tessoulin B, Li J, Ivanescu C, Reaney M, Chaudhry A, Mohamed H, Ambati S, Harnett J, Chi L, Kamat S, Walewski J; ELM-2 Investigators. Leuk Lymphoma. 2025 Dec;66(12):2214-2225. IF: 2.2.

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC). Medina Á, Muntañola A, Crespo M, Ramírez Á, Hernández-Rivas JÁ, Abrisqueta P, Alcoceba M, Delgado J, de la Serna J, Espinet B, González M, Loscertales J, Serrano A, Terol MJ, Yáñez L, Bosch F; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC). Med Clin (Barc). 2025 Mar 28;164(6):305-305.e17. English, Spanish. IF: 2.1.

Exploring communication preferences for disclosing breast cancer risk in women with a family history. López-Fernández A, Pardo M, Pérez-Ballestero E, Darder E, Alfonso R, Torres-Esquius S, Navarro Garcés V, Ramón Y Cajal T, Brunet J, Balmaña J. J Genet Couns. 2025 Oct;34(5):e70114. IF: 1.9.

Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study. Cerezuela-Fuentes P, Aguado de la Rosa C, Crespo G, Berciano-Guerrero MÁ, Soria A, Muñoz-Couselo E, López Castro R, Majem M, Ayala de Miguel P, Manzano JL, Bellido L, Lecumberri MJ, Corral Subias M, Villa Guzmán JC, Hernández B, Espinosa E, Puértolas T, Gutiérrez Sanz L, Medina Martínez J, Palomar Abril V, Martín Algarra S, Márquez-Rodas I. Melanoma Res. 2025 Dec 1;35(6):399-408. IF: 1.9.

Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy. Vitiello F,Vivaldi C,Rimini M,Lo Prinzi F,Rizzato MD,Saborowski A,Antonuzzo L,Rossari F,Satake T,Peeters F,Salani F,Pressiani T,Lucchetti J,Kim JW,Abidoye O,Rapposelli IG,Gallio C,Tamberi S,Finkelmeier F,Giordano G,Pircher C,Chon HJ,Braconi C,Qaisar A,Pastorino A,Castet F,Tamburini E,Yoo C,Parisi A,Diana A,Scartozzi M,Prager GW,Avallone A,Schirripa M,Kim IH,Perkhofer L,Oneda E,Verrico M,Couto N,Adeva J,Chan SL,Spinelli GP,Personeni N,Garajova I,Rodriguez MG,Leo S,Alvim CM,Roque R,Farinea G,Genovesi V,De Rosa A,Lavacchi D,Camera S,Ikeda M,Dekervel J,Niger M,Balsano R,Tonini G,Kang M,Tesini G,Esposito L,Boccancino A,Himmelsbach V,Landriscina M,Ahcene S,Bekaii T,Masi G,Vogel A,Lonardi S,Fornaro L,Rimassa L,Casadei A. Oncology. 2025 Aug 14. doi: 10.1159/000546856. IF: 1.8.

A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX. Álvarez-Gallego R, Macarulla T, Laquente B, Peinado P, Castet F, Muñoz C, Fabregat-Franco C, Ugidos L, Vega S, Busquets J, Sanz-García E, Toledano C, Quijano Y, Vicente E, Cubillo A. Am J Clin Oncol. 2025 Sep 10. doi: 10.1097/COC.0000000000001253. IF: 1.8.

The importance of data transformation in RNA-Seq preprocessing for bladder cancer subtyping. Acedo-Terrades A, Perera-Bel J, Nonell L. BMC Res Notes. 2025 Feb 10;18(1):61. IF: 1.7.

Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics. Manzano-Nunez R, Gomez DA, Toledo-Mendoza C, Perez-Otero M, Matilla IL, Prats C, Perez-Lopez E, Pardo H, Díaz-Pellicer P, De La Torre-Fornell R, Aldea AM. Clin Neuropharmacol. 2025 Jan-Feb 01;48(1):13-19. IF: 1.5.

Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium. Carbonell-Asins JA, Jiménez-Martí E, Romero S, García E, Miralles-Marco A, Lopez B, Huerta M, Caballero C, Boggino H, Gauna C, Acevedo-Funes OB, Nuñez GB, Céspedes-Cardozo CM, Fernandez-Figueroa EA, Ortiz-Olvera N, Ruiz-García E, Carneiro F, Barros R, Figueiredo C, Ferreira RM, Groen-van Schooten TS, van Santvliet D, Derks S, Luca R, Alsina M, Riquelme A, Cervantes A, Fleitas T. J Cancer Educ. 2025 Oct;40(5):804-811. IF: 1.3.

Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial. González San Segundo C, López-Campos F, Gómez Iturriaga A, Santos M, Ocanto A, Montezuma L, Boladeras-Inglada AM, Glaria L, Guardado S, Rodríguez A, Henríquez I, Olivera J, Duque-Santana V, Garre J, Moreno S, Valero J, Conde AJ, Doval A, Sancho G, Martin Nieto P, Castaño Cantos A, García N, Fernández Alonso S, García García R, Díaz Gavela A, Buchser D, Maldonado X, Mases J, Hernando Requejo O, Sanmamed N, Martínez Salamanca JI, Couñago F. Actas Urol Esp (Engl Ed). 2025 Sep;49(7):501823. English, Spanish. IF: 1.2.

Combined neuroendocrine carcinoma of the penis: clinical, pathological and therapeutic insights. Palomino Escobar LC, Díaz-Mejía N, Maldonado X, Semidey ME, Mast R, Trilla E, Morales R, Carles J. BMJ Case Rep. 2025 Jul 1;18(7):e265257. IF: 0.5.

Articles (co) authored by VHIO investigators in 2025 without Impact Factor.

Methods for Selective Gene Expression Profiling in Single Tertiary Lymphoid Structure Using Laser Capture Microdissection. Gutierrez-Chavez C, Knockaert S, Dieu-Nosjean MC, Goc J. Methods Mol Biol. 2025;2864:107-126.

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia. Hutchings M, Korfi K, Montesinos P, Santoro A, Hou HA, Martinez-Sanchez P, Vives S, Galimberti S, Chen TY, Frigeni M, Garciaz S, Salamero Garcia O, Yeh SP, Yee K, Esteve J, Bajel A, Fleming S, Bretz AC, Attig J, Sun M, Nassiri S, Rutishauser T, Klein C, Ma YM, Schnetzler G, Vauleon S, Yu H, Barata T, Richard M, Simon S, Hinton H, Keshelava N, Subklewe M. Blood Neoplasia. 2025 May 11;2(3):100110.

Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques. González-López TJ, Sanchez R, Pastoriza C, Olivera P, Bernat S, Fernandez-Fuertes F, Caparrós-Miranda IS, Pérez-Rus G, Jarque I, Moreno-Beltrán ME, López-Abadía E, De Cabo E, Marcellini S, Pérez-Segura G, Fernández-Miñano C, Peñarrubia MJ, Matarraz S, Pérez-Caro M, Orfao A, Provan D, Martínez-López J. Blood Vessel Thromb Hemost. 2025 Feb 17;2(3):100061.

Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy. Lamarca A, Adeva J, Ales Díaz I, Alvarez Gallego R, Muñoz Martín AJ, Macarulla Mercade T. ESMO Gastrointest Oncol. 2025 Jan 4;7:100116.

European screening platform for EORTC clinical trials in advanced colorectal cancer `SPECTAcolor’. Folprecht G, Morfouace M, Collienne M, Salazar R, Stein A, Elez E, Wagner AD, Arnold D, Kohne CH, Ducreux M, Lordick F, Borelli B, Stevovic A, Gorlia T, Fontana E, Aust D, Golfinopoulos V, Moehler M, Tejpar S. ESMO Gastrointest Oncol. 2025 Apr 9;8:100168.

MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry. Muñoz Martín AJ, Castet F, Soto Alsar J, Adeva J, Peinado P, Graña B, Alés Díaz I, Rodríguez-Alonso RM, Lobo de Mena M, Vera R, Ruiz de Mena I, Aguilar S, Vega S, Ortega Morán L, Macarulla T. ESMO Gastrointest Oncol. 2025 May 27;8:100187.

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab. Fakih M, Ciardiello F, Prager GW, Élez E, Calleja E, Caussé-Amellal N, Taieb J, Van Cutsem E. ESMO Gastrointest Oncol. 2025 Jun 16;9:100191.

Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study. Garcia-Carbonero R, Elez E, García-Alfonso P, Cubillo Gracían A, López López R, Jimenez-Fonseca P, Limón Mirón ML, Dasari A, Lonardi S, Zhu H, Chen L, Yang Z, Schelman WR, Tabernero J. ESMO Gastrointest Oncol. 2025 Jul 15;9:100205.

Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany. Lonardi S, Potthoff K, Procaccio L, Yoo C, Macarulla T, Hedouin-Biville F, Prager GW. ESMO Gastrointest Oncol. 2025 Aug 13;9:100217.

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations. Ros J, Navarro V, Villacampa G, Baraibar I, Salvà F, Rodriguez M, Vaghi C, Garcia A, Alcaraz A, Tabernero J, Élez E, Dienstmann R. ESMO Gastrointest Oncol. 2025 Aug 18;9:100225.

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial. Kasper S, Elez E, Neumann U, Lang S, Trampe AK, Salva F, Dopazo C, Virchow I, Hartmann S, Herrmann K, Tabernero J, Westendorf A, Schuler M, Schramm A. ESMO Gastrointest Oncol. 2025 Sep 1;9:100226.

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients. Salvà F, Catani G, Saoudi N, Baraibar I, Ros J, Rodriguez M, Salvà de Torres C, Alcaraz A, Garcia A, Comas R, Ruiz-Pace F, Rezqallah A, Dienstmann R, Tabernero J, Elez E. ESMO Gastrointest Oncol. 2025 Aug 26;9:100230.

Association between neutropenia and efficacy in patients with refractory mCRC receiving trifluridine/tipiracil. Prager GW, Elez E, Fakih M, Ciardiello F, Van Cutsem E,Roby L, Yao W, Choucair E, Taieb J. ESMO Gastrointest Oncol. 2025 Sep 8:10:100234.

Sex differences in the incidence trends of early-onset gastrointestinal cancer—the European/Mediterranean perspective. Ben-Aharon I, Fokter Dovnik N, van Laarhoven HWM, Guren MG, Baraibar I, Gordon N, Goshen-Lago T, Verhoeven R, Sokop T, Obermannova R, Lordick F. ESMO Gastrointest Oncol. 2025 Sep 12:10:100238.

Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. Macarulla T, Muñoz A, Martínez de Castro E, Castillo A, Cano MT, Castet F, Vidal R, Ferrández A, Ghanem I, Ales I, Vera R, Lobo M, Adeva J, Melian M, Gallego I, Laquente B, Fernández Montes A, Peinado P, García Paredes B, Pazo R, García Escobar I, Ruiz de Mena I, Carrato A, Aranda E. ESMO Real World Data Digit Oncol. 2025 Feb 17;7:100116.

Core variables for real-world clinicogenomic data collection in precision oncology. Dienstmann R, Hackshaw A, Blay JY, Le Tourneau C. ESMO Real World Data Digit Oncol. 2025 Feb 27:7:100117.

Real-world radiology data for artificial intelligence-driven cancer support systems and biomarker development. Navarro-Garcia D, Marcos A, Beets-Tan R, Blomqvist L, Bodalal Z, Deandreis D, Crispin-Ortuzar M, Gallagher F, Giandini T, Graves MJ, Lassau N, Maier-Hein K, Prelaj A, Schader P, Schlemmer HP, Sedlaczek O, Vaiani M, Perez-Lopez R. ESMO Real World Data Digit Oncol. 2025 Mar 22;8:100120.

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study. Martínez-Sáez O, Tapia M, Marín-Aguilera M, Hernández-Illán E, Tébar C, Martinez-Puchol AI, Jares P, Marín-Liébana S, Magro A, Puig-Butille JA, Palomar L, Sanfeliu E, Martinez MT, Losada MV, Hernando C, Adamo B, Iranzo V, Pascual T, Pouptsis A, Schettini F, Santaballa A, Conte B, Torregrosa MD, Brasó-Maristany F, Walbaum B, Gómez-Bravo R, Burgués O, Fructuoso IG, Garrido-Cano I, Seguí E, Paré L, Muñoz M, Carcelero E, Sànchez J, Villagrasa-González P, Buckingham W, Prat A, Villacampa G, Chic N, Rivera P, Rezqallah A, Saura C, Escrivà S, Bermejo B, Lluch A, Llombart A, Cejalvo JM. ESMO Real World Data Digit Oncol. 2025 Mar 7;8:100123.

Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes. García-Díaz HC, Larrosa-Garcia M, Gómez-Alonso J, Cruellas M, Felip E, Macarulla T, Farriols A, Carreras MJ. Farm Hosp. 2025 Sep-Oct;49(5):286-290. English, Spanish.

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers. Gallagher P, Rolfo C, Elez E, Taieb J, Houlden J, Collins L, Roberts C, André T, Lawler M, Di Nicolantonio F, Grayson M, Boyd R, Popovici V, Bardelli A, Carson R, Khawaja H, Laurent-Puig P, Salto-Tellez M, Hennessy BT, Maughan TS, Tabernero J, Adams R, Jones R, Peeters M, Middleton MR, Wilson RH, Van Schaeybroeck S; MErCuRIC Trial Consortium. BJC Rep. 2025 Mar 26;3(1):17.

Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort. Osterlund E, Hammarström K, Nunes L, Mathot L, Mezheyeuski A, Sjöblom T, Glimelius B. BJC Rep. 2025 May 28;3(1):38.

Cancer prognosis and treatment results in patients with PTEN Hamartoma Tumour Syndrome (PHTS)-a European cohort study. Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, de Putter R, Brems H, Van Daele SH, Anastasiadou VC, Foretová L, Benusiglio PR, Gerasimenko A, Colas C, Villy MC, Houdayer C, Branchaud M, Hüneburg R, Aretz S, Jahn A, Steinke-Lange V, Innella G, Turchetti D, Barili V, Genuardi M, Panfili A, Baldassarri M, Irmejs A, de Jong MM, Links TP, Leter EM, Bosch DGM, Donze SH, van der Post RS, Mensenkamp AR, Westdorp H, Høberg-Vetti H, Tveit Haavind M, Jørgensen K, Mæhle L, Briskemyr S, Garcia JD, Blatnik A, Balmaña J, Torres M, Brunet J, Lleuger-Pujol R, Tham E, Tischkowitz M, Evans DG, Hyder Z, Hoogerbrugge N, Vos JR. BJC Rep. 2025 Jun 4;3(1):42.

ASSET: A Framework for Decoding Aptamer Specificity of an Enriched Library by Next-Generation Sequencing of Experimental Samples. Barros M, Kasirajan G, Jones A, Schlichting A, Ruiz-Ciancio D, Lin LH, Narayan C, Veeramani S, Thiel KW, Kennedy GC, Darcy I, Thiel W. bioRxiv [Preprint]. 2025 Aug 30:2025.08.27.672406.

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway. Tsuda M, Keith D, Daniel CJ, Pelz C, Blise KE, Ozmen TY, Ozmen F, Hawthone K, Eng JR, Li X, Wang X, Zimny H, Sivagnanam S, Betre K, Kirchberger N, Chong B, Lee J, Matter A, Smith A, Agritelley ES, Waugh T, Sannecy A, Alarcon K, Youm I, Protzek S, Egger J, English IA, Yang M, Shah VM, Link JM, Creason AL, Worth PJ, Goodyear SM, Chin K, Muschler JL, Suciu CG, Corless CL, Cao S, Soucek L, Kardosh A, Coussens LM, Brody JR, Lopez CD, Mills GB, Sears RC. bioRxiv [Preprint]. 2025 Dec 15:2025.12.12.693851.

Body size and intracranial volume interact with the structure of the central nervous system: A multi-center in vivo neuroimaging study. Labounek R, Bondy MT, Paulson AL, Bédard S, Abramovic M, Alonso-Ortiz E, Atcheson NT, Barlow LR, Barry RL, Barth M, Battiston M, Büchel C, Budde MD, Callot V, Combes A, De Leener B, Descoteaux M, de Sousa PL, Dostál M, Doyon J, Dvorak AV, Eippert F, Epperson KR, Epperson KS, Freund P, Finsterbusch J, Foias A, Fratini M, Fukunaga I, Wheeler-Kingshott CAMG, Germani G, Gilbert G, Giove F, Grussu F, Hagiwara A, Henry PG, Horák T, Hori M, Joers JM, Kamiya K, Karbasforoushan H, Keřkovský M, Khatibi A, Kim JW, Kinany N, Kitzler H, Kolind S, Kong Y, Kudlička P, Kuntke P, Kurniawan ND, Kusmia S, Laganà MM, Laule C, Law CSW, Leutritz T, Liu Y, Llufriu S, Mackey S, Martin AR, Martinez-Heras E, Mattera L, O'Grady KP, Papinutto N, Papp D, Pareto D, Parrish TB, Pichiecchio A, Prados F, Rovira À, Ruitenberg MJ, Samson RS, Savini G, Seif M, Seifert AC, Smith AK, Smith SA, Smith ZA, Solana E, Suzuki Y, Tackley GW, Tinnermann A, Valošek J, Van De Ville D, Yiannakas MC, Weber Ii KA, Weiskopf N, Wise RG, Wyss PO, Xu J, Cohen-Adad J, Lenglet C, Nestrašil I. Imaging Neurosci (Camb). 2025 May 7;3:imag_a_00559.

The role of digital tools and artificial intelligence in supporting antimicrobial stewardship: Study protocol for a systematic review. Cortés Sánchez CJ, Salazar González F, Gómez Portolés JM, Giménez Castellanos J, Climente Martí M. Farm Hosp. 2025 Dec 26. English, Spanish. doi: 10.1016/j.farma.2025.11.014.

End-to-end prediction of clinical outcomes in head and neck squamous cell carcinoma with foundation model-based multiple instance learning. Meneghetti AR, Hernández ML, Kühn JP, Löck S, Carrero ZI, Perez-Lopez R, Bressem KK, Brinker TJ, Pearson AT, Truhn D, Nebelung S, Kather JN. BMC Artif Intell. 2025;1(1):3.